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The main focus of the presented work concentrated on understanding the biosynthetic pathway of 
viridofungin, exploring the enzymatic properties of the key enzymes from the byssochlamic acid 
pathway, and engineering the PKS of tenellin. In a combined genetic and chemical approach, the 
biosynthetic pathway of viridiofungin and functions of enzymes from of byssochlamic acid 
pathway and programming of the tenellin PKS (TENS) system were elucidated. 
Trichoderma viride MF5628 was firstly genome sequenced by Illumina and Oxford 
nanopore sequencing. Then, using a combination of targeted gene knockout and RNA 
interference-based silencing in the native organism, a novel unreported tRNA ligase like enzyme 
involved in the biosynthetic pathway was identified. A citrate synthase like enzyme and a tRNA 
ligase like enzyme were found to be essential to the biosynthesis of viridiofungin.  
The biosynthesis of byssochlamic acid was investigated by protein expression and in vitro 
study. A hydrolase, citrate synthase, two 2-methyl citrate dehydratases, two KSI and two PEBP 
proteins were expressed in E. coli or yeast, in addition, in vtiro assay was carried out by using 
these proteins. During maleic anhydride monomer biosynthesis, a hydrolase can hydrolyze the 
hexaketide from ACP. Citrate synthase can use hexaketide CoA and oxaloacetate as substrates to 
form (2S, 3R) citrate. 2-Methyl citrate dehydratase takes (2S, 3R) citrate diasteroisomer as 
substrate to form a 2, 3-alkene product, and the product can spontaneously form a cyclised maleic 
anhydride monomer. Two KSI finally used maleic anhydride monomer to form the dimerised 
product byssochlamic acid. Two PEBP enzymes are not thought to be involved in catalysis of 
dimerization. 
Based on KR domain swap experiment on TenS, chain-length programming in TenS was 
elucidated. Six KR domain subfragments were swapped with the homologous fragments from 
hexaketide desmethylbassianin synthase (DMBS) and three with the heptaketide militarinone 
synthase (MILS) resulted in the synthesis of different chain length of polyketide products. 
Particularly, the MILS KR domain swap resulted in the synthesis of penta, hexa and heptaketides. 
The results of these and previous experiments in our group are rationalised by considering the 
existence of competition between the C-MeT and KR domains. 
 









Das Hauptaugenmerk der vorgestellten Arbeit lag auf dem Verständnis des Biosynthesewegs von 
Viridofungin, der Untersuchung der enzymatischen Eigenschaften der Schlüsselenzyme aus dem 
Byssochlaminsäure-Weg und der Entwicklung der PKS von Tenellin. In einer  kombination aus 
genetischen und chemischen experimenten Ansatz wurden der Biosyntheseweg von 
Viridiofungin und die Funktionen von Enzymen aus dem Byssochlaminsäure-Weg sowie die 
Programmierung des Tenellin-PKS (TENS) -Systems aufgeklärt.  
Das Trichoderma-virid MF5628 wurde zunächst durch Illumina- und Oxford-Nanoporen-
Sequenzierung genomsequenziert. Es wurde unter Verwendung einer Kombination aus gezielter 
Gen-Knockout- und RNA-Interference-basierter Stummschaltung im nativen Organismus ein 
neuer, nicht veröffentlicht Biosyntheseweg identifiziert, an dem eine tRNA-Ligase beteiligt ist. 
Es wurde festgestellt, dass ein Citrat-Synthase-ähnliches Enzym und ein tRNA-Ligase-ähnliches 
Enzym für die Biosynthese von Viridiofungin essentiell sind.  
Die Biosynthese von Byssochlaminsäure wurde durch Proteinexpression und in-vitro-
Studie enukleiert. Eine Hydrolase, Citrat-Synthase, zwei 2-Methylcitrat-Dehydratase, zwei KSIs 
und zwei PEBPs-Proteine wurden in E. coli und Hefe exprimiert. Während der 
Maleinsäureanhydridmonomer Biosynthese kann eine Hydrolase die Hexaketidform vom ACP 
hydrolysieren. Die Citrat-Synthase kann Hexaketid-CoA und Oxalacetat als Substrat verwenden, 
um (2S, 3R) -Citrat zu bilden. 2-Methylcitrat-Dehydratase nimmt (2S, 3R) -Citrat-Diasteroisomer 
als Substrat, um ein 2, 3-Alken im Produkt zu bilden, und das Produkt kann ein  spontan 
cyclisiertes Maleinsäureanhydridmonomer bilden. Zwei KSI verwenden schließlich 
Maleinsäureanhydrid-monomer, um das dimerisierte Produkt Byssochlaminsäure zu bilden. 
PEBP-Enzyme sind nicht der Katalyse der Dimerisierung beteiligt.  
Basierend auf dem KR-Domain-Swap-Experiment mit TenS wurde die 
Kettenlängenprogrammierung in TenS aufgeklärt. Sechs KR-Domänen-Subfragmente, die mit 
den homologen Fragmenten der Hexaketid-Desmethylbassianin-Synthase (DMBS) und drei mit 
der Heptaketid-Militarinon-Synthase (MILS) ausgetauscht wurden, führten zur Synthese 
unterschiedlicher Kettenlängen von Polyketid-Produkten. Insbesondere der MILS KR-
Domänenaustausch führte zur Synthese von Penta, Hexa und Heptaketiden. Die Ergebnisse dieser 
und vorherger Experimente in unserer Gruppe werden einbezogen, indem die Existenz einer 
Konkurrenz zwischen den CMeT- und KR-Domänen berücksichtigt wird.  
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AA amino acid KR β-ketoreductase 
ACP acyl carrier protein ΨKR pseudo-ketoreductase 
acetyl-CoA     acetyl-coenzyme A LCMS liquid chromatography mass spectrometry 
AntiSMAS
H 
antibiotic and Secondary Metabolite Analysis 
Shell DAD diode-array detection 
AT acyltranferase MCoA malonyl-CoA 
att site-specific attachment MeOD deuterated methanol 
bp base pair MeOH methanol 
BLAST basic local alignment search tool MS mass spectrometry 
CDCl3 deuterated chloroform MeT methyltransferase 
cDNA copy deoxyribonucleic acid MAT malonyl/acetyl tranferase 
C-Met C-methyltrasferase mFAS mammalian fatty acid synthase 
CoASH coenzyme A mRNA messeinger ribonucleic acid 
CS citrate synthase 
NAD(P)
H 
nicotinamide adenine dinucleotide 
(phosphate) 
COSY homonuclear correlation spectroscopy NOESY nuclear overhauser effect spectroscopy 
dATP deoxyadenosine triphosphate NPRS nonribosomal peptide synthetase 
DH dehydratase NMR nuclear magnetic resonance 
DNA deoxyribonucleic acid nr-iPKS nonreducing iterative PKS 
ELSD evaporative light scattering detector ORF open reading frame 
ESI electrospray ionization PamyB AmyB promoter 
ER enoyl reductase PgpdA GpdA promoter 
FAS fatty acid synthase PCR polymerase chain reaction 
FAD flavin adenine dinucleotide PKS polyketide synthase 
gDNA genomic DNA pr-iPKS partially reducing iterative PKS 
HMBC heteronuclear multiple bond correlation RNA ribonucleic acid 
HRAM high resolution accurate mass RT retention time 
1H NMR proton NMR SAM S-adenosyl-methionine 
HPLC high performance liquid chromatography SAT starter unit: ACP transacylase 
hr-iPKS highly reducing iterative PKS SM secondary metabolite 
HRMS high resolution molecular weight TE thiolesterase 
HSQC heteronuclear single quantum coherence tf transformant 
ITS internal transcribed spacer TIC total ion current 
iPKS iterative PKS UV ultraviolet 
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Chapter 1. Introduction and Background of the Projects 
1.1 General overview of projects. 
Fungi are excellent producers of various metabolites with a wide range of bioactivities. Some 
filamentous fungi like Byssochlamys fulva and Trichoderma viride can produce alkyl citrates such 
as byssochlamic acid 1 and viridiofungin 2. Fungi like Beauveria bassiana can produce tenellin 
3. Although these compounds appear to be structurally quite different from each other, they do 
have interesting similarities. For example, tenellin 3 and viridiofungin 2 both contain a tyrosine 
unit (blue in Fig. 1.1.1); byssochlamic acid 1 and viridiofungin 2 both contain a citrate-derived 
unit (red in Fig. 1.1.1); and tenellin 3 and byssochlamic acid both contain a polyketide or fatty 
acid moiety (black in Fig. 1.1.1) 
 
 
Fig. 1.1.1 Structures of byssochlamic acid 1, viridiofungin A 2 and tenellin 3. Citrate blocks highlighted in red, amino 
acid blocks highlighted in blue, alkyl chains in black. 
 
Byssochlamic acid 1 is known to be derived from polyketide chains modified with oxaloacetyl 
moieties. Compound 1 features a 9-membered carbocyclic core, with two fused furan-2,5-
dione/maleic anhydride moieties.[1-3] The gene cluster of  Byssochlamic acid 1 was first reported 
by the Cox group in 2016. Genes encoding a polyketide synthase (PKS), a hydrolase, a citrate 
synthase and a 2-methyl citrate dehydratase are involved in the core early steps in the biosynthetic 
pathway to form the maleic anhydride moieties.[3] Ketosteroid isomerase (KI)-like enzymes and 
phosphatidylethanolamine binding protein (PEBP)-like enzymes appear to conctrol the 
dimerization steps to form the central carbocyclic ring. 
The byssochlamic acid 1 project is focused on exploring mechanisms and selectivity of the 
enzymes for maleic anhydride monomer and ring-forming enzymes. The project is designed to 
use heterologous expression in E. coli or yeast to obtain the enzymes for in vitro assay. The 
chemical approach involved application of analytical HPLC to analyse crude extracts from the 
reactions.
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Viridiofungin A 2 is a secondary metabolite of Trichoderma viride. It is a member of the 
alkyl citrate family of metabolites and is an inhibitor of squalene synthase.[4] Viridiofungins have 
a characteristic citric acid structural element that is alkylated at the  2-position. Viridiofungins 
were first found in 1993, and a lot of total synthesis work has been conducted by different groups 
in recent years.[5, 6] However, the biosynthesis of viridiofungins is still unknown.   
The viridiofungin 2 project is aimed to explore the biosynthetic pathway of viridiofungins. 
The project should start with genome sequencing of Trichoderma viride MF 5628. Then different 
bioinformatics analysis software will be used to find a possible viridiofungin biosynthetic gene 
cluster. Based on sequencing and bioinformatic analysis, the project is designed to use chemical 
(analytical) and biological (genetic engineering) methods to explore the gene cluster.  
Tenellin 3 is a secondary metabolite of B. bassiana and its structure was elucidated by Wat 
and co-workers.[7] It is a member of a large class of related compounds including other structurally 
complex 2-pyridones and acyltetramic acids isolated from fungi. The Cox group found the gene 
cluster of tenellin 3 in 2008.[8] The gene cluster of tenellin 3 encodes two cytochrome P450 
oxygenases (TenA and TenB), a trans-acting enoyl reductase (ER, TenC) and an iterative 
polyketide synthase nonribosomal peptide synthetase (PKS-NRPS, TenS).[9] In 2011 using 
rational domain swaps between the polyketide synthases encoding the biosynthesis of the closely 
related compounds tenellin 3 and desmethylbassianin, the Cox group found that expression of the 
hybrid polyketide synthases in Aspergillus oryzae led to the production of reprogrammed 
compounds in which the changes to the methylation pattern and chain length could be mapped to 
the domain swaps.[10]  The reprogrammed compounds always related to the changes in keto 
reductase (KR) and C-methyltransferase (C-MeT) domain. 
In the tenellin 3 project, efforts will be made to understand programming of fungal PKS by 
using much smaller sub-domain swaps within the KR domain, to try to find out the molecular 
basis of methylation and chain-length programming in fungal iterative highly reducing polyketide 
synthases (hr-PKS). 
 
1.2 Natural products, secondary metabolites and their major classes. 
Natural products can be defined as any chemical compounds derived from nature. However, the 
traditional definition of natural products of organic and medicinal chemistry communities are 
small organic molecules whose molecular weight is less than 1500 daltons which are generated 
from conditional metabolic pathways.[11] Here the conditional metabolic pathway usually refers 
to secondary metabolite pathways of organisms such as bacteria, algae, fungi or plants.[12] 
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Different from primary metabolites, secondary metabolites are not present in all organisms 
and are not essential for life. Secondary metabolites are usually thought to confer some form of 
advantage or protection to the producers. Natural products and secondary metabolites are a great 
source for the pharmaceutical industry to find the new molecules for medicine (50% of the drugs 





















































































Fig. 1.2.1 Examples of different classes of natural products (polyketide, peptide, terpene and alkaloid). 
 
Based on their biosynthetic origin, natural products are classified as polyketides (and some fatty 
acid derived compounds), peptides, terpenes and alkaloids. Some secondary metabolites are 
hybrids of more than one class. Most of these compounds’ building blocks come directly from 
primary metabolism, and these natural products are derived from common precursors. For 
example: polyketides are derived from acetyl-CoA; peptides and alkaloids are derived from amino 
acids; and mevalonic acid is the precursor of terpene biosynthesis. Oxytetracycline 4, 
erythromycin 5, squalestatin S1 7 and lovastatin 6 are polyketides; tyrocidine 8 is peptide; tenellin 
3 is a mixed compound from a polyketide and peptide hybrid system; artemisinin 9 is a terpene; 
and morphine 10 is an alkaloid (Fig. 1.2.1).  
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1.3 Polyketides and Fatty acids. 
1.3.1 Basic enzymology of polyketide and fatty acid biosynthesis.  
Polyketides are a very diverse group of natural products. They constitute one of the major classes 
of fungal metabolites. Polyketides are secondary metabolites which are built by polyketide 
synthase enzymes (PKS). Most fatty acids are primary metabolites, these fatty acids are 
synthesised by a complex biosynthetic machinery named fatty acid synthase (FAS). Polyketides 
and fatty acids share a common pattern of biosynthesis. Polyketides and fatty acids are generated 
from the same acyl and malonyl CoA building blocks by repeated condensation reactions.[14] The 
general biosynthetic process of both polyketides and fatty acids is the same, but polyketide 
biosynthesis is more highly programmed. 
 
1.3.1.1 Acyl transfer. 
Both fatty acid and polyketide biosynthetic pathways start with the acyl transfer step. The acyl 
carrier protein (ACP) plays an important role in the acyl transfer steps. The starter and extender 
units, and the growing acyl chain are held by an ACP. The ACP is a small protein (ca 10 kDa) 
which has a phosphopantetheine (PP) prosthetic group attached to a highly conserved serine. The 
PP has a terminal thiol to which the acyl groups are attached as thiolesters. ACP-bound acyl units 
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Scheme 1.3.1.1 Structures of Acyl-CoA and Acyl-ACP. 
 
The starter group for FAS is the thiolester acetyl-CoA 11. The starter group in PKS biosynthesis 
can be other acyl CoAs such as benzoyl-CoA 12, for example as used by the hexaketide synthase 
of squalestatin 7.[4] During this reaction an acyl-transferase (AT) domain transfers the acyl group 
Ⅰ Basic enzymology of polyketide and fatty acid biosynthesis 
 
5 
form CoA 11 to ACP 13. The acyl-CoA is connected as a thiolester to the terminal thiol of a 
phosphopantetheine which is linked to ACP through the side-chain –OH of a serine residue in the 
protein (Scheme 1.3.1.1). The acyl group of 13 is then transferred to a cysteine residue in the β–
ketosynthase (KS) domain giving an acyl-KS 14 which is used in the next condensation step.[17] 
Malonyl-CoA is the common extender unit for both FAS and PKS. Malonyl-CoA is 
synthesized from acetyl-CoA 11. In this step, acetyl-CoA 11 is carboxylated by transferring CO2 
to it with the help of the coenzyme biotin to form malonyl-CoA. Malonyl-CoA is then transferred 
to ACP by the AT to give malonyl-ACP 15.[18] 
 
1.3.1.2 Condensation step. 
Malonyl-ACP 15 as extender, and acetyl-KS 14 as starter, then undergo a Claisen-like  
Condensation to extend the chain. The mechanism of the condensation involves decarboxylation 
of malonyl-ACP 15 to give an enolate ion, followed by immediate addition of the enolate ion to 
the carbonyl group of acetyl-KS, to form acetoacetyl-ACP 17. In this step, acetyl-KS 14 is an 



























Scheme 1.3.1.2 Claisen condensation step catalysed by the KS domain of PKS or FAS. 
 
1.3.1.3 β-processing. 
The KS thus creates a β-ketone. This ketone is then reduced by FAS. The first step is catalysed 
by the keto-reductase (KR) domain. The β-ketone carbonyl group is reduced to an alcohol forming 
β-hydroxybutyryl-ACP 19 (Scheme 1.3.1.3). The cofactor in this step is NADPH 18. [19] 
 
 























NADPH 18  
Scheme 1.3.1.3 Ketone reduction step catalysed by KR domain of PKS or FAS. 
 
The next steps of β-processing are dehydration and enoyl reduction which are catalysed by 
dehydratase (DH) and enoyl reductase (ER) domains respectively. During the dehydration step, 
the 2-pro-S hydrogen of compound 20 is stereoselectively removed in an E1cB elimination 
mechanism to obtain olefin 22 (Scheme 1.3.1.4 A). The elimination is thought to proceed through 
an intermediate thiolester enolate 21.[20] Catalysis is thought to proceed by histidine abstraction 
of a proton from the α position, and aspartic acid protonation of the departing hydroxyl from the 
β position.[21] 
The enoyl reduction step occurs by conjugate addition of a hydride ion from NADPH 18 















































Scheme 1.3.1.4 Mechanisms of dehydration and reduction of PKS and FAS intermediates: A, DH domain; B, ER 
domain. 
 




After further elongation rounds by C2 units and β-processing, the complete fatty acid chain is 
released by a thiolesterase (TE) domain. The product of fatty acid biosynthesis is a carboxylic 
acid. The fatty acid undergoes a hydrolytic release.  
In the case of polyketide biosynthesis, the most well-studied chain release mechanism 
involves macrolactonization catalysed by a TE domain appended to the C terminus of the PKS 
(e.g. biosynthesis of erythromycin).[22] Examples of TE domains that catalyse chain release via 
thiolester hydrolysis or macrolactamization are also known.[23, 24] In addition, several other types 
of catalytic domains have been reported to catalyse chain release. Examples include thiolester 
reductase (TR) domains, which catalyse reductive release to form an aldehyde or alcohol.[25, 26] 
Furthermore, α-oxoamine synthase (OAS) domains, release the polyketide chain via 
decarboxylative condensation with the α-carbon of an amino acid.[27]  
 
1.3.1.5 Programming of PKS 
Polyketides and fatty acids bear strong resemblance in biosynthesis, which is divided in three 
phases: extender unit loading, chain elongation, and β-processing (Scheme 1.3.1.5). In fungal 
PKS, malonyl-CoA 25 is used as extender unit and loaded to ACP forming 26. Chain elongation 
undergoes a claisen condensation from 27 to 28. β-processing includes C-methylation 29, keto-




























































Scheme 1.3.1.5 General mechanisms involved in fatty acid and polyketide biosynthesis. 
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The key difference between FAS and PKS is that of programming. Full reduction of the β–carbon 
chain always takes place during fatty acid biosynthesis and without methylation. However, PKS 
is sophisticatedly programmed so that β-processing occur optionally give an alcohol 30, an alkene 
31 or an unmodified ketone group 28 on particular carbons. It can additionally control starter and 
extender unit selection.[28] In addition, fungal PKS often have a functional C-methylation (C-MeT) 
domain which can methylate the α-carbon at the beginning of the β-processing cycle. 
 
1.3.2 Classification of FAS and PKS. 
FAS and PKS can be classified into different types based on the architecture of the proteins, 
whether they are iterative or non-iterative, and the degree of reduction at the β position. 
1.3.2.1 Different types of FAS and PKS. 
Based on the structure of the enzyme, FAS are divided into type I and II systems. Type I FAS 
systems are multi-domain enzymes which contain all domains in one or two multifunctional 
proteins. Type II FAS systems consist of non-covalently linked enzyme complexes that are 
characterised as a set of dissociated monofunctional proteins. Type I FAS is usually found in 
animals and fungi, and type II FAS is usually found in bacteria and plants.  
According to the differences in architecture, PKS can be classified into three types: type I, 
type II and type III PKS. Type I PKS are multifunctional proteins containing all active domains 
for biosynthesis of polyketide. Type I PKS can be sub-classified into two types: Type I modular 
PKS and the type I iterative PKS. Type I modular PKS are usually found in bacteria, but the 
biosynthesis of fungal polyketides is usually driven by type I iterative PKS. In type I modular 
PKS, each single module of the PKS catalyses one cycle of polyketide chain elongation, such as 
the deoxyerythromycin B synthase (DEBS) during the biosynthesis of erythromycin A 5. In 
contrast, type I iterative PKS, use a single set of catalytic domains in a single module which is 
highly programmed and works iteratively.[29] 
Type II PKS are non-covalent aggregates of monofunctional proteins, and they are involved 
in the synthesis of aromatic polyketides in bacteria. Type II PKS are not found in fungi. Type III 
PKS do not contain acyl carrier protein (ACP) domain, and are exemplified by systems such as 
chalcone synthase.[28, 30] Type III PKS are homodimeric KS that synthesize smaller aromatic 
compounds in bacteria, fungi and plants, and which are very different from type I and type II PKS 
systems.[31] 
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9 
1.3.2.2 Type I iterative PKS and eukaryotic FAS. 
Type I iterative PKS can be classified into three types thus: highly reducing PKS (hr-PKS); partial 
reducing PKS (pr-PKS); and non-reducing PKS (nr-PKS). hr-PKS are a large subgroup of type I 
iterative PKS which are involved in the biosynthesis of highly reduced compounds such as 
lovastatin 9 and squalestatin S1 13. The basic domains of hr-PKS include KS, AT and ACP. hr-
PKS also include the β-processing domains like KR, DH, ER and C-MeT. The domain 
architecture and assembly line of the hr-PKS closely resembles that found in mammalian fatty 
acid synthases (mFAS). However, there are also many differences between mFAS and hr-PKS. 
For example, mFAS only contains a broken C-MeT domain (known as ψC-MeT), and hr-PKS 
use the special set of β-processing domains in different extension cycle, which result in the 
different degree of reduction and methylation at individual α- and β- position in the final product. 
Additionally, hr-PKS usually have no thiolesterase (TE) domain at the C-terminus of the 
megasynthase.[32] 
In summary, the type I iterative PKS and most of eukaryotic FAS (like fungal FAS and 
mFAS) are multifunctional proteins which catalyse multiple rounds of precursor elongation by 
the same set of enzymatic domain in one mutienzyme.[33] Eukaryotic FAS are highly optimized 
molecular machines specifically for producing fatty acids. While multienzymes like type I 
iterative PKS might have the overlapping set of functional domains not belong to primary fatty 
acid metabolism. The typical catalytic domains of type I iterative PKS are closely related to mFAS 
which include KS, AT, DH, ER, KR, C-MeT and ACP domains.  
 
1.3.3 Protein structure of FAS and PKS. 
In recent years, several protein structures of fungal FAS and mFAS have been reported. The 
similarities and differences between FAS and PKS in protein structures are also discussed in 
various studies. 
1.3.3.1 Fungal FAS. 
Fungal FAS from Thermomyces lanuginous is a 2.6 MDa α6β6 heterododecamer with a barrel 
shape enclosing two large chambers which contain three sets of active sites separated by a central 
wheel-like unit (Fig. 1.3.3.1 A). There are three distinct units in structure of the fungal FAS, the 
central wheel formed with 6 α units which form the equatorial disk of the particle, and two domes 
formed by 3 β units build up the reaction chambers (Fig. 1.3.3.1 B).[34] 
There are interactions between the subunits. The α chains in the wheel like central unit will 
contact with β units (Fig. 1.3.3.1 C). At the same time, the interaction between α- α subunits 
mainly involve homodimeric interfaces and interlocking modules arranged along the two-fold 
axis of synmmetry. Two α helices constitute a thin spoke in the central of the wheel (Fig. 1.3.3.1 
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C A).  One of the sequence insertions in the KS core domain form the second spoke (Fig. 1.3.3.1 
C C). In the position of Fig. 1.3.3.1 C B, peripheral domain forms which exhibits flexibility with 
the body of the FAS. Another peripheral domain is formed by expansion segment helices at the 
outside of the KS. The β- β contacts in the dome like structure are related with the formation of 
the trimeric apical connection of the arches (Fig. 1.3.3.1 D K). The three different α- β connections 
are all contributed by expansion segments (Fig. 1.3.3.1 D J, H, I). In this research, ACP is attached 
in the reaction chamber together with the spatial distribution of active sites which indicate that 




Fig. 1.3.3.1 Structure and diagrams of fungal FAS: A protein structure; B α6β6 structure; C wheel like structure; D 
dome like structure 
 
1.3.3.2 mFAS 
Animal FAS (the crystal structures of natively purified mFAS from pigs) is a single protein which 
forms a 540 kDa X-shaped homodimer with two lateral reaction clefts (Fig. 1.3.3.2 A). mFAS 
can be segregated into two parts, the condensing part with KS and malonyl-CoA ACP transacylase 
AT domains and an upper part, and a modifying part, containing all of the domains for β-
processing.[36] The arrangement of domains in the 3D structure actually does not follow the linear 
order at the sequence level. mFAS is segregated into a lower condensing portion, containing the 
chain-building KS and the AT domains, and an upper portion including the β-processing domains. 
The KR domain divides into a functional (catalytic) part and a “structural” part known as ψKR. 
There is also a non-functional C-MeT domains known as ψC-MeT (Fig. 1.3.3.2 B). Dimerization 
of mFAS is mainly mediated through interations of the lower KS domain part with ER domain 
Ⅰ Protein structure of FAS and PKS 
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upper part. Compared with fungal FAS, mFAS does not have tightly embedded core enzymatic 
domains. The linkers between the upper and lower domains are only short strtches of extended 
polypeptide which is only wrapped around the surface of the catalytic domains. Only the KS-AT 
linker domain acts as a true adapter between two domains and adopts a folded core structure.[37] 
 
 




hr-PKS are closely related to mFAS with a sequence identity of approximately 20% and the same 
domain order overall.[38] However, there is no structural information about fungal hr-PKS except 
the trans acting ER of LovC which is not structurally related to the ER domains of mFAS or hr-
PKS.[39] Due to the fact that mFAS and fungal hr-PKS show end-to-end sequence homology, it 
seems highly likely that hr-PKS are structurally similar to mFAS. They probably share the same 
overall dimeric structure in which the elongation domains (KS and AT) form a discrete structural 
unit known as the “elongation block,” and the modifying domains (C-MeT, KR, DH and ER) 
form a separate structural unit, known as the “modifying block”. The organization in the 
modifying region is likely to be particularly similar between hr-PKS and mFAS too. mFAS 
maintain degraded non-functional C-MeT remnants (ΨCMeT). But hr-PKS usually contain a fully 
function C-MeT domain at the same position. 
Differences among the mFAS and PKS modifying blocks are certain to arise as a result of 
the absence of either the ER or both the DH and ER domains in many PKS modules. The ACP 
domains, which are fused to the C terminus of the modifying block, also differ in PKS and mFAS 
systems.[38, 40] In summary, the organization of hr-PKS modifying regions remains unclear, but 
current data suggest a considerable similarity to mFAS. 
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 1.4 Nonribosmal peptide and PKS-NRPS compounds in fungi. 
1.4.1 Nonribosmal peptide and NRPS. 
Both prokaryotic and eukaryotic organisms can produce small peptides, many of which are 
nonribosomaly constructed. In general, the peptides which belong to secondary metabolites are 
nonribosomal peptides, however, there are also exceptions, for example cyanobactins are small 
ribosomally derived cyclic-peptides from species of cyanobacteria.[41, 42]  
Biosynthesis of the nonribosomal peptide is independent of any mRNA or other RNA 
templates. Nonribosomal peptide synthetases (NRPS) are the key enzymes involved in the 
biosynthesis of nonribosomal peptides. NRPS assembly lines share a similar chemical logic with 
PKS assembly lines. There are initiation modules, elongation modules, and termination modules 
in NRPS assembly lines and in some cases additional tailoring domains. NRPS enzymes are 
modular and act in a stepwise assembly from amino acid monomers. NRPS enzymes can 
introduce functional group diversity in their products by utilizing all 20 naturally occurring amino 
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Scheme 1.4.1.1 Example of NRPS biosynthetic pathway. 
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Four main domains are necessary for complete synthesis:[43] the adenylation domain (A) selects 
and activates the monomer, transforming it into the adenylate form; the thiolation (T) or peptidyl 
carrier protein (PCP) domain binds the activated monomer to the synthetase; the condensation (C) 
domain catalyses the formation of peptide bonds; the thiolesterase domain, releases the peptide 
from the synthetase.  
Taking the biosynthesis of Tyrocidine 8 as an example, there are 10 NRPS modules 
involved in the biosynthetic pathway. Module 1 is the initiation module which activates L-Phe, 
then a PCP domain binds the activated monomer to the synthetase to obtain 33. The epimerization 
(E) domain of module1 then convert L-Phe to D-Phe. The module 2 A domain activates the second 
anmino acid, PCP domain binds the second monomer to the synthetase, then C domain catalyses 
the formation of peptide bonds to form 34. Module 3 and 4 follow the next two cycles to obtain 
35 and 36. After 10 rounds of reaction, the compound 38 is formed. At the last step, the TE domain 
of module 10 releases the peptide chain using a macrocyclization mechanism and 8 forms. 
Tyrocidine undergoes a head to tail macrolactamization as the free amine of Phe1 captured the 
carbonyl of Val10 (Scheme 1.4.1.1).[42] 
 
1.4.2 PKS-NRPS compounds in fungi. 
Some natural products are also synthesized by a hybrid PKS-NRPS systems. In bacteria, there are 
many known modular systems which place the PKS module and NRPS module together in the 
assembly lines.[43] However, in fungi, PKS and NRPS usually combine as a single module of an 
iterative PKS followed by a single NRPS module. The architecture of the PKS part in the iterative 
hybrid PKS-NRPSs closely resembles that found in mFAS.[42, 44] The PKS module in iterative 
PKS-NRPS has a general domain organisation of KS, AT, DH, C-MeT, ψKR, ER, KR and ACP. 
Normally in PKS-NRPS the ER is broken (ER0) and replaced by a trans-acting ER typified by 
LovC and TenC.[9, 39] The NRPS modules of the iterative hybrid PKS-NRPS contain C 
(condensation), A (adenylation) and T (thiolation) domains. The C-terminal domain normally 
catalyse either reductive release (R) or Dieckmann cyclisation (DKC). 
The intermediate compound 39 of cytochalasin is synthesised by a PKS-NRPS (CheA) with 
a trans-ER (CheB). CheA contains an hr-PKS and a single module of NRPS. The hr-PKS 
produces a C18 highly reduced polyketide after 8 rounds of elongation. The polyketide firstly loads 
on the ACP domain of PKS. The A domain of NRPS activates the Trp, and the active Trp bind to 
PCP domain. The C domain of NRPS catalyses the condensation of amino acid and polyketide. 
Finally the reduction (R) domain catalyzes a reductive release  (Scheme 1.4.2.1).[45] 
 
 
































Scheme 1.4.2.1 Example of PKS-NRPS. 
 
Here, the natural products from fungi such as tenellin 3 and its related compounds bassianin 40 
and militarinone C 42, cytochalasins 43, equisetin 41 and pseurotin A 44 are examples to explain 






















































Fig. 1.4.2.1 Examples of hybrid PKS-NRPS compounds, the NRPS part is highlighted in red. 
 




1.5 The alkyl citrates – an overview. 
The generic term ‘alkyl citrate’ is proposed to encompass biosynthetically-related compounds 
where a citrate synthase (CS) like enzyme is involved in the biosynthetic pathway. These CS 
enzymes can combine oxaloacetic acid 45 and polyketides (or fatty acids) to form an alkyl citrate 
structure.   
 
 
Scheme 1.5.1 Citric acid cycle. 
 
Citrate synthase is a key enzyme in the primary metabolism citric acid cycle catalysing an 
irreversible step during primary metabolism. It catalyses the condensation of oxaloacetic acid 45 
and acetyl-CoA 46 forming a citrate 47 (Scheme 1.5.1).[46, 47] Natural product pathway such as 
those involved in alkyl citrate and maleidride biosynthesis also contain CS-like enzymes. These 









Maleidrides are a large group of alkyl citrates which contain a maleic anhydride in the structure. 
The collective name “nonadrides” was introduced by Barton and Sutherland for fungal 
metabolites which containing the core structure of at least one maleic anhydride unit fused on a 





































































































R = H  glaucanic acid
R = OH  glauconic acid
R1 = H  R2 = H byssochlamic acid
R1 = H  R2 = OH 1-hydroxybyssochlamic acid
R1 = OH  R2 = H 10-dihydrobyssochlamic acid
heveadride
R1 = O  R2 = O epiheveadride
R1 = O  R2 = H, OH  dihydroepiheveadride
R1 = O  R2 = H, H  deoxoepiheveadride
R1 = H, H  R2 = H, H  tetrahydroepiheveadride
R1 = OH, H  R2 = H, H  deoxodihydroepiheveadride
R1 = O  R2 = H, H  dideoxoepiheveadride
castaneiolide R = H  scytalidin
R = OH  deoxyscytalidin
R = H, OH rubratoxin A
R = O rubratoxin B
phomoidrideA phomoidrideB
R = H  bornexistin
R =  OH  1'-hydrcxyornexistin
zopfielin viburspiran
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Glaucanic 50 and glauconic 51 acids were the first two compounds isolated from the fungus 
Penicillium glaucum by Wijkamn in 1931.[49] Byssochlamic acids (1, 48 and 49) were found by 
Raistrick and Smith in the fungus Byssochlamys fulva in the 1930. Its structure was elucidated in 
the 1960s,[50] and the structures of its isomers glaucanic acid 51 and heveadride 52 were also 
elucidated at that time. Later, other nonadrides related to heveadride were also identified, for 
example, epiheveadride 53, dihydroepiheveadride 54, deoxoepiheveadride 55, 
tetrahydroepiheveadride 56, dideoxoepiheveadride 57 and deoxodihydroepiheveadride 58.[51, 52] 
From Macrophoma castaneicola castaneiolide 59 was isolated, and from Scytalidium sp. 
scytalidin 60 and its dehydroxyanalogue 61 also indentified.[53-55] In 1999, Baldwin and coworkers 
isolated phomoidrides A 64 and B 65 at the Pfizer Central Research Laboratories from an 
unidentified fungus. These two compounds are inhibitors of squalene synthase and the Ras-
farnesyl transferase.[56, 57] Rubratoxins [58, 59] A 62 and B 63 are produced by P. rubrum. 
Cornexistin 66 and 1’-hydroxycornexistin 67 produced by Paecilomyces variotii, are potent wide-
specturm herbicides against weeds but with low activity against maize.[60] In addition to 9 
membered carbocyclic rings fused to one or two maleic anhydrides, there are also 8-membered 
rings (octadrides) like zopfiellin 68[61] and viburspiran 69.[62, 63] In 2015, Cox and coworkers found 
two novel 7-membered heptadrides, agnestadride A 70 and B 71 from Byssochlamys fulva.[2] In 
summary, the compounds from 48 to 71 use two anhydrides to form 7, 8 and 9- membered 
carbocyclic rings. 
In nature, maleic anhydride units are not only seen from the dimerized carbocyclic rings. 
Some compounds are linear compounds with a few maleic anhydride units in the structures like 
cordyanhydrides A 72, B 73 and C 74.[64] Furthermore, maleic anhydride units sometimes 
combine with other natural product structures, for example Lienhwalide A 75 and B 76 are the 
compounds which combine one maleic anhydride unit with a tropolone structure. Two 
sporothriolide-related compounds (77, 78, 79) were obtained from an extract of the fungus 
Hypoxylon monticulosum CLL- 205, isolated from a Sphaerocladina sponge collected from the 
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Squalestatin is an alkyl citrate compound which contains a citrate unit in its structure. Squalestatin 
S1 7 first discovered in 1992, is a heavily oxidized fungal polyketide that offers potent cholesterol 
lowering activity.[67] Many different squalestatins like zaragozic acid C 81 and zaragozic acid B 
82 have been isolated from more than ten taxa of filamentous fungi, mostly varying in the attached 
1-alky and 6-O-acyl side chains (Fig. 1.5.2.1).[68] Squalestains share a 2,8-dioxobicyclic octane-
3,4,5- tricarboxyclic acid core. The biosynthesis involves the production of two polyketides: a 
hexaketide initiated by benzoate; and a tetraketide produced by a hr-PKS. The other carbon atoms 



































polyketide arm B (Loaded by acyltransferase)
polyketide arm A (forming the core)








The viridiofungins also belong to the family of alkyl citrates. The structural element of citric acid 
is present in viridiofungins A-C (2, 84, 85), A1-4 (86, 87, 88 and 89), B2 90 and Z2 91, obtained 
from the solid fermentation of T.viride (Fig. 1.5.3.1).[6, 70] Viridiofungins have different numbers 
of carbon atoms on the lipophilic tail attached at the 2-position of citric acid. At the same time, 
viridiofungins are distinguished by the presence of an aromatic amino acid moiety in their 
structures.[71]  
The viridiofungins have potent, broad spectrum antifungal activity and were found to 
inhibit the yeast and rat squalene synthases at the micromolar level. Viridiofungins are also 
nanomolar inhibitors of the first enzyme in the sphingolipid biosynthetic pathway, serine 
palmitoyltransferase, and that inhibition of sphingolipid synthesis accounts for their antifungal 
activity.[4, 72] 
The previous research on viridiofungins has been focused on natural product isolation and 
structure elucidation, biological activities and total synthesis. However, the biosynthetic pathway 
of viridiofungins is still unknown. 









viridiofungin A : R = H, R' = OH
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Fig. 1.5.3.1 Structures of viridiofungins. 
 
1.6 Biosynthesis of Maleidrides 
The biosynthesis of maleidrides is known to proceed in three basic steps, namely: early steps for 
maleic anhydride monomers; middle step for dimerization and the late tailoring steps. In 1965, 
Barton and Sutherland described that nonadrides such as byssochlamic acid 1 and glaucanic acid 
50 are constructed from two indentical C9 units.[73] The C9 units are known to be maleic anhydride 
monomers. Barton et al also proposed that the combination of the two C9 units may involve an 
anionic-type coupling mechanism which would furnish glaucanic acid 50 with the two ethylenic 
linkages in the correct positions.[74] However, compounds like phomoidrides 64, 65, rubratoxins 
A and B (62 and 63) and castaneiolide 59 are not dimerised by C9 units, but these compounds are 
also proposed to use similar dimerization mechanism as glaucanic acid 50 with different chain 
length of maleic anhydride monomers. 
The earliest evidence for the biosynthesis of the monomers and the dimerization steps 
mostly come from feeding experiment and chemical synthesis of the putative substrates. 
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With the development of genome sequencing technology, gene clusters of byssochlamic acid 1, 
cornexstin 66, rubratoxins A and B (62 and 63) and phomoidrides 64 and 65 have been found, 
and much more information about the biosynthesis of maleic anhydride monomers (section 1.6.1) 
and dimerization (section 1.6.2) have been obtained from gene knock-out experiments, 
homologous expression experiments, and in vitro assays. 
 
1.6.1 Early steps for maleic anhydride monomers. 
Before the availability of genome information, labelling experiments to introduce small labelled 
molecules into the pool of primary metabolites in producing strains was a good way to explore 
the biosynthesis. Barton et al used [1-14C] and [2-14C]-acetate in feeding experiments in P. 
purpurogenum, which resulted in the production of radiolabelled glauconic acid 50. Furthermore, 
the result indicated that C9 maleic anhydride was a hybrid unit containing two chains of C3 and 
C6 respectively. The C6 unit was confirmed to come from a polyketide or fatty acid. The C3 unit is 
derived from oxaloacetate.[73, 75, 76] Holker carried out a feeding experiment by adding [2,3-13C2]-
succinic acid to P. purpurogenum. The results confirmed that the succinic acid was incorporated 
into the C3 unit.[77] Another feeding experiment carried out by Sulikowski et al. on phomoidride 




































Scheme 1.6.1.1 Biosynthetic pathway of maleic anhydride monomers. 
 
Although feeding experiments gave hypotheses that the monomers are formed from the 
combination of polyketide/ fatty acid and oxaloacetate, the biosynthetic details were still unclear. 
In 2015 the Oikawa group reported a possible gene cluster for phomoidride B 64 from the 
unidentified fungus ATCC 74256. The BGC encodes one highly reducing polyketide synthase 
(phiA), a citrate synthase (phiJ) and a 2-methylcitrate dehydratase like enzyme (phiI). These three 
genes were transformed into A. oryzae.  The transformant AO-phiAIJ produced a new metabolite 
which have an identical UV abosorption (λmax 312 nm) for maleic anhydride conjugated with an 
olefin.[61] 
The Oikawa group also expressed phiJ and phiI in E. coli and carried out an in vitro tests 
using polyketide CoA and oxaloacetate as substrates. They added PhiJ and PhiI at the same 
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time, which resulted in a maleic anhydride product. The in vivo and in vitro results from the 
phomoidride B 64 gene cluster show that the PKS synthesizes a polyketide 94, the citrate synthase 
uses oxaloacetate 45 and polyketide as substrates to synthesise the citrates 95 and the dehydratase 
forms the alkene citrate 96 (Scheme 1.6.1.1).[61] 
 
1.6.2 Dimerization step of maleidrides. 
The study of dimerization steps during nonadrides biosynthesis started with feeding experiments. 
Sutherland et al carried out a feeding experiment on P. purpurogenum to explore glaucanic acid 
50 dimerization. They directly used labelled maleic anhydrides [1-3H]-2-n-butyl-3-methylmaleic 
anhydride 97 and [7-14C]-2,3-n-butenyl-3-methylmaleic anhydride 98 to feed the fungus, and 50a 
and 50b were formed (Scheme 1.6.2.1). [73] The results demonstrated that the incorporation 
happened at the positions that were expected for the product of head-to-head dimerization of the 
































Scheme 1.6.2.1 Labelled maleic anhydride feeding experiment on. 
 
Holker also carried out a labelling experiment using [2,3-13C2]-succinate 99 in P. purpurogenum. 
The 13C NMR spectrum of glauconic acid 102 showed the presence of two paris of split and 
enhanced signals corresponding to 13C-15, 13C-16 (J= 33 Hz) and 13C-6, 13C-7 (J= 48 Hz). This 
result suggested that the intact succinic acid 99 or oxaloacetate 100 was incorporated into the C3 
chain of the nonadride precursor (Scheme 1.6.2.1 A). Furthermore, Sulikowski and co-workers 
also carried out a labelling experiment on phomoidride B 64 in fungus ATCC 74256 with 
[2,313C2]-succinate 103a and [1,4-13C2]-succinate 103b. The 13C NMR showed the enhanced 
intensities of C-12, 13, 14 and 18 resonances, which were the positions expected to be derived 
from 103a. The enhanced intensities of C-27, 29 and 30 positions is from 103b (Scheme 1.6.2.2). 
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In addition, results from feeding with singly [2-13C]-104a or doubly labelled [1,2- 13C]-104b (as 
SNAC thiolesters) were in full accordance with the longer C12-chain of the monomer 105. [77] 
 
 
Scheme 1.6.2.2 Labelling studies of maleidrides: A, glauconic acid 50; B phomoidride B 64. 
 
The feeding experiments give some evidence for the dimerization process, but not enough to 
explain the biosynthesis and enzymology of the dimerization step. In 2016 the Cox group 
expressed the B. fulva byssochalmic acid genes in A. oryzae. Byssochlamys fulva also produces a 
novel 7-membered heptadride, agnestadride A 70. By comparing different nonadride BGC from 
different organisms, they found that the BGC always includes genes encoding putative ketosteroid 
isomerase (KI) like enzymes and putative phosphatidylethanol-amine-binding proteins (PEBP). 
In the case of byssochlamic acid 1 there are two sets of KI and PEBP genes. When core early 
genes were expressed, only compounds 110 and 111 were formed. But when they co-expressed 
core genes with the two KI-like enzymes in A. oryzae, byssochalmic acid 1 and agnestadride A 
70 were produced. In addition, when both KI like genes and both PEBP like enzymes were 
expressed, the production increased more than 10 times.  The results indicated that one set of KI 












































































































Scheme 1.6.2.3 Gene cluster and proposed biosynthetic pathway of byssochlamic acid 1. 
 
According to the in vivo studies, including knockout experiments in the wild type strain and 
heterologous expression in A. oryzae, it was shown that the biosynthesis of byssochlamic acid 1 
and agnestadride A 70 is based on the dimerization of maleic anhydride monomers. The 
precursors for cyclization were formed by an iterative highly reducing fungal polyketide synthase 
followed with a hydrolase (BfL1), a citrate synthase (BfL2) 108, and a 2-methy citrate 
dehydratase (BfL3) 109. In addition, the enigmatic ring formation was catalyzed by two KI (BfL6 
/ 10) and assisted by two PEBP (BfL5 / 9) enzymes. A. oryzae transfomants did not produce 10-
dihydrobyssochlamic acid 112, or agnestadride B 71, while wild type B. fulva did, so it was likely 
that some unspeicifed reductase and dehydratse genes from outside of the currently defined cluster 
were involved (Scheme 1.6.2.3). The A. oryzae transformants can also produce 113 and 114 
which is thought to from the ring-opening of one maleic anhydride moiety.[3]
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1.6.3 Tailoring steps of maleidrides. 
For the simple maleidrides like byssochlamic acid 1, agnestadride A 70 and glaucanic acid 50, 
the dimerization step is the last step to form the final structure. However, there are also more 
complicated maleidrides whose biosynthetic pathways contain more tailoring steps, such as 











































































Scheme 1.6.3.1 Gene cluster and proposed biosynthesis of cornexistin 66. 
 
The biosynthesis of the herbicide cornexistin 66 in the fungus Paecilomyces variotii was 
investigated by full sequencing of its genome in 2017 from the Cox group.[1, 79] Cornexistin 66 is 
different from the other nonadrides, because of the removal of one maleic anhydride moiety. But 
the biosynthesis of the anhydride monomer 110 and the dimerization to form cornexstin 66 should 
be highly similar to that of byssochlamic acid 1. By sequencing and bioinformatics analysis, a 
gene cluster containing core genes pvL11 (PKS), pvL17 (citrate synthase), pvL13 (2-methylcitrate 
dehydratase), pvL14 (KI), and pvR1 (PEBP) was found. At the same time, there are also a lot of 
tailoring genes that might be involved in the pathway. According to the results of knock-out 
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experiments, the Cox group found the final steps of the pathway involve decoration of the carbon 
skeleton of cornexistin by oxygenases encoded by pvL13 and pvL5. These steps involve selective 
hydroxylation at the 6- position of 117 to 118 by a non-heme iron dependent monooxygenase. 
Dehydrogenation of the 2-2’ position of 118 to obtain 119  then occurs (Scheme 1.6.3.1).[1] 
However, the details of the steps from compound 116 to 117 are still unknown. 
In 2017, the Hu group found the BGC which encodes the biosynthesis of rubratoxins 62 
and 63 from Penicillium dangeardii Pitt. The core genes for the monomer formation and the KI-
like and PEBP-like enzymes for dimerization were found in the gene cluster. There are six 
encoded redox enzymes including four α-ketoglutarate- and iron(II)-dependent dioxygenases, one 
flavin-dependent dehydrogenase and the ferric-reductase-like enzyme RbtH. All of these six 
genes take part in the tailoring steps of rubratoxin biosynthesis. RbtB, G, E and U are α-
ketoglutarate- and iron(II)-dependent dioxygenases which could hydroxylate the different sp3 
carbons from compound 121 to 127. And they found that RbtH can regioselectively reduces one 
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Scheme 1.6.3.2 A summary of gene cluster and reactions catalysed by different redox enzymes in the rubratoxin 62 
pathway. 
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1.7 Method for biosynthetic studies 
1.7.1 Genome sequencing.  
Whole-genome sequencing of microorganisms is an efficient way of discovering natural-product 
biosynthetic gene clusters. Illumina sequencing and Oxford nanopore sequencing are two 
common methods for genome sequencing. At the moment, combining the result from Illumina 
sequencing and Oxford nanopore Sequencing is a good way to get longer reads and more precise 
genome data. 
Illumina sequencing methods are based on reversible dye-terminators that enable the 
identification of single bases as they are introduced into DNA strands (Fig. 1.7.1.1 A).[81] Illumina 
gives short reads which are hard to assemble, but great depth which means it is highly accurate. 
In Oxford nanopore sequencing single molecules of DNA can go through the nanopore and be 
sequenced without the need for PCR amplification or chemical labelling of the sample. Nanopore 
sequencing uses electrophoresis to transport an unknown sample through an orifice of diameter 
10-9 meters (Fig. 1.7.1.1 B).[82] Oxford nanopore sequencing gives low depth, which means high 
errors, but very long reads. Combining the two methods is better to give overall, fast, accurate 
and long sequences, which is ideal for finding BGC. 
 
 A            B   
Fig. 1.7.1.1 Diagram of Illumina Sequencing and Oxford Nanopore Sequencing methods: A, Illumina sequencing 
method; B, Oxford Nanopore Sequencing. 
 
1.7.2. Bipartite knockout. 
Target gene knockout is a useful tool to elucidate the biosynthesis of natural products. A 
commonly used strategy to disrupt a gene of interest (GOI) from the biosynthetic gene cluster 
(BGC) is based on stable integration of exogenous DNA into the fungal genome by homologous 





To increase the level of targeted integration of transformed DNA into the genome, a gene 
knockout method has been developed based on the bipartite strategy. The method requires 
transformation with two DNA fragments which overlap in the resistance gene (usually 
hygromycin resistance gene) to reduce the chance of ectopic integration.[84] 
Each of the two overlapping DNA fragments (left and right fragment) are built up from a 
region of the gene targeted for disruption, amplified from gDNA (the blue part), and a region of 
resistance gene (yellow part), amplified from a plasmid which already contains this part (like 
pTHygGS-eGFP). By yeast recombination, a new plasmid will be constructed which can give a 
PCR template (Fig. 1.7.2.1). 
 
 
Fig 1.7.2.1 The bipartite gene knockout strategy. 
 
1.7.3 CRISPR-Cas9 gene editing. 
Because sometimes bipartite knockout is not an efficient method for the creation of  the real K.O 
transformants, gene editing methods like the CRISPR-Cas9 systems are good choices to try. 
CRISPR is an abbreviation of Clustered Regularly Interspaced Short Palindromic Repeats.  The 
CRISPR/Cas system is a prokaryotic immune system which protects the cell from the invasion of  
virus particle.[84]  In bacteria, there are three steps for CRISPR-Cas9 working with virus. First of 
all, when the virus invades the cell, the Cas protein like CAS1 and CAS2 can cut a DNA fragment 
(protospacer) on the foreign DNA, and integrate the protospacer into the original CRISPR 
sequence (Fig.1.7.3.1 a). Then the new CRISPR sequence from the first step transcribes into pre-
crRNA and tracrRNA (a sequence binds to crRNA), and they will assemble with Cas9 protein 
finally change into mature CRISPR-Cas9 system (Fig.1.7.3.1 b). The complex 
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will work on the foreign DNA to cut it up (Fig.1.7.3.1 c). Fig.1.7.3.1 d is an example of the use 
of CRISPR-Cas9 to introduce a donor gene to edit the genome.[86] 
 
 
Fig. 1.7.3.1 The working mechanism and the application of CRISPR-Cas9 system. 
 
In recent years,  several methods to apply CRSPR-Cas9 technology in filamentous fungi have 
been published.[87-89] Amongst the first is a single vector based method developed by Nϕdvig et 




Post-transcriptional gene silencing is a method of gene interference which relies on degradation 
of targeted mRNA, intercepting transfer of genetic information between the transcriptional and 
translational machinery. Gene silencing has been extensively used in studies of gene function,[90-
92] and has been successfully applied to the characterisation of fungal genes controlling polyketide 
biosynthesis such as chaetoglobosin A  in Penicillium expansum and bikaverin  in Fusarium 




The most commonly exploited pathway leading to post-transcriptional gene silencing is the 
RNA interference (RNAi) system (Fig. 1.7.4.1). Initiation of RNAi is usually via introduction of 
double stranded RNA (dsRNA), a form of RNA generally aberrant to eukaryotic organisms, but 
common in viruses, [95] and from transcription of the inverted repeat regions of transposons.[90] As 
a defense against these invasive genetic parasites the RNAi pathway relies minimally on two 
proteins, Dicer and Argonaute. Dicer is an RNAse which degrades dsRNA into short, 21-22 bp 
fragments known as small interfering RNA (siRNA).[96] These siRNA fragments bind to 
Argonaute as part of the RNA-induced silencing complex (RISC)[97] which, guided by the anti-
sense component of the siRNA, seek out and catalytically degrade complementary mRNA. 
 
Fig. 1.7.4.1 The RNA interference pathway. 
 
Activation of the RNAi pathway can be achieved directly by introduction of siRNA to the 
organism of interest or by incorporation of a transgene expressing targeting RNA. The simplest 
form of targeting RNA is antisense to the sequence to be downregulated (asRNA). If asRNA can 
diffuse to its sense partner before it reaches the ribosome the two complementary strands anneal, 
forming dsRNA and removing the target from the mRNA pool.[98] 
Annealed dsRNA will also function as a substrate for Dicer and activate the RNAi pathway 
for catalytic degradation of targeted mRNA. However, this method is limited by the requirement 




due to formation of strong RNA secondary structure. Strategies have been designed to increase 
dsRNA levels, including vectors which express both sense and antisense sequences from the same 
locus, and constructs expressing a hairpin RNA with both sequences on the same transcript.[99] 
These advanced methods can be considerably more effective than a simple asRNA approach, but 
at a cost of more complex vector construction (Fig. 1.7.4.2). 
 
 
Fig. 1.7.4.2 Two different strategy for silencing. 
 
1.7.5 Heterologous expression. 
To explore the biosynthetic pathway of the natural products, heterologous expression is also a 
very useful tool. Heterologous expression hosts for secondary metabolites or specific enzymes in 
the biosynthetic pathway include E. coli, yeast and some fungi like A. oryzae and T. reesei. 
Compared to E. coli and yeast expression systems, fungi have the advantage of being able to 
heterologous express multigene clusters. E. coli and yeast have the disadvantage that, they cannot 
process eukaryotic introns and often possess a significant codon bias. Bacteria also have 
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difficulty in correctly folding fungal polypeptides. So E. coli and yeast are better to overexpress 
proteins for in vitro study. 
The first successfully expressed complete multigene fungal cluster was the tenellin 3 gene 
cluster in 2010.[100] The biosynthesis of tenellin was reconstituted by expressing four genes 
responsible for the production of tenellin in an arginine auxotrophic A. oryzae M-2-3 strain. Latter, 
more and more complete and partial biosynthetic pathways have been expressed in fungi such as 
that encoding byssochlamic acid 1 and squalestatin 7 biosynthesis.[3, 101] 
 
 
Fig. 1.7.5.1 Cartoon example for heterologous expression in A. oryzae. 
 
A. oryzae strain NSAR1 is deficient of arginine (∆argB), sulphate reductase (sC-), adenine (adeA-) 
and ammonium (niaD-) metabolism which enable its use as a multi-selection marker system. In 
addition, the natural sensitivity of A. oryzae NSAR1 towards the antibiotics bleomycin and the 
herbicide glufosinate (bleR and bar) can be two more selection markers. The pTYGS vectors are 
a series of fungal expression vectors which are available with all of the auxotrophic and sensitive 
selection markers (argB, sC, adeA, niaD, bleR and bar) containing four sets of fungal 
promoter/terminator (P/TamyB, P/Tadh, P/TgpdA and P/Teno), so A. oryzae strain NSAR1 and the 
vectors are enough for the heterologous expression of up to 16 individual genes.[102]
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1.8 Overall aims. 
The main aims of this thesis is trying to understand the biosynthesis of alkyl citrates produced by 
filamentous fungi: viridofungin 2 and byssochlamic acid 1. At the same time, programming of 
hr-PKS (TenS) from tenellin 3 biosynthetic pathway will also be explored by domain swap 
experiments. 
Using most up to date methods for natural product biosynthesis such as gene knockout, 
RNA-interference based silencing, CRISPR-Cas9 gene editing, in vivo study of heterologous 
expression in A. oryzae and T. reesei and in vitro studies with E. coli and yeast expression should 
uncover the functions and mechanism of genes involved in the three biosynthetic pathways. 
 In particular, the viridiofungin 2 project is focused on finding more evidence on the 
biosynthesis of the citrate and amino acid moieties in the structure. In addition, the oxidation of 
C-13 is also unknown. 
For the byssochlamic acid 1 project, more effort will be put into understanding the exact 
substrate and stereochemistry of citrate synthase and 2-methyl citrate dehydratase. The chemical 
property of the maleic anhydride monomer and the dimerization mechanism of maleidrides will 
additionally be explored by in vitro study.  
Finally, the tenellin 3 project will focus on the research of the molecular basis of 
methylation and chain-length programming in fungal iterative highly reducing polyketide 













Chapter 2. Exploring the Biosynthetic Pathway of Viridiofungin 
2.1 Background and aims of the project 
2.1.1 Introduction  
The previous researches on viridiofungins were focused on natural product isolation and structure 
elucidation, biological activities and total synthesis. However, the biosynthetic pathway of 
viridiofungins is still unknown. Based on structure analysis (section 1.1.1), viridiofungin 2 
belongs to the family of alkyl citrates. The alkyl citrate moiety is made by the condensation of a 
fatty acid (or polyketide) and oxaloacetate, catalyzed by a citrate synthase-like enzyme (CS). This 
kind of CS belongs to secondary metabolism (section 1.5.3). Hexylaconitic acid 128, oryzines 
129/130, pilifomic acid 131, byssoclamic acid 1, cornexstin 66 and squalestatin 7 are known to 
be created by alkyl citrate biosynthetic pathways (Fig. 2.1.1.1). The biosynthesis of these 
compounds should be similar in the early steps with viridiofungin. 
 























































Fig. 2.1.1.1 Examples of alkyl citrate (oxaloacetate part in red). 
 
The Pham group reported a possible hexylaconitic acid 128 biosynthetic gene cluster in A. niger 
NRRL3. They performed BLASTP to locate orthologous gene clusters using the sequences of 
fungal fatty acid synthase and the citrate synthase. The orthologous gene cluster contained FAS 
genes (akcA and akcD) as well as CS (akcB) and DH (akcC) genes (Scheme 2.1.1.2).[103, 104] AkcA 




of the fatty acyl CoA 132 and oxaloacetate 45. Then citrate product 133 is then dehydrated by 
AkcC to form 128.  By overexpressing the transcription regulator (akcR), the Pham group 
obtained hexylaconitic acids 128. When they overexpressed both cis-aconitate decarboxylase 
gene cadA (this gene is outside the hexylaconitic acid cluster in A. niger NRRL3) and akcR 
together, the products shifted the profile of alkylcitrates production from hexylaconitic acids (red) 
128 to mainly hexylitaconic acid (blue) 134/136 (Scheme 2.1.1.1). This study showed that 
phylogenomic analysis together with experimental manipulations (introduction of a 
decarboxylase) can be used to reconstruct a more complete biosynthetic pathway in generating a 
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Scheme 2.1.1.1 Proposed biosynthetic pathway of hexylaconitic acid.  
 
Other examples of FAS based alkylcitrate biosynthetic pathway are involved in the biosynthesis 
of oryzine A 129 and pilifomic acid 131.[105, 106] The Cox group discovered two new metabolites 
in extracts of A. oryzae M-2-3 with an unusual maleidride backbone, which were named oryzine 




(oryfasA and B), citrate synthase (CS), 2-methy citrate dehydratase (oryR) and a decarboxylase 
(oryM), with a series of tailoring other genes in the BGC. Like hexylaconitic acid A 128, the 
biosynthesis of the oryzines 129 also appears to use a C8 fatty acid 137 to produce the basic 
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Scheme 2.1.1.2 Proposed biosynthetic pathway of oryzine A 129 and B 130. 
 
As demonstrated in section 1.3 and 1.4, the core structures of byssochlamic acid 1, cornexstin 66 
and squalestatin 7 are also derived from the condensation of a secondary metabolism CS (Fig. 
2.1.1.2).[1, 3, 100] However, these three compounds were derived from an hrPKS based biosynthetic 
pathway rather than FAS. The CS is thought to use either a CoA or ACP bound polyketide as 
substrate combining with oxaloacetate to give a citrate intermediate. It was shown that some 
hydrolases (bfL1/ pvL1/ Mfm8 and Mfm10) were involved in these three BGC (Fig. 2.1.1.2). These 
hydrolases could be involved in the PKS off-loading step. The Cox group heterologous expression 
study of byssochlamic acid 1 biosynthesis in A. oryzae indicated that bfL1 is important for the 
production of maleic anhydride.[3] Compared with PKS, fungal FAS is known to be able to 
produce fatty acyl CoAs without the need for a separate hydrolase, which could be directly used 
for the condensation step of CS.[107] This would explain why there is no hydrolase encoded within 





Fig. 2.1.1.2 Gene clusters of different compounds which contain citrate synthase inside. 
 
The most important and interesting part of viridiofungin 2 biosynthesis is the attachment of an 
amino acid to the citrate structure. As far as we know, NRPS or PKS-NRPS systems are the most 
common enzymes which can catalyse the attachment of amino acids to polyketides during 
secondary metabolism.[108-110] Taking tenellin 3 (a PKS-NRPS derived compound) as an example, 
the C domain of the NRPS catalyses the condensation of tyrosine with a polyketide, finally 
producing a pretenellin 144 product (Scheme 2.1.1.3 A).[100] Therefore, a PKS-NRPS or an NRPS 
single domain might be also involved in the biosynthetic pathway of viridiofungin 3 which could 





































Scheme 2.1.1.3 Biosynthesis of tenellin based on PKS-NRPS and prediction of viridiofungin biosynthesis: A, 





Other types of NRPS independent amino acid attachment are known. For example, some enzymes 
have been shown to catalyse the transfer of amino acids from tRNA.[111] Cyclodipepetides are well 
known secondary metabolites synthesized predominantly by microorganisms. For a long time, 
the formation of the cyclodipeptides constituting the diketopiperazines (DKP) scaffolds were 
thought to be catalysed by NRPS. However, in 2002, the biosynthesis of albonoursin 147 was 
shown to involve AlbC which is a small enzyme later characterized as a cyclodipeptide synthase 
(CDPS).[112] AlbC can catalyse the formation of the cyclo (L-Phe-L-Leu, cFL) intermediate 150, 
into which a cyclic dipeptide oxidase (CDO) introduces two α,β-dehydrogenations (Scheme 
2.1.1.4 A).[113] In addition, pulcherriminic acid 152 (further converted into pulcherrimin 153)[114, 
115] and mycocyclosin 156 were also shown that a CDPS involved in their biosynthetic pathways 











































































Scheme 2.1.1.6 Biosynthesis of albonoursin 147, pulcherriminic acid 153 and pulcherrimin 156 based on CDPS: A, 
albonoursin 147; B, pulcherriminic acid 153; C, pulcherrimin 156. 
 
The structure of viridiofungin also indicates that there should be some tailoring genes inclucded 
in the viridiofungin gene cluster. Oxidation at C-13 of viridiofungin might be catalyzed by a P450 
monooxygenase, or it could also be a non-heme iron type of oxygenation as observed in the 
squalstatins 7 [101] or oryzines 129 (e.g. oryG).[105] These enzymes could catalyze oxidation of 
intermediate 157 to form a hydroxyl group 158 or a carbonyl group 2 at C-13 (Scheme 2.1.1.5). 
 








































Scheme 2.1.1.5 Proposed reaction at C-13 position of viridiofungin 
 
Based on these analogies to other known biosynthetic pathways we can predict that a biosynthetic 
gene cluster which encodes the biosynthesis of the viridiofungins should include: genes encoding 
either fatty acid or polyketide production; a gene encoding a citrate synthase; genes encoding 
either a PKS-NRPS or tRNA-dependent transferase; and genes for tailoring processes such as 
cytochrome P450 or non-heme iron oxygenases. 
 
2.1.2 Project aims 
The overall aim of this project is to explore the biosynthetic pathway of viridiofungin. More 
concretely, we want to achieve the goals as follows: 
 
1. Work on the wild type T. viride and find out a suitable condition for reproducing of 
viridiofungin and related compounds. 
2. Obtain the genome data of T. viride and annotate the genes in the genome. 
3. Try to find out the possible gene cluster of viridiofungin by using different 
bioinformatic methods, and analyze the gene cluster to give a prediction of the 
biosynthetic pathway. 
4. Based on the genome data and analysis of the gene cluster, carry out knockout (KO) 
experiments to confirm the gene cluster of viridiofungin. 
5. If the gene cluster is confirmed by KO experiment, heterologous expression work 
will be carried out to express the gene cluster in A. oryzae to get more biosynthesis 
details. 
6. On the other hand, gene editing and gene silencing will also be used for knockout or 
knockdown to analyze the biosynthetic pathway. 
 




2.2.1 Optimization of production conditions 
Trichoderma viride (MF5628, ATCC 74084) was obtained from CBS-KNAW. First of all, 
different media were used to test the producing conditions of viridiofungin in T. viride (section 
5.2).  Because Trichoderma species grow well, all of the cultures were incubated at 28 ℃ and 
160 rpm, in liquid media. 
After 7 days growth, different cultures displayed different colours (Fig. 2.2.1.1). In PDB, 
the fungi produce spores quickly, so the culture turned to green. In YEME, the fungi grow slowly, 
and there were not so many mycelia in the culture. In DPY, a lot of foam was produced. This 
might be because of gas-production. In producing medium (cornmeal medium), the culture was 
not sticky anymore, the cornmeal was digested by fungi. 
 
 
Fig. 2.2.1.1 T. viride grown in different media for 7 days (the producing medium is cornmeal medium). 
 
Time-course experiments were carried out by growing T. viride in different media. Producing 
media (cornmeal medium) was the only one which produced the viridiofungin related compounds. 
The cornmeal in the production medium appears to be important. We found that the strains start 
to produce viridiofungin after 5 days fermentation, and produce most from 7 days fermentation. 
However, if the strain grew for a long time, the products would be oxidised (Table 2.2.1.1).  




Table 2.2.1.1 Time course of T. viride producing condition testing. 
 
100 mL of culture (mixture of media and mycelia) was extracted with 100 mL of ethyl acetate, 
which was dried (MgSO4) and concentrated. The crude extract was dissolved in 1 mL methanol 
and analysed by LCMS.  According to the literature, viridiofungin A is known to have m/z 591, 
and viridiofungin B has m/z 575. According to the LCMS results (Fig. 2.2.1.2), peaks eluting at 
7.9 and 8.9 min corresponded to  viridiofungin A and B respectively. 
 
Fig. 2.2.1.2 LCMS result of producing medium culture: A, extracted ion chromatogram (EIC) ES- 413; B, EIC ES- 574; 
C, EIC ES- 590; D, evaporative light scattering detector (ELSD.) 
 




Fig. 2.2.1.3 MS results of the 2, 84 and 159 peaks. 
 
Compound 2 had [M - H]- 590  (Fig. 2.2.1.2 C) and compound 84 had [M - H]- 574  (Fig. 2.2.1.2 
B) which were consistent with viridiofungin A 2 and B 84 respectively (Fig. 2.2.1.3). The peak 
at 10.7 min [M - H]- 413 (Fig. 2.2.1.2 A and 2.2.1.3 ) corresponds to citrate intermediate 159, it 
had very low concentration which could only be detected by MS. Compounds X mixed with each 
other, but they could also be viridiofungin analogues (Fig. 2.2.1.2 D). 
More detailed analysis of the LCMS data showed that there were more than ten compounds 
eluted in the region between 5 min and 7.5 min (Fig. 2.2.1.4 A). According to the MS result of 
ten major compounds, x1, x2 and x7 had [M - H]- 606. x3 and x4 had [M - H]- 604, x5 and x6 had 
[M - H]- 590, x8 and x10 had [M - H]- 588, and x9 had [M - H]- 592 (Fig. 2.2.1.4 B). These 
compounds are likely to be derivatives of viridiofungin A and B which are produced by various 
tailoring enzymes (Fig. 2.2.1.4 C).  These compounds are more polar than 2 and 84, which is 
consistent with higher levels of oxygenation. The tailoring enzymes could be monooxygenase (+ 
O atom, + 16 m/z), dehydrogenase (± H2, ± 2 m/z), hydratase (+ H2O, + 18 m/z) and dehydratase 
(- H2O, - 18 m/z) and combinations. 
 






Fig. 2.2.1.4 LCMS result of mixture X: A, ELSD; B, MS spectrum; C, structure prediction. 
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2.2.2 Viridiofungin purification and characterization 
Two liters of culture was fermented for 7 days, and 3 L of ethyl acetate was used for extraction. 
Finally, 0.9 g of crude extract was obtained. After pre LCMS purification, 1.2 mg of the peak a 
compound was obtained. The UV spectrum of the compound a eluting at tR = 7.9 min with a 
nominal mass of 591 showed maximum UV absorption at 223 nm (Fig. 2.2.2.1 A), which is 
consistent with the literature data for viridiofungin A 2 (Fig. 2.2.2.2).  
Negative and positive ions provided a nominal mass of 591 ([M - H]-  = 590 and [M + H]+  
= 592). The 13C NMR spectrum showed 28 unique resonances, with two equivalents by symmetry 
(C-24 and C-25) and overlapped carbons (C-12/14), for a total of 31 carbons. Four carbons were 
observed between 172 to 177 ppm which are carboxyl and amide carbons. The acquired 1H NMR 
data were identical to the literature data of  2 (Fig. 2.2.2.3).  
 
 
Fig. 2.2.2.1 UV spectrum of peak 2: A, UV; B, MS spectrum. 
 
 
Fig. 2.2.2.2 Structure of viridiofungin A 2. 
 




Fig. 2.2.2.3 1H NMR spectrum of peak 2. The most identifiable signal was marked with different colors. 
 
In the literature, the placement of the tyrosine at C-22 was suggested by an EIMS fragment ion 
from a trimethyl ester of 2 at m/z 296 resulting from neutral loss of the tyrosine and hydroxy- 
succinic acid moieties. From our experiment, correlation of the tyrosine α-proton to the 172.1 
ppm carbonyl (C-22) of 2 using an HMBC experiment optimized for a 1H-13C multiple bond 
coupling of 4.5 Hz allowed the assignment. In the literature, assignment of the side chain carbonyl 
to C-13 was based upon the observation of an m/z 127 ion in the EIMS of 2 resulting from α-
cleavage yielding the odd mass acylium ion.  
In summary, by analyzing the HMBC data (Fig. 2.2.2.4) and comparing with the data from 
the literature (Table 2.2.2.1), the spectroscopic data of peak 2 was identical with the data of  
viridiofungin A 2, so compound 2 was viridiofungin A 2 produced by T. viride. 




Fig. 2.2.2.4 HMBC spectrum for peak a compound. 
 
 
Table 2.2.2.1 Summary of NMR data of peak a compound and the viridiofungin NMR data from literature. 
position dH /ppm Mult./J dc / ppm HMBC (H to C )
1 – – 174.3 –
2 2.82/2.59 2.82(d, J =15.9Hz,1H); 2.59(d, J =16.2Hz, 1H) 42.5 1, 3, 4, 21
3 – – 76.5 –
4 3.21 3.21(d, J =8.4Hz, 1H) 56.9 5, 6
5 5.59 5.59(m, 1H) 135.3 4, 6, 7
6 5.59 5.59(m, 1H) 124.1 5，7
7 2 2.00(m, 1H) 32.2 5, 6, 8
8 1.31 1.31(m, 2H) 28.7 –
9 1.31 1.31(m, 2H) 28.7 –
10 1.31 1.31(m, 2H) 28.8 –
11 1.55 1.55(m,2H) 23.4 12, 13, 14
12 2.45 2.45(td, J =7.4Hz, 2.9Hz, 2H) 42.1 13,14
13 – – 213.2 –
14 2.45 2.45(td, J =7.4Hz, 2.9Hz, 2H) 42.1 12,13
15 1.55 1.55(m,2H) 23.4 13, 16, 17
16 1.31 1.31(m, 2H) 28.8 –
17 1.31 1.31(m, 2H) 28.9 –
18 1.31 1.31(m, 2H) 31.5 –
19 1.31 1.31(m, 2H) 22.3 –
20 0.92 0.92(t, J =7.0Hz, 3H) 13.1 18, 19
21 – – 177.1 –
22 – – 172.1 –
23 – – 155.6 –
24 7.08 7.08(m,1H) 130.3 25, 26, 27
25 6.67 6.67(m,1H) 114.6 24, 26
26 – – 128.2 –
27 3.10/2.95 3.10(dd, J =13.8Hz, 4.9Hz ,1H); 2.95(dd, J =13.8Hz, 6.8Hz ,1H) 37.1 23, 24, 28
28 4.51 4.51(dd, J =8.7Hz, 5.1Hz, 1H) 55.4 27, 29
29 – – 175.7 –
N-H – 8.54(s, 1H) – –
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As for the peak 84, negative and positive ions provided a nominal mass of 575 ([M-H]- = 574 and 
[M+H]+ = 576) and it had a maximum UV absorption at 224 nm (Fig. 2.2.2.5) which is identical 
with viridiofungin B 84 in literature (Fig. 2.2.2.6).  However, due to the low concentration (0.1 
mg/L, 0.2 mg obtained) of 84, only 1H NMR data was obtained, which is consistent with literature 
data for viridiofungin B (Fig. 2.2.2.7). 
 
 




Fig. 2.2.2.6 Structure of viridiofungin B 84. 
 




Fig. 2.2.2.7 1H NMR spectrum of compound 84. The signal from benzene was marked with red. 
 
2.2.3 Genome sequencing, bioinformatics and development of a biosynthetic hypothesis 
2.2.3.1 gDNA extration 
Studying the biosynthesis of a natural product usually starts with genomic DNA extraction and 
genome sequencing. In this part of work, GenElute Plant Genomic DNA miniprep kit (Sigma) 
was used to extract gDNA from 0.5 g frozen dried mycelia of Trichoderma viride.  
The concentration of the obtained gDNA was 150 ng/µl (total volume 120 µl). The 
A260/A280 value was 1.79, and the A260/A230 value was 2.37. Agarose gel electrophoresis analysis 
of gDNA showed a single band (Fig. 2.2.3.1). The quality of the gDNA was good enough for 
sequencing. The gDNA sample was sent for Illumina and Oxford nanopore sequencing. 
 
 
Fig. 2.2.3.1 1% agarose gel electrophoresis analysis of gDNA 
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2.2.3.2 ITS PCR  
Internal transcribed spacer (ITS) refers to the spacer DNA situated between the small-subunit 
ribosomal RNA (rRNA) and large-subunit rRNA genes in the chromosome or the corresponding 
transcribed region in the polycistronic rRNA precursor transcript. Because ITS is quite specific 
from every single species of fungi, it can be considered as a fingerprint of one fungus.[117, 118] So 
ITS PCR was performed in this part of work to make sure the species of Trichoderma viride. 
According to ITS sequence alignment, we could find out whether a transformant was from the 
original strain. 1% agarose gel electrophoresis analysis showed one single ITS PCR product (Fig. 
2.2.3.2 A). 
The PCR product was sequenced and a phylogenetic tree was built (Fig. 2.2.3.2 B). The 
result was compared to ITS sequences from Aspergillus, Penicillium, Hypocrea and Trichoderma 
species, which were downloaded from GeneBank. The ITS sequence of T. viride ATCC 74084 
has not been previously reported, however, our results show that it clusters closely with the ITS 
sequences of other known T. viride strains (Fig. 2.2.3.2). 
 
A              B  
Fig. 2.2.3.2 ITS analysis: A, 1% agarose gel electrophoresis analysis of ITS PCR product; B, a neighbor-joining tree 
derived from the nucleotide sequences of ITS sequences from different fungus. 
 
2.2.3.3 Genome sequencing and gene cluster prediction  
Genomic DNA (gDNA) of T. viride was obtained by GenElute Plant Genomic DNA miniprep kit 
extraction of freeze-dried fungal mycelia (taken from 3 d old PDB liquid culture). The gDNA was 
sequenced with Illumina technology. The raw data were processed by Dr Daniel Wibberg using 
an in-house software platform based on CASAVA 1.8.2.[119] The sequenced 300 bp reads were 
assembled with gs Assembler 2.8 with default setting.[120] From genome assembly data, the 
genome size of T. viride was estimated as 35.9 MB.  This is similar to the average size of fungal 
genomes (31.4 MB). GC content was 48.95%, which was within the normal range for fungal 
 AY380904.1 Trichoderma vinosum strain GJS 99-158
 AY380908.1 Trichoderma viride strain CBS 101526
 AY380909.1 Trichoderma viride strain ATCC 28038
 FJ904855.1 Trichoderma viride strain Gr135
 EU732725.1 Trichoderma viride isolate NW536
 Trichoderma viride MF 5628 ATCC 74084
 NR 138448.1 Trichoderma turrialbense CBS 112445
 NR 134372.1 Trichoderma arundinaceum ATCC 90237
 KX100362.1 Hypocrea sp. Sib4-3-6
 KX100361.1 Hypocrea sp. ID2-3
 JX091426.1 Penicillium annulatum strain CV37
 JX091454.1 Penicillium hirayamae strain CV916
 JX091453.1 Penicillium hirayamae strain CV887
 EU680476.1 Aspergillus oryzae strain 112822












Ⅱ Genome sequencing 
 
50 
genomes (32-56%). 100 scaffolds were obtained from the assembly data.  N50 is a statistic used 
to assess the quality of genome assemblies. Although, there is no minimum value of N50 to 
determine whether an assembly is of good or bad quality, N50 of the T.viride sequencing was 108 
kb. It means half of the genome was within contigs of sufficient size to encompass complete gene 
clusters which average around 30 kb in fungi (Table 2.2.3.1). However, these values were lower 
than in some other finished genomes, such as Sporothrix schenckii (N50 4.3 MB),[121] Sporothrix 
brasiliensis (N50 3.8 MB),[122] Grosmannia clavigera (N50 1.2 MB) [123] and Penicillium 
griseofulvin (N50 2.8 MB).[124] 
Because a secondary metabolism CS is considered to be involved in the biosynthetic 
pathway of viridiofungin, the CS genes from the squalestatin 7 BGC (mfr3) and byssocolamic 
acid 1 BGC (bfl2) were chosen to search the genome data (at DNA level). Three citrate synthase 
– encoding genes were found: Tcirideg1094.t1 was predicted to be a mitochondrial CS; 
Tcirideg8362.t1 was a predicted 2-methylcitrate synthase which was also likely to be from 
primary metabolism. Tvirideg7173.t1 was predicted to be the most likely secondary metabolism 
CS enzyme. It is similar to CS from the Squalestatin 7 and Maleidrides 1 BGC. However, Illumina 
Sequencing data was not good quality enough to obtain the whole gene cluster of viridiofungin 2. 
Because the CS gene was exactly at the terminus of one scaffold, and it was difficult to find the 
other part of the cluster because of the limited information about the biosynthesis of viridiofungin 
2. 
To get better genome data, the genome was sequenced again. This time the Oxford 
nanopore method was chosen for sequencing. Therefore higher quality and longer gDNA was 
needed.[125] After genome sequencing and assembly, 52 contigs were obtained with an N50  of 2145 
kb, and 35 of these contigs were more than 50 kb (Table 2.2.3.2). Then the Oxford nanopore 
genome data was polished with Illumina data, finally, a good quality genome data was obtained. 
 
Sequencing method Total contigs/ scaffolds N50 (kb) 
Oxford nanopore 52 contigs 2145 
Illumina 100 scaffolds 108 
Table 2.2.3.1 Summary of genome assembly in T. viride genome 
 
The whole sequencing data was submitted to antiSMASH online software and database for gene 
cluster analysis (https://fungismash.secondarymetabolites.org).[126] There were 32 possible PKS, 
NRPS and terpene related gene cluster found in the genome of T. viride (Table 2.2.3.2). But there 











Table 2.2.3.2 Summary of gene cluster prediction by antiSMASH. 
 
After bioinformatic analysis and annotation of the genome based on InterPro,[127, 128] one gene 
cluster was found to be the possible gene cluster of viridifungin. Firstly, CS like enzymes involved 
in the secondary metabolism were searched in the genome. Three citrate synthase like genes were 
found in the genome (Tcirideg1094.t1, Tcirideg8362.t1, Tvirideg7173.t1), but only one namely 
Tvirideg7173.t1 was not from primary metabolism. A 20 kb genomic DNA fragment, centred on 
Tvirideg7173, was then selected for more detailed manual annotation. Twelve open reading 
frames were found using the software pBlast (Table 2.2.3.3). The cluster was not recognized by 
Fungi SMASH, because it does not contain genes encoding core synthases such as PKS, FAS, 
NRPS or terpene cyclase. If the biosynthesis used a fatty acid from primary metabolism then the 
associated BGC would not have to encode a FAS or PKS.  
 
Original name Gene Protein 
protein 
size(AA) 




Tvirideg7169.t1 tvL4 TvL4 435 cytochrome p450 monoxygenase  NAD(P) 
Tvirideg7170.t1 tvL3 TvL3 402 acyl-CoA oxidase  FAD 
Tvirideg7171.t1 tvL2 TvL2 192 NAD dependent dehydrogenase  NAD(P) 
Tvirideg7172.t1 tvL1 TvL1 288 multidrug resistance transporter / 
Tvirideg7173.t1 tvCS  TvCS 366 citrate synthase  / 
Tvirideg7174.t1 tvR1 TvR1 247 unknown / 
Tvirideg7175.t1 tvR2 TvR2 401 Flavin monooxygenase  
FAD and 
NADP 
Tvirideg7176.t1 tvR3 TvR3 208 nucleotide phosphatase  
divalent 
metal cation  
Tvirideg7177.t1 tvR4 TvR4 659 glutamate-tRNA ligase  ATP 
Tvirideg7178.t1 tvR5 TvR5 291 translational repressor protein / 
Tvirideg7179.t1 tvR6 TvR6 298 COG complex component / 
Tvirideg7180.t1 tvR7 TvR7 627 transcriptional regulator / 
 





Tvirideg7173.t1 is the core gene CS, and a “tRNA ligase” like enzyme was involved in this gene 
cluster. This “tRNA ligase” like enzyme was considered to be related to the amino acid linkage 
step. Moreover, some oxygenase (tvL4 and tvR2) and a dehydrogenase (tvL2) were also found in 
the gene cluster. Upstream of the CS, there are three potential regulators (tvL 5/ 6 and 7), and a 
potential transporter (tvL1) which might be involved in resistance to viridiofungin. Moreover, 
there is a possible acyl-CoA oxidase (tvL3) and a putative nucleotide phosphatase (tvR3) encoded 
by the gene cluster (Table 2.2.3.3). 
The amino acid sequence of the gene CS and “tRNA ligase” like enzyme were submitted 
to pBLAST online software to analyse the function and feature of the enzymes (Fig. 2.2.3.3). A 
conserved database (CDD) analysis clearly showed that the protein belongs to the CS_ACL-
C_CCL superfamily. Sequence alignment revealed the conserved active site and CoA binding site. 
 
 
Fig. 2.2.3.3 Graphical summary of CS enzyme BLAST result 
 
Based on pBLAST results, sequences with high similarities were chosen to build an evolutionary 
tree.  Different CS sequences from primary metabolism (E. coli, Aurantimicrobium mintutum, 
Geitlrinema sp., T. thermophilus and P. furiosus) and 2-methyl-citrate synthase from S. 
typhimurium were downloaded from GeneBank.  In addition, various CS sequences from 
secondary metabolism (B. fulva (BfL2), P. divaricatus (PvL7) and Phoma sp. MF5453 (MfR3) 
and TvCS of T. viride) were also chosen to build up a phylogenetic tree.  According to the 
neighbor-joining tree of different CS and 2-methyl-citrate synthase, TvCS from T. viride had the 
closest evolutionary relationship with the CS from the squalestatin 7 biosynthetic pathway (green). 
Two CS (BfL2 and PvL7) from maleidride biosynthetic pathway had closest relationship (blue). 
Four CS from secondary metabolism had relatively far evolutionary relationship with the ones 
from primary metabolism (red). The bacterial 2-methyl-citrate synthase (yellow) had the farthest 






Fig. 2.2.3.4 A neighbor-joining tree derived from the amino acid sequences of CS and 2-methyl-citrate synthase from 
secondary and primary metabolism. 
 
According to the structural imformation from the primary metabolism T. thermophilus, His-274, 
His-320 and Asp-375 are the conserved residues in the active site.[129]  The amino acid sequences 
of primary metabolic CS from P. furiosus and E. coli (crystal structure already known), as well 
as secondary metabolic CS from B. fulva (BfL2), P. divaricatus (PvL7) and Phoma sp. MF5453 
(MfR3) were aligned using ClustalX. The CS have high similarity with each other, especially the 
residues nearby the active sites (red line). The results indicate that the three residues (Fig. 3.2.8.1 
black frame) in the active site are conserved in both primary and secondary metabolic CS. 
 
Fig. 3.2.8.1 Multiple alignment of primary metabolic and secondary metabolic CS sequences. Red highlight = 100% 
similarity; Yellow highlight = more than 60% similarity. 
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TvR4 is a “tRNA ligase” like enzyme which belongs to the nucleotidyltransferase superfamily. 
This superfamily includes the class I amino-acyl tRNA synthetases, pantothenate synthetase 
(PanC), ATP sulfurylase, and the cytidylyltransferases, all of which have a conserved 
dinucleotide-binding domain.[156] TvR4 also contains a conserved active site  HIGH motif, and 
KMSKS motif for ATP binding  (Fig. 2.2.3.4). But TvR4 has a longer amino acid sequence than 
normal tRNA ligases, meaning that TvR4 might contain other active domains which could 
catalyse other reactions. 
 
 
Fig. 2.2.3.4 Graphical summary of TvR4 BLAST result 
 
2.2.3.3 Biosynthetic pathway prediction  
As is described in section 2.1.1, in nature, there are some NRPS independent processes that add 
amino acids to other molecules. In the proposed viridiofungin gene cluster, a “tRNA ligase” like 
enzyme (TvR4) and a nucleotide phosphatase (TvR3) could work together with the TvCS. These 
three genes should be the core genes for connection of the amino acid, primary metabolism fatty 
acid 160 and oxaloacetate 45, and additionally release the product from the tRNA (Scheme 
2.2.3.1). Acyl-CoA oxidase could catalyse the formation of the α, β – alkene 161 in the fatty acid 
CoA. The P450 monooxygenase and dehydrogenase are obvious tailoring proteins (Scheme 
2.2.3.1). The fatty acyl CoA 160 and aminoacyl tRNA 162 are from the primary metabolism in 
the T. viride.  
The reason why TvR4 was thought to be a tRNA related enzyme is because of a nucleotide 
phosphatase (TvR3) encoded by the BGC. It could be reasonably explained that TvR3 releases a 
viridiofungin intermediate 157 from a tRNA intermediate 163. Additionally, the P450 
monooxygenase (TvL4) and dehydrogenase (TvL2) could be involved in the tailoring steps to 
form 157 and final product 2 (Scheme 2.2.3.1). 
From this general pathway, a variety of different viridiofungins (section 1.4.3) could be 












































































































Scheme 2.2.3.1 The proposed biosynthetic pathway of viridiofungin 2. 
 
2.2.4 Transformation condition testing  
2.2.4.1 Antibiotic test  
Based on the proposed biosynthetic pathway, a series of knockout experiments were planned. In 
fungi knockouts are normally achieved by inserting a suitable antibiotic resitance cassette into the 
target gene. Antibiotic testing is the first step of the process. Hygromycin is an antibiotic produced 
by the bacterium Streptomyces hygroscopicus, it is an aminoglycoside that kills fungi and higher 
eukaryotic cells by inhibiting protein synthesis.[130] In this part of work, different concentrations 
of hygromycin were used to test the minimum concentration to kill wild type Trichoderma viride. 
Seven different concentrations of hygromycin PDB plates were set up: 0 µg/ml, 25 µg/ml, 
62.5 µg/mL, 125 µg/mL, 187.5 µg/mL, 250 µg/mL and 375 µg/mL. Wild type T. viride was 
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incubated on these plates at 28 ℃ for 10 days . T. viride could not grow on plates that contained 





Fig. 2.2.4.1 Result of Testing of antibiotics. different concentration of hygromycin: 0 µg/ml, 25 µg/ml, 62.5 µg/ml, 125 
µg/ml, 187.5 µg/ml, 250 µg/ml and 375 µg/ml. 
 
2.2.4.2 Preparation of T. viride protoplasts 
Protoplasts are cells that have had their cell wall completely or partially removed using either 
mechanical or enzymatic means. Protoplasts can be used for DNA transformation for making 
genetically modified organisms.[131] Therefore, protoplast preparation is a very important step and 
the first step for knockout experiment and transformation experiment on T. viride. 
In order to get a good number and quality of the protoplasts, different isotonic solutions 
(1.2 M sorbitol, 1.0 M sucrose, 0.8 M MgSO4, 0.8 M NaCl) were tested. The mycelia were 
collected from 2-day-old PDB culture by filtration using sterile miracloth as a filter, then rinsed 
with sterilized distilled water and 0.8 M MgSO4. The mycelia were added to 10 mL of sterilized 
solutions (1.2 M sorbitol, 1.0 M sucrose, 0.8 M MgSO4, 0.8 M NaCl) and 300 mg of Trichoderma 
lysing enzyme and incubated at 30 ℃, 120 rpm. After three hours fermentation, 5 µl of digestion 
solution was checked under the microscope.  
 
 




Fig. 2.2.4.2 Result of 3 h of enzyme digestion in different solutions. 1.2 M sorbitol, 1.0 M sucrose, 0.8 M MgSO4, 0.8 
M NaCl 
 
The results showed that in NaCl and sucrose solutions, no protoplasts appeared; in sorbitol 
solution, only a few protoplasts could be produced; but in MgSO4 solution, a large number of 
protoplasts were observed. So the solution: 0.8 M MgSO4, 20 mM sodium phosphate pH 5.6, was 
then used for the preparation of  protoplasts of T. viride (Fig 2.2.4.2). 
In parallel, different media (PDB, GNB, ME) were used to grow the fungi, and different 
solutions and different digestion times were also checked. T. viride grew most mycelia in PDB 
medium, and it could produce enough protoplasts in 0.8 M MgSO4 solution and digested for more 
than three hours (Table 2.2.4.1). The best condition is as follows: 2g mycelia, digesting solution: 
0.8 M MgSO4, 20 mM sodium phosphate pH 5.6, digesting time: 3 h, temperature: 30 ℃. 
 
 
Table 2.2.4.1 Best condition for protoplast preparing 
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2.2.4.3 Transformation of T. viride 
Trichoderma viride ATCC 74084 has not been reported to have been transformed before. As a 
control transformation we decided to first transform T. viride with a pre-existing eGFPe/hygR 
plasmid already in use in our group. This would allow us to test several aspects of the 
transformation. First it would allow the protoplast mediated protocol itself to be assessed. Second, 
it would test the PgpdA and PamyB promoters used for the hyg
R and eGFP genes respectively. Finally, 
observation of green florescence would confirm correct translation and protein production 
Protoplasts were prepared as section 2.2.4.2, then they were resuspended in 0.5 ml 1M 
sorbitol-10 mM Tris-HCl, pH 7.5. The suspension was diluted 3 times for counting. The 
concentration of protoplast was about 8 × 107 / ml. This concentration was enough for 
transformation (Fig. 2.2.4.3). 
 
 
Fig. 2.2.4.3 Calculate the number of protoplasts. 
 
The protoplasts were transformed with pTH-GS-eGFP, and the transfomants were selected on 
HYG plates. The pTH-GS-eGFP plasmid contains a HYG selection marker expressed from PgpdA. 
The eGFP gene was driven by PamyB with TamyB at the 3’ end (Fig. 2.2.4.4). 
 
Fig. 2.2.4.4 Plasmid map of pTH-GS-eGFP. 
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A PEG-mediated transformation method was used for the T. viride transformation (section 5.2.x). 
After the first round of selection, the transformants grow on the 125 µg/mL HYG PDA plates. 10 
to 20 transfomants were observed on each plate (Fig. 2.2.4.5 A). These transformants were then 
transfered to the second and third round of HYG selection to obtain stable transformants. After 
two rounds of additional selection, 10 out of 40 of the colonies from the first round selection 
survived on the teriary125 µg/mL HYG PDA plates (Fig. 2.2.4.5 B). 
 
A                 B  
 
Fig. 2.2.4.5 Transformants on plate: A, first round of selection; B, third round of selection 
 
Five transformants from the tertiary plate were then grown on PDB agar plates. After 7 days, they 
were grown in liquid medium for 3 days. The mycelia were observed under a microscope with 
UV irradiation. But the result showed that there was no difference between wild type and 
transforments, and there was no detectable florescence. 
Although tansformation was successful, the expression of eGFP was not good enough to 
see under UV. We assumed that this could be because PamyB is not a strong promoter in T. viride. 
Therefore, the next work on expression of T. viride would be change a different promoter to 
improve the expression level. 
 
2.2.4.4 Promoter exchange 
Expression of eGFP in T. viride was not successful, the reason might be that PamyB from A. oryzae 
could not be recognised by T. viride causing no transcription of eGFP. So in this part of the work, 
a promoter Ppki (pyruvate kinase) form Trichoderma reesei was combined with eGFP for better 
expression. 
Ppki is a constitutive promoter in fungi. The pki gene sequences from several other fungal 
species were download from geneBank.  These genes were used to search the T. reesei genome. 
A pki gene was found in T. reesei by using artemis.  4000 bp upstearm sequence of pki gene was 
send to Promoterscan to predict the promoter sequence. From the prediction tool, 600bp of the 
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sequence was recongnised as the promoter. After finding out the sequence of the Ppki, yeast 
recombination (section 5.5.2) was used to clone Ppki upstream of eGFP in the pE-YA plasmid.  
The plasmid pEYA-pki-eGFP was then transformed to E. coli. eGFP primers were then 
used for colony PCR. Because Ppki contains a Not I, five positive colonies of pE-YA-pki-eGFP 
were also confirmed by Not I digestion. All of these 5 colonies were real transformants containing 
Ppki. LR recombination (section 5.7.3) was then performed to get pTYH-GS-pki-eGFP. After LR 
recombination, colony PCR indicated that the vector had been successfully constructed. Then, 
three positive colonies were picked for the plasmid extraction and transformation. Using the same 




Fig. 2.2.4.11 pki-eGFP transformants on secondary plate fragmentst transformation 
 
After 3 days growth in PDB medium, the florescence of mycelia was detected under 
microscope with UV (Fig. 2.2.4.12). pik-eGFP transformants had more florescence than wild 
type, but the florescent was not so strong. It means Ppki from Trichoderma reesei can work in 
Trichoderma viride somehow, but this promoter is not a strong promoter, and the expression 
level of eGFP is low. So, to get better expression, some stronger promoter like PgpdA should 
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2.2.5 Gene knockout   
Knockout experiments are the most direct way to explore the biosynthetic pathway of a specific 
natural product. Because the changes in the genome can directly reflect on the production of the 
secondary metabolites in the native organism. There are two common ways to knock-out the genes. 
These are: exogenous DNA targeting the gene by recombination; and Crispr-Cas9 mediated gene 
editing and knockout.  Homologous recombination has been very successful previously in the 
Cox group and will therefore form the main methodology here. 
The regular gene knockout is designed to use exogenous DNA to disrupt the targeted gene 
once the DNA is integrated into the genome. The transformed DNA is designed to contain two 
sequences homologous to the gene of interest which flank a selection marker on either side. By 
homologous integration of this KO cassette the targeted gene is disrupted. The common marker 
for fungal selection is hygromycin B phosphotransferase (hph).[132] In this part of work, the 
bipartite KO method (section 1.5.1) will be used to knockout the target genes in the proposed 
viridiofungin gene cluster. 
 
2.2.5.1 Citrate synthase knockout 
2.2.5.1a Gene function analysis 
As demonstrated in section 2.1.1, a citrate synthase like gene is likely to be involved in the 
biosynthetic pathway of viridiofungin 2. According to the analysis of the T. viride genome data, 
one secondary metabolism CS like gene (TvCS) was found. The encoded enzyme is similar to the 
CS involved the biosynthetic pathway of byssochlamic acid 1 and squalestatin 7.[3, 4] TvCS is 
considered to use oxaloacetate 45 and a C18 fatty acyl CoA 160 as substrates to form an alkylcitrate 
intermediate 159 (Scheme 2.2.3.1). Because this is likely to be a very early step of viridiofungin 
biosynthesis, the KO of TvCS would abolish the production of viridiofungin. 
 
2.2.5.1b Vector construction and transformation 
The TvCS gene was amplified from gDNA in two parts (TvCS-LF and TvCS-RF, from the 5’- and 
3’- ends respectively). The primers used (CS-LR and CS-RF) had short tails (30 bp) of sequence 
homologous to the ends (5’ and 3’ respectively) of the amplified hygromycin resistance cassette, 
which was amplified from pTHygGS-Egfp plasmid (using primers HygF and HygR). The specific 
primers used (CS-LF and CS-RR) contained tails that introduced DNA sequences homologous to 
the ends of the linearized pE-YA plasmid (Fig. 2.2.5.1).  
 




Fig. 2.2.5.1 PCR fragments for yeast recombination. 
 
Upon purification of the PCR products, and using gel electrophoresis to estimate the amounts of 
DNA to be used, all fragments were transformed  into S. cerevisiae for recombination (Fig. 2.2.5.2 
A), together with the pE-YA vector cut open with NotI, using a LiOAc/SS-DNA based 
transformation protocol (section 5.5.2). 
 
 
Fig. 2.2.5.2 Yeast assembly and PCR fragment: A, yeast assembly of the pE-YA-TvCS-KO plasmid; B, preparation of the 
transTvCS-LF and transTvCS-RF via PCR. 
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The reconbined plasmid was then extracted from yeast and transformed into E. coli TOP 10 cells 
for amplification, which recovered correctly recombined pE-YA-TvCS-KO plasmid (proved by 
colony PCR). The transTvCS-LF and transTvCS-RF knockout constructs were then PCR-
amplified (CSLF-F/ THygR and CSRF-R/THygF primer pairs) from pE-YA-TvCS-KO plasmid 
(Fig. 2.2.5.2 B). 
Then the left (transTvCS-LF) and right (transTvCS-RF) PCR products were inserted into 
T. viride by protoplast-mediated transformation (section 5.6.3). Six transformants were obtained 
after three rounds of selection on hygromycin (Fig. 2.2.5.3). 
 
 
Fig. 2.2.5.3 Work flow of knockout experiment.  
 
2.2.5.1c Knockout result 
Six transformants and the wild type strain were grown in producing medium as section 2.1.1. The 
fermentations were extracted for LCMS analysis. According to the LCMS analysis, one of these 
six transformants didn’t produce any viridiofungins (viridiofungin A 2 and viridiofungin B 84 ) 
compared with wild type strain (Fig. 2.2.5.4 shade in red). So the citrate synthase gene of SY2040-
3 might be disrupted, and the biosynthetic pathway was consequently blocked. 
According to the total ion chromatogram (TIC), from wild type T. viride, peak 2 (t = 7.9 
min) is consistent with viridiofungin A 2 and peak 84 (t = 9.0 min) is consistent with viridiofungin 
B 84. However, the KO strain SY2040-3 lost both peaks 2 and peak 84 in the ESI trace compared 
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to the wild type strain and other transformants. Moreover, SY2040-3 also lost the peaks of the 




























Fig. 2.2.5.4 ELSD analysis of citrate synthase knockout experiment: A-D, KO transfromats; E, wild type. 
 
The extracted ion chromatograms (EIC) of [M - H]- 590 and [M - H]- 574 from the SY2040-3 
strain were then analysed. Only noise was observed in the chromatograms (Fig. 2.2.5.5). The 
possible citrate intermediate compound 159 discussed in the section 2.2.1 was also analysed ([M 
- H]- 413) and shown to be absent (Fig. 2.2.5.5). It means that the target gene is probably replaced 
by a marker gene (resistance gene hygromycin B). Therefore viridiofungin and citrate 
intermediate are no longer produced. 
 









[M-H]- 413 159  
 
However, the extracted ion chromatogram of the wild type strain showed that viridiofungin A 2, 
viridiofungin B 84 and putative citrate intermediate 159 were present (Fig. 2.2.5.5). 
 
 
Fig. 2.2.5.5 LCMS analysis of citrate synthase knockout: A-D, KO transfromats; E, wild type. 
 
2.2.5.1d Genome confirmation 
To confirm that the non-producing transformant SY2040-3 is real knockout strain, genomic DNA 
of SY2040-3 was isolated for PCR confirmation. Four primers were designed (primer 1 and 4 
outside of the gene, primer 2 and 3 inside of the gene Fig. 2.2.5.8). 
 




Fig 2.2.5.8 Primer designing for KO confirmation. 
 
In principle, primer CS-2\3, primer CS-1\3 and primer CS-2\4 pairs can produce PCR product 
700bp, 1640bp and 1600bp by using wild type gDNA as template. However, K.O strain cannot 
produce any PCR product. However, the PCR results were not as expected (Fig. 2.2.5.9). 
 
    
Fig. 2.2.5.9 PCR confirmation of K.O. KO is knock-out transformant, WT is wild type. 2\3, 1\3, 2\4 are primer pairs. 
 
The results indicate that the citrate synthase like gene in the KO transformant is only partially (C 
terminal) disrupted by integration. This has been observed before in the Cox group. It probably 
arises because of ectopic integration of the PgpdA-HygR cassette elsewhere in the genome, plus an 
additional partial intergration into the target sequence. This is supported by the fact that the other 
transformants are clearly hygromycin resistant, but viridiofungin is still produced indicating a 
high frequency of ectopic integration. 
On the other hand, another set of primers was also designed to confirm the transformant 
(Fig. 2.2.5.10). The PCR result indicated that the wild type can still get the full gene PCR product 
by primer HCS-1\4, while the CS K.O transformant could not get any PCR product, which means 
the target gene was somehow broken. However, the left (HCS-1\2) and right (HCS-3\4) fragment 
confirmation was not successful. Because the wild type and KO strain showed the same PCR 
results (Fig. 2.2.5.11).  
 





Fig 2.2.5.10 Primer designing for KO confirmation. 
 
 




2.2.5.2 tRNA ligase like gene knockout 
2.2.5.2a Gene function analysis 
Examination of the structures of viridiofungins shows that tryrosine, phenylalanine and 
tryptophan are the most common amino acids incorporated. In some rare case, glycine is also 
found in the viridiofungin structure like viridiofungin Z 89.[4] 
However, there is no PKS or NRPS module in the proposed viridiofungin BGC. But a 
tRNA ligase like enzyme (TvR4) is encoded in the gene cluster, close to the citrate synthase in 
the genome. This is the only enzyme which might be related to the amino acid attaching step (eg. 
Scheme 2.1.1.6). Other peptidic secondary metabolites are known to be made by non NRPS 
systems. For example, albonoursin 147 biosynthesis is mediated by a cyclodipeptide synthetase 
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(CDPS) using Phe-tRNA 149 and Leu-tRNA 148 as substrates (Scheme 2.2.6.1). Crystal structure 

































Scheme 2.2.6.1 Biosynthesis of Albonoursin mediated by CDPS 
 
Biosynthesis of albonoursin 147 suggestes that the tRNA ligase like enzyme (TvR4) in 
viridiofungin BGC might catalyse the reaction between a tRNA amino acid and the fatty acid 
chain. It is interesting that a nucleotide phosphatase is also encoded in the cluster, which might 
relate to release of the product from the tRNA. To put the information together, the tRNA ligase 
might act as the C domain of the NRPS, and tRNA is like the PCP to load the amino acid (Scheme 
2.2.3.1), then a phosphatase can release the product from tRNA. To test the hypothesis, target 
knockout on the tRNA ligase (TvR4) was conducted following the method in 2.2.5.1. If the tRNA 
ligase like enzyme is the key enzyme of the pathway, deletion of this enzyme will block the whole 
pathway.  
 
2.2.5.2b Knockout result 
After transformation and three rounds of selection, 12 T. viride transformants were grown in 
liquid medium. The fermentations were extracted for LCMS analysis after 7 days. According to 
the LCMS results, two of the transfomants (SY2017-1 and 2, shaded in yellow) lost the ability to 
synthesise viridiofungins. The other transformants still produced viridiofungins (Fig. 2.2.6.1). 
 




Fig. 2.2.6.1 LCMS analysis of tRNA ligase like enzyme knockout experiment: A-D, KO transfromats; E, wild type. 
 
According to the total ion chromatogram (TIC), the KO strains SY2017-1 and 2 lost the peak 2 
and peak 84 in the ESI trace compared to wild type strain and other transformants. Moreover, 
SY2017-1 and 2 also lost the peaks of proposed viridiofungin relatives from 5.8 min to 7.1 min 
(Fig. 2.2.5.4). 
The extracted ion chromatograms (EIC) of [M - H]- 590 and [M - H]- 574 only show noise 
(Fig. 2.2.5.4). The putative citrate intermediate compound 159 discussed in the section 2.2.1 was 
also analysed.The EIC for the [M - H]- 413 ion was examined. There were peaks shown in the 
chromatograms of the SY2017-1 and 2 transformants. The EIC of wild type strain and other 
transformants showed viridiofungin A 2, viridiofungin B 84 and citrate intermediate 159 peaks 
(Fig. 2.2.6.2). This shows that the 159 compound must be formed before the action of the tRNA 
ligase. It also shows that the 5,6 alkene is likely to be present from early in the pathway. 
 




Fig 2.2.6.2 LCMS analysis of tvR4 knockout experiment: A-D, KO transfromats; E, wild type. 
 
2.2.5.2 c Genome confirmation 
To confirm that the non-producing transformant was a real knockout strain, the genomic DNA of 
transformant SY2017-1 and 2 were isolated, primers were designed for PCR (Fig. 2.2.6.3). The 
PCR result (HR4 - 1\4 pairs) showed that the tRNA ligase gene in KO transformants are broken. 
For left fragment confirmation (HR4 - 1\2 pairs), the PCR product of the transformants were 
complex but different from the wild type. The right fragment confirmation (HR4 - 3\4 pairs) 
showed that tranformant SY2017-1 has a weak PCR product bind about 1500 bp (Fig. 2.2.6.4). 
The situation is similar to the CS KO experiments. The PCR results also indicate that SY2017-1 
and 2 transformants also contain ectopic integration of the PgpdA-HygR cassette elsewhere in the 
genome, plus an additional partial intergration into the target sequence. 
 
 




Fig. 2.2.6.3 Primer designing for KO confirmation. 
 
 
Fig. 2.2.6.4 PCR confirmation of tRNA ligase like enzyme K.O 
 
2.2.5.3 KO of the tailoring genes in viridiofungin cluster 
According to the knockout experiment of citrate synthase TvCS and tRNA ligase like enzyme 
TvR4, it is confirmed that these two enzymes are involved in the biosynthetic pathway of 
viridiofungins. This is consistent with a pathway in which the fatty acid chain (blue) and the 
oxaloacetate (red) are combined by citrate synthase, and the amino acid part is then  attached to 
the fatty acid chain by using tRNA ligase, so the basic skeleton of viridiofungin is synthesized by 
these two enzymes (Fig. 2.2.5.1) . 
In addition, two positions need tailoring to form the final structure. These are the (5, 6) 
alkene (purple) and the C-13 ketone (yellow). Correspondently, there are several tailoring genes 
in the BGC: acyl-CoA oxidase (tvL3), P450 oxygenase (tvL4), FAD dependent monooxygenase 
(tvR2) and an NAD dependent dehydrogenase (tvL2). Acyl-CoA oxidase could be related to the 
formation of the alkene, while the P450 oxygenase, FAD dependent monooxygenase and an NAD 
dependent dehydrogenase could be related to the formation of the ketone. 
 




Fig. 2.2.5.1 Structure of viridiofungin A 
 
To explore the function of the tailoring enzymes in the viridiofungin gene cluster, knockout 
experiments were also conducted on these genes.  
By using gDNA of T. viride as a template, the left and right fragments (from tvL4, tvR2, 
tvL3 and tvL2) for PE-YA vector construction got from PCR (section 2.2.5.1b), and after yeast 
recombination the fragments together with hygromycin resistance cassette fragment (hyg) built 
up the pE-YA plasmid for knockout. The PCR product of pE-YA vector was then transformed 
into the T. viride protoplast. After three rounds of selection several transformants were obtained 
(Table 2.2.5.1). These transformants were then grown in liquid medium. The fermentations were 
extracted for LCMS analysis after 7 days. 
 
Genes tvL4 (P450 oxygenase)  tvR2 (FAD dependent 
monooxygenase)  
tvL3 (acyl-CoA oxidase) tvL2 (NAD dependent 
dehydrogenase) 
numbers 18 26 16 30 
 
Table 2.2.5.1 Number of the transformants 
 
2.2.5.3 a Attempted knockout of P450 enzyme genes 
TvL4 was predicted as a P450 monooxygenase, it indicated that TvL4 might be involved in the 
oxidation of C-13 carbon (Scheme 2.2.4.3). If the tvL4 was successfully disrupted, the strain 
could produce intermediate 157. 
 
 



























Scheme 2.3.4.3 Proposed reaction of TVR4 
 
However, the LCMS analysis result shows that all of the transformants can still produce 
viridiofungin A 2, B 84 and related compounds. EIC of [M - H]- 590, [M - H]- 574 and  [M - H]- 
413 also show that all of the transformants can produce viridiofungins 2 and citrate intermediate 
159. The proposed intermediate 157 has m/z 577, but none of the transformant is shown to produce 
157 in the ion EIC of [M - H]- 576 (Fig. 2.2.5.7).  
 
 
Fig. 2.2.5.7 LCMS analysis of P450 K.O transformants 
 
Several transformants’ gDNA were isolated for genome confirming. Primers (HL4 - 1\4) outside 
of the target gene were used for PCR. A 1430 bp PCR product was obtained from all of the 
transforrmants and the wild type strain. This result indicated that the P450 gene tvL4 was not 
disrupted in the genomes of the transformants. This is consistent with the LCMS result. 




Fig. 2.2.5.7 PCR confirmation of tvL4 KO. 
 
2.2.5.3 b Attempted knockout of the other genes 
Acyl-CoA oxidase (tvL3), FAD dependent monooxygenase (tvR2), NAD dependent and 
dehydrogenase (tvL2) knockout experiment showed the similar result to the P450 gene K.O. All 
of the transformants can still produce viridiofungins and related compounds, but none of them 
can produce any new related intermediate. The genome confirming also show that the target genes 
are not disrupted. 
In conclusion, P450 monooxygenase (tvR4), acyl-CoA oxidase (tvL3), FAD dependent 
monooxygenase (tvR2) and NAD dependent dehydrogenase (tvL2) were not successfully knocked 
out.  It is difficult to knockout the target gene in T. viride based on the homologous recombination 
mechanism.  
 
2.2.6 Attempted Gene silencing of TvR3 
Because bipartite knockout is not efficient in T. viride, another strategy was tried in this study. 
Post-transcriptional gene silencing is a method of gene interference which relies on degradation 
of targeted mRNA, intercepting transfer of genetic information between the transcriptional and 
translational machinery.[90] In this part of the work, an RNA interference (RNAi) system (section 
1.7.4) will be used to knockdown the genes in viridiofungin cluster. 
TvR3 is predicted as a nucleotide phosphatase. The proposed activity of this enzyme is to 
catalyze the release of viridiofungin 2 from tRNA-viridiofungin complex 163 (Scheme 2.2.6.1). 
If TvR3 is successfully silenced, the biosynthetic pathway of viridiofungin would be blocked, and 
the product should be heavily decreased. 
 










































Fig. 2.2.6.1 The proposed reaction of TvR3 
 
2.2.6.1 Vector construction 
Based on the mechanism of RNAi (section 1.7.4), the Ppki promoter from the Trichoderma reesei 
(section 2.2.4.4) was used to promote the transcription of the reverse gene (revGOI). The revGOI 
is cloned from target gene (GOI) by using a pair of reverse primers. If the revGOI can be 
successfully transcribed in T.viride, the dsRNA would anneal with mRNA to form a siRNA. The 
siRNA can degrade the targeted mRNA (Fig. 2.2.6.1 A).[91]  
The revGOI of tvR3 was cloned from the cDNA of T. viride. The Ppki promoter was cloned 
from the Trichoderma reesei genome. These two fragments were combined together and inserted 
into the vector pTYH-GS-pki which contain a HYG marker. The vector pTYH-GS-pki-reGOI 
was constructed by yeast recombination (Fig. 2.2.6.1 B). 
 
 
Fig. 2.2.6.2 Mechanism of RNAi and vector construction: A, mechanism; B, RNAi vector construction. 
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2.2.6.2 Transformation, LCMS analysis and PCR confirmation 
The vector pTYH-GS-pki-reGOI was then transformed into T. viride by using PEG-mediated 
transformation. After three rounds of selection, 10 transformants were obtained. The 
transformants were grown in liquid medium for 7 days, and the compounds were extracted for 
LCMS analysis. 
According to the ELSD chromatograms, the transformants do not show significant 
difference with the wild type strain. The extracted ion chromatograms trace of [M - H]- 590, [M - 
H]- 574 and [M - H]- 413 also show no significant difference between wild type and transformants 
(Fig. 2.2.6.3). 
 
                     Fig. 2.2.6.3 LCMS analysis of TvR3 RNAi transformants: A-D, KO transformants; E, wild type. 
 
Genomic DNA of the transformants was also extracted for PCR confirmation. A pair of primers 
(1\2) was designed for the fragment of Ppki promoter part. The transformants DNA template could 
produce the PCR products (650 bp), while the wild type not (Fig. 2.2.6.4). It means the RNAi 
vector has been successfully transformed into the fungi. The reason why RNAi transformants 
didn’t make any difference of the production might because of the weakness of the pki promoter. 




Fig. 2.2.6.4 PCR confirmation of RNAi transformants 
 
2.2.7 Heterologous expression in A. oryzae   
To explore the biosynthesis pathway of the natural products, heterologous expression is also a 
very useful tool. Heterologous expression hosts for secondary metabolites or specific enzymes in 
the biosynthesis pathway are usually known to be E. coli, yeast and some fungi like A. oryzae and 
T. reesei.[100] Because of the difficulties of knockout and silencing in T. viride, the viridiofungin 
BGC will express in A. oryzae in this section. The original vectors and strains used in this part of 
work have been described in section 1.7.8. 
 
2.2.7.1 Plasmid construction 
All PE-YA entry and pTYGS (arg/ ade) vectors for expression of genes in the pathway were 
constructed by in vivo homologous recombination in S. cerevisiae and in vitro LR recombination. 
Genes were amplified by PCR using T. viride cDNA as a template with oligonucleotides which 
were designed to introduce the 30 bp homologous overlaps. Assembly of genes in pTYGS 
expression vectors was achieved by designing oligonucleotides with an overlap to Tadh / PgpdA or 
TgpdA / Peno and Peno, which resulted in the removal of the 2480 bp Tadh / PgpdA or the respective 800 
bp TgpdA / Peno DNA fragment 
According to the proposed biosynthesis of viridiofungin, the citrate synthase (TvCS) and 
tRNA ligase (tvR4) are the core genes in the pathway, so these two genes were cloned into the 
pTYGSarg vector, then nucleotide phosphatase (tvR3) and acyl-CoA oxidase (tvL3) were also 
cloned into this vector to confirm the function of these two genes. The three tailoring genes (P450 
monooxygenase tvL4, monooxygenase tvR2 and NAD dependent dehydrogenase tvL2) were 
cloned into the pTYGSade vector. Finally, ten vectors were constructed with different 
combinations (Fig. 2.2.7.1). 
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2.2.7.2 Transformation and LCMS analysis 
To test if the viridiofungin biosynthetic pathway can be rebuilt in A. oryzae, the plasmid SY2133-
3 and SY2133-7 which contains all of the possible genes (i.e the complete pathway) from the 
viridiofungin BGC were used for fungal transformation (Fig. 2.2.7.2). 
 
Fig. 2.2.7.2 The plasmid used for A. oryzae transformation 
 
CaCl2/PEG mediated protoplast protocol was used to transform  these two plasmids to A. oryzae 
NSAR1. Arginine and adenine auxotroph minimal medium was used for selection. After three 
rounds of selection, 20 transfomants survived (Fig. 2.2.7.3). The colorless transformants are more 
likely to be the real transformants. Because the adenine biosynthesis pathway blocked strain (like 
A.oryzae NSAR1) can produce pink pigments which are intermediates of adenine.  This 
phenomenon usually happens when the environment is short of adenine. So pTYGS-Ade 
plasmind transformation can provide adenine auxotroph strain with enough adenine, the 
transformants should not produce the pink pigments. Five colorless transformants, wild type, and 
four dark color transformants were selected for compound extraction and LCMS analysis 
 
                         
Fig. 2.2.7.3 Results of transformation 
 
The LCMS result indicated that there was no transformant had obvious changes compared to 
A.oryzae NSAR1 wild type, but the T. viride wild type strain produced viridiofungins (Fig. 
2.2.7.4).  
 




Fig. 2.2.7.4 LCMS analysis of A. oryzae transformants and T. viride wild type strain: A, T.viride wild type strain; B-D, 
A. oryzae transformants; E, A. oryzae NSAR1. 
 
The genomic DNA of A. oryzae transformants was extracted for PCR confirmation.  Seven pairs 
of primers were designed to amplify the seven target genes. Transformant SY2153-6 was the real 
transformant which contain all of the genes inside. Transfomant SY2153-4 also contains all of 
the genes. However, there were two bands in the tvL4 lane, it might be because of the 
contamination of gDNA samples (Fig. 2.2.7.5). 
 
 




Even the real transformants cannot produce viridiofungin. It might because the fatty acid substrate 
(fatty acid CoA) in A. oryzae is not enough for viridiofungin synthesis. Furthermore, the tRNA 




2.3.1 Oxidation of fatty acid 
Viridiofungin BGC encodes an acyl-CoA oxidase (TvL3). This acyl-CoA oxidase is thought to 
introduce the alkene in C18 fatty acid chain of viridifungins (160 to 161). Based on the in vitro 
assay of the CS from byssochlamic acid pathway (Chapter 3, section 3.2.2), BfL2 can take 2, 3- 
alkene as a substrate and isomerise it to a 3, 4 -alkene. This is also observed in the structure of the 
viridiofungins. Therefore, oxidation of fatty acid is thought to be the first step of the pathway. 
















Scheme 2.3.1.1 Proposed reaction of TvL3, and function of acyl-CoA dehydrogenase. 
 
Acyl-CoA dehydrogenase from the primary metabolism involved in fatty acid β-oxidation.[133-135] 
The function of this dehydrogenase is to introduce the double bond which is the first step of fatty 
acid β-oxidation.[136] Acyl-CoA dehydrogenase is an FAD dependent enzyme which removes two 
hydrogen atoms from carbons 2 and 3 in the fatty acyl CoA 165 (Scheme 2.3.1.1). The X- ray 
crystal structure of the active site in an enzyme-substrate complex of acyl-CoA dehydrogenase 
shows the flavin ring and the disposition of the two hydrogens that are removed. Glu-376 removes 
the pro-R hydrogen of the fatty acyl-CoA, The pro-R β hydrogen is simultaneously donated to the 
Re face of the N-5 position of FAD 165. Finally, the α, β-unsaturated acyl-CoA 167 results as a 
trans double bond 169 (Scheme 2.3.1.2).[137] Because of the similar activity of acyl-CoA 
dehydrogenase in the primary metabolism, the KO experiment on the acyl-CoA oxidase gene of 
viridiofungin might not totally block the production of the compounds. Because there is no fatty 





















































Scheme 2.3.1.2 Reaction of acyl-CoA dehydrogenase meditate FAD 
 
2.3.2 Citrate synthase in primary and secondary metabolism  
The knockout experiment of TvCS indicates that this secondary metabolism CS is involved in the 
biosynthesis of viridiofungin. The TvCS KO strain cannot produce viridiofungins or the putative 
citrate intermediate 159 (section 2.2.5.1c). Therefore, TvCS is thought to take C18 fatty acyl CoA 
161 and OAA 45 as substrates to form a citrate precursor 159 (Scheme 2.3.2.1). The alkene of 
C18 fatty acid CoA substrate 161 is produced by an acyl-CoA oxidase (section 2.3.1). The 
sterochmistry of these CS is explored in section 3.3.2 and is consistent with the C-3 stereochmistry 



















Scheme 2.3.2.1 Proposed reaction of TvCS. 
 
In primary metabolism CS catalyzes the condensation of acetyl coenzyme A (AcCoA) and 




1.5.1). While in secondary metabolism, CS catalyzes the condensation of OAA and fatty acid (or 
polyketide) CoA (or ACP bond) to form citrate and CoA (or ACP). CS involved in secondary 
metabolism is the key enzyme for the basic structure of alkyl citrates.  More detail discussion of 
CS can see Chapter 3 (section 3.3.2) including substrate selection and stereochemistry of the 
secondary metabolic CS. 
 
2.3.3 tRNA ligase like enzyme in viridiofungin pathway 
During the biosynthesis of viridiofungins, the key step is attaching the amino acid to the alkyl 
citrate. The first propose of this step is that a reaction catalysed by a PKS and NRPS hybrids 
system. There are two kinds of assembly line of PKS and NRPS hybrids. When an NRPS module 
is upstream of a PKS module the growing chain will form a new C-C bond. Correspondingly, 
when the PKS module is upstream of an NRPS module, the condensation domain recognizes the 
polyketide thiolester as an electrophilic partner for amide bond formation (Fig. 2.3.3.1). [109, 138, 
139 ] Therefore, if the NRPS module is involved in the biosynthesis of the viridiofungin, the NRPS 
module should be situated at the downstream of the PKS or FAS.  
 
 
Fig. 2.3.3.1 Recognition issues at PKS and NRPS hybrid module interfaces. 
 
However, the genome annotation (section 2.2.3.3) and TvCS knockout experiment (section 2.2.5.1) 
indicated that the viridiofungin BGC does not encode PKS or NRPS. But there is a tRNAa ligase 
like enzyme TvR4 involved in the BGC. According to the knockout results, disruption of tvR4 
leads to abolition of viridiofungins. It means tvR4 is involved in the biosynthesis of 




2.2.5.2). It means TvR4 should use citrate 159 rather than a fatty acid 161 as a substrate, and the 

































































Scheme 2.3.3.1 Proposed function of TvR4. 
 
Based on the gene annotation, TvR4 might process an aminoacyl-tRNA dependent catalysis.  
However, the mechanism of this enzyme need more studies..An example of AAtRS is 
cyclodipeptide synthases (CDPSs).[111] By using a sensitive sequence profile method, Aravind et 
al found that the CDPSs were members of Rossmannoid domains and are likely to be highly 
derived versions of the class I AAtRS catalytic domains. [140] In 2009, Muriel et al found that in 
the cyclodipeptide biosynthetic pathway there was a small protein unrelated to NRPS named 
AlbC which could use aminoacyl-tRNA as substrates to catalyse the formation of the 
cyclodipeptides peptide bonds. Moreover, some other bacterial proteins which are similar to AlbC 














Albonoursin 147 Cyclo(L-Phe-L-Leu)  174 Cyclo(L-Leu-L-Leu) 175  
Fig. 2.3.3.2 Structures of cyclodipeptides. 
 
In 2011, Ludovic et al described the crystal structure of AlbC, it was surprising that this enzyme 
is highly similar to the catalytic domain of class-I aminoacyl-tRNA synthetase (or tRNA ligase). 




thought to catalyse its two-substrate reaction via a ping-pong mechanism with a covalent 
intermediate in which L-Phe 176 is shown to be transferred from Phe-tRNA to an active serine 
177  (Scheme 2.3.3.3). [141, 143] This study shows that the molecular basis of the interactions 
between CDPS and their substrates. All the studies performed on CDPS suggest that these 
enzymes use the two aa-tRNA substrates in a sequential ping-pong mechanism, with a similar 
first catalytic step: the binding of the first aa-tRNA and the transfer and storage of its aminoacyl 











































176 177  
Scheme 2.3.3.3 Proposed mechanism of covalent phenylalanyl-enzyme formation for AlbC. 
 
In general, CDPS can use two aa-tRNA substrates in a sequential ping-pong mechanism, which 
is a hijack aminoacyl-tRNA pathway from secondary metabolism. First of all, the enzyme can 
catalyse the transformation of first aa-tRNA to the aminoacyl moiety on the conserved serine 
residue of the enzyme pocket which forms an amino acyl enzyme. Then the second aa-tRNA to 
form either a dipeptidyl-enzyme or a dipeptidyl-tRNA intermediate undergo intramolecular 
cycliztion to generate the final cyclodipeptide product. The released tRNA can either go into the 






Fig 2.3.3.4 CDPS hijack aa-tRNAs to produce cyclodipeptides. aa-tRNAs are generated from amino acid, ATP and tRNAs 
by aaRSs (in green). aa-tRNAs are typically delivered to the ribosome (in yellow) for the synthesis of peptide bonds in 
nascent polypeptides, but CDPSs (in purple) hijack some aa-tRNAs to make cyclodipeptides. 
 
The information of CDPSs suggests that some of the aminoacyl-tRNA synthases like enzyme are 
related to the formation of peptide bonds by using aminoacyl-tRNA as substrates. Similar with 
CDPS, TvR4 might also hijack aminoacyl-tRNA in the biosynthesis of viridiofungin.  
TvR4 is annotated as a glutaminyl-tRNA synthetase (GlnRS). These enzymes attach Gln 
to the appropriate tRNA. Like the other class I tRNA synthetases, they aminoacylate the 2'-OH 
of the nucleotide at the 3' end of the tRNA.[145] The core domain is based on the Rossman fold 
and is responsible for the ATP-dependent formation of the enzyme bound aminoacyl-adenylate. 
GlnRS contains the characteristic class I HIGH and KMSKS motifs, which are involved in ATP 
binding. According to the bioinformatic analysis of TvR4, it shows that TvR4 also contains HIGH 
and KMSKS motifs (section 2.2.3.3).[146, 147] Moreover, most bacteria lack GlnRS. In these 
organisms, the "non-discriminating" form of GluRS aminoacylates both tRNA(Glu) and 
















178 159  
Fig. 2.3.3.5 structure of glutamic acid and proposed viridiofungin precursor 
 
Since the structure of Glu 178 is somehow similar with the head of alkyl citrate 159 which is 
thought to be the precursor of viridiofungin (Fig. 2.3.3.5), and the function annotations of TVR4 
is glutaminyl-tRNA synthetase. So the catalytic mechanism of TvR4 can be proposed based on 
the knowledge about the normal glutaminyl-tRNA synthetase involved in the primary metabolism. 
The three substrates of TVR4 should be ATP, alkyl citrate and a Tyr or Phe specific tRNA. The 
energy of ATP hydrolysis is used to attach each amino acid to its tRNA molecular in a high-
ennergy linkage. 
The citrate is first activated with ATP through the linkage of its carboxyl group to form an 
AMP moiety forming an adenylated citrate 179. This linkage is driven by the hydrolysis of the 
ATP molecule that donates the AMP 164. And this step happens in the activate domain of the 
protein which contain a ATP binding site inside. Then without leaving the synthetase enzyme, the 
AMP-linked carboxyl group on the citrate is then transferred to an amino group on the amino acyl 
tRNA 162, this transfer joins the citrate by an activated ester linkage to the tRNA and forms the 
tRNA bound viridofungin 163 (Fig. 2.3.3.6). Therefore, there should be a condensation domain 
which can catalyse the linkage between activated citrate substrate and the amino actyl tRNA. 
As we can see, tRNA bound viridiofungin is an intermediate. A nucleotide phosphatase 
gene tvR3 is located next to the tRNA ligase like gene in the viridiofungin BGC (section 2.2.3.3). 
It is suggested that the nucleotide phosphatase could be involved in the biosynthetic pathway of 
viridiofungin which could release the viridiofungin from tRNA. The exact activity of this 
nucleotide phosphatase could be to catalyse the hydrolysis of the phosphate bond between the 






Fig. 2.3.3.6 Proposed tRNA ligase like enzyme. The main protein structure in blue, the condensation domain in red, 
the active site in yellow. 
 
2.3.4 Tailoring genes in viridiofungin pathway 
The function of other tailoring steps encoded by the gene cluster like P450 enzyme(tvL4), FAD 
dependent monooxygenase(tvR2) and a NAD dependent dehydrogenase(tvL2) are still not very 
clear. According to the bioinformatic analysis, it can be proposed that the P450 enzyme might be 
related to the formation of the C-13 ketone group on the fatty acid. The oxygenase might add a 
hydroxyl group and the formation of ketone could be catalysed by the NAD dependent 
dehydrogenase. or the oxygenase could catalyse a two steps reaction to directly form the ketone 
group. 
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If TVL4 is responsible for the oxidation of the C-13 of viridiofungin, the FAD dependent 
monooxygenase TVR2 might be related to the oxidation of other different places in viridiofungin, 
because we could also be able to find other oxidised viridiofungin analogous in the extraction of 
wild type T.viride strain. 
 
2.4 Conclusion and outlook 
The aim of this project was to elucidate the biosynthesis of viridiofungin and to delineate enzymes 
involved in the novel pathway of the attachment of amino acid Try or Phe with the citrate 
precursor, and the tailoring enzymes involved in the region selective C-13 carbon oxidation.  
First of all, the wild type strain T. viride was re-grown in a cornmeal contained producing 
medium, the suitable condition for reproducing of viridiofungin was found. The compounds 
viridiofungin A and B were then isolated and elucidated. The gDNA of T. viride was sequenced 
by using both Illumina and Oxford nanopore methods. According to the bioinformatic analysis of 
T. viride genome data, a CS and tRNA ligase like enzyme containing BGC was found to be the 
possible for the biosynthesis of viridiofungin. In the mean time, the transformation condition of 
T. viride was tested. T. viride is hygromycin sensitive, and can be transformed by protoplast PEG-
mediated method. 
Based on the BGC predition and fungal transformation condition, seven targeted 
knockout experiments were carried out. From two of these knockout experiments, citrate synthase 
gene (tvCS) and tRNA ligase like enzyme gene (tvR4) was successfully disrupted and the KO 
strain showed no production of viriodiofungins. According to the CS and tvR4 knockout, the BGC 
of viridiofungin was confirmed. However, the knockout of tvL2 /3 /4 and tvR2 / 3 were not 
successful. 
Because knockout experiments gave were not efficient (less than 1%), other biological 
methods were used to study this project such as RNA interference based silencing and 
heterologous expression. Silencing of nucleotide phosphatase like enyzme TvR3 didn’t gave 
significant changes in viridiofungin production. Heterologous expression of TvR4, TvCS, TvL2/ 
3/ 4 and TvR2/ 3 in A. oryzae didn’t give the production of viridiofungin. 
In conclusion, a novel non-NRPS dependent biosynthetic pathway of viridofungin was 
found in T. viride, and the core genes CS and tRNA ligase like enzyme tvR4 were found to be 
involved in the biosynthesis of viridofungin by knockout experiment. However, the function of 
the enzymes and the tailoring steps like the oxidation of C-13 carbon are still unclear. 
In the future, the transcriptome data should be obtained from cDNA sequencing to get 
more precise information of the open reading frame information of every gene in the BGC which 
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can help to carry out a better heterologous expression experiment. Then in vitro study of the novel 
tRNA ligase like enzyme TVR4 would be the better way to understand how the enzyme TvR4 
possibly hijacks the primary metabolite amino acyl tRNA to form the secondary metabolite 
viridiofungin. The substrate of TVR4 is thought to be amino acyl tRNA and citrate intermediate. 
However, the tRNA from different organism should be different, so it is also important to figure 
out if TvR4 can admit tRNA form different organism. In vitro study of Nucleotide phosphatase 
TvR3 study should also followed with the TvR4 to make sure the mechanism of the releasing 
steps. Furthermore, the tailoring genes like tvL2, tvL4 and tvR2 could be good elements for genetic 




















Chapter 3. Heterologous Expression of the Enzymes from 
Nonadride Biosynthetic Pathways and in vitro Assay 
3.1. Background and aims of the project 
3.1.1 Introduction 
As described in section 1.5.1.2, the core early genes and two sets of KSI-like and PEBP-like genes 
from the byssochlamic acid pathway were investigated in A. oryzae by heterologous expression.[3] 
Byssochlamic acid 1 and heptadrides were produced by the host strain.  The KSI-like enzymes 
BfL6 and BfL10 from B. fulva appear to act together, to possibly forming a heterodimer that 
shows flexibility to create both nonadrides and heptadrides. Real ketosteroid isomerase enzymes 
(KSI) are involved in the biosynthesis of steroids in mammals and bacteria. They can isomerise 
3-oxo-∆5 ketosteroids to ∆4-conjugated isomers.[150] For example, KSI from Pseudomonas 
testosteroni catalyzes the allylic isomerization of a variety of ∆5-3-ketosteroids 180 to ∆4-3-
ketosteroids 182 by a highly stereoselective intramolecular transfer of the 4β-proton to the 6β 
position (Scheme 3.1.1.1).  Asp-38 was identified as the general base abstracting the 4β-proton 
of the steroid substrate and Tyr-14 as the general acid protonating or providing a hydrogen bond 








































Scheme 3.1.1.1 General mechanism of the ketosteroid isomerase catalysis.  
 
The PEBP-like proteins also appear to take part in the dimerization step by greatly increasing the 
production of the dimerized compounds. The Cox group speculated that the PEBP-like proteins 
posssibly had an anionic binding ability, therefore PEBP proteins might the chaperone highly 
unstable carboxylates to prevent premature decarboxylation prior to dimerization. However, 
PEBP-like proteins BfL5 and BfL9 are not absolutely necessary for the dimerization, and KI 
proteins are critical.[3] To more deeply look into the mechanism of the dimerization step, in vitro 




As discovered for the core early proteins in the byssochlamic acid pathway, there are likely 
to be many problems awaiting in vitro study. Although both the Cox group and Fujii et al 
confirmed that the hrPKS, (alkyl)citrate synthase and (methyl)citrate dehydratase are used for 
forming the maleic anhydride monomers 186 (Scheme 3.1.1.2 A), the mechanism and chemo and 
stero selectivities of these enzymes are still unknown. Fujii et al obtained the anhydride monomer 
183 from the incubation of alkylcritate synthase (TstJ) and methylcitrate dehydratase (TstI) with 
oxaloactete 45 and a synthetic polyketide CoA 187 (Scheme 3.1.1.2 B and C).[3, 61] However, 
according to the results of these in vitro studies, Fujii et al thought the product they obtained was 
the ring closed and decarboxylated compound 188, but the UV spectrum (λmax about 270 nm) does 
not corresponded to the general UV spectrum of the anhydride monomers (λmax over 300 nm). 
Actually, according to the studies of our group, the λmax 270 nm compounds are the ring opened 
dicarboxylic acids.[8] So further work is needed to know how the methylcitrate dehydratase works. 
Furthermore, there is a hydrolase BfL1 involved in the bysschlamic acid gene cluster, but the 




























































Scheme 3.1.1.2 in vivo and in vitro studies on maleidride early steps from Fujii group:A, gene clusters; B, in vivo 





To investigate the dimerization of nonadrides, chemical synthesis work has also been carried out. 
During the 1960s, Sutherland et al synthesized compound 189 as a substrate and treated it with 
base (Et3N), and DMF as the solvent. This gave racemic 3-epi-glucanic acid 50a (Scheme 3.1.1.3 
A) in low yield.[153]  In parallel, they also used compound 190 as a substrate, and the same product 
was produced as from compound 189, which might be due to anhydride 190 being converted back 
to 189 under the reaction conditions. Baldwin et al used the anhydride with the longer chain 191 
as substrate and also treated it with Et3N but used DMSO as the solvent. This gave a mixture of 
products including nonadride 192, hexadride 193 and heptadride 194. They found that higher 
polarity of the solvent was important to stabilize anions and favour dimerization (Scheme 3.1.1.3 








































Et3N, DMSO + +
191  192
 193  194
B
 
Scheme 3.1.1.3 In vitro investigation on dimerization: A, by Sutherland et al; B, Baldwin et al.  
 
Later, Sulikowski et al changed the method for the reaction. They synthesized compounds 
containing two maleic anhydride units using different linkers (195, 197, 198, 199 and 203) and 
used DBU and MeCN as base and solvent. The yields of cyclised products were again low. The 
result indicated that compound 195 underwent a cyclization reaction, while the other substrates 






























































































Scheme 3.1.1.4 In vitro investigation on dimerization by Sulikowski et al.  
 
Baldwin also used the linked anhydride monomers 205, 207, 210, 212 and 213 as substrates to 
explore the stereo- and regioselectivity of dimerization. In this work, they used DBU in THF: 
DMSO (1:4) at 20 ℃. Finally, it was shown that compounds 205, 207 and 210 can be cyclized 

























































































Scheme 3.1.1.5 In vitro experiments of Baldwin et al.  
 
In the case of the dimerization step involved during the biosynthesis of byssochlamic acid 1, our 
group worked on the purification of maleic anhydride monomer 110 and characterized it by NMR. 
The result indicated that the maleic anhydride monomer 110 spontaneously decarboxyltes to 111 
(Scheme 3.1.1.6 A).[2] The subsequent cyclization step can be explained by a mechanism 
involving Michael addition of the reactive anionic species 216/217/218, generated by 
decarboxylation. The decarboxylation also appears to provide the intermediate 219 necessary for 
cyclisation with an additional 110 during the biosynthesis of byssochlamic acid 1 (Scheme 3.1.1.6 
B). This dimerization step is thought to be catalysed by KSI-like enzymes according to the in vivo 






















































































e.g. heptadrides  
Scheme 3.1.1.6 Possible mechanism of dimerization step: A, formation of reactive anionic species; B, dimerization 
step. 
 
According to these in vivo results,[3] the Cox group proposed the general pathway to nonadrides, 
and three different ways of dimerization by using 3 types of anhydride monomers 221/ 222/223 
(Scheme 3.1.1.7). The first one was head-to-tail dimerization for byssochlamic acid-type 
nonadrides 224, the second was head-to-head dimerization for glauconic acid 227 type nonadrides 
and heveadride type 226 nonadrides, the third one was head-to-side dimerizatioin for heptadrides 
225.[89] [3] The KSI enzymes should react 221 with either 222 or 223, the orientation of the reacting 
species, determine the size, substitution pattern, and stereochemistry of the central carbocyclic 
ring. KSIs and PEBPs were thought to be related to the dimerization. These enzymes might have 
activities that could protect carbanions from reaction with water and protonation by other 
situations that can make them unreactive, furthermore, these enzymes should prompt close contact 
between two monomers, in addition, they could help to ensure the proper species-specific 
structure and stereochemistry.  



































































































221 222 223A B C
Scheme 3.1.1.7 Proposed general pathway to nonadrides and heptadrides. 
 
3.1.2 Project aims 
To obtain more information about the mechanisms and selectivities of the nonadride enzymes we 
plan to study them in vitro. We therefore plan to try to express all of the genes, including the early 
core genes (except the PKS) and the genes for dimerization. The biosynthetic proteins will then 
be reassembled in vitro with suitable substrates. Because the cornexstin 66 biosynthetic pathway 
is similar to byssochlamic acid 1, some enzymes from the cornexstin 66 pathway will also be 
chosen as candidates for expression and in vitro study.  
For citrate synthase (BfL2), it is important to find out whether it uses a carboxylic acid, a 
polyketide CoA or an ACP bound polyketide as its substrate, and find out whether it produces a 
single stereoisomer or mixed stereoisomers of citrate products. 2-Methyl citrate dehydratase (DH 
BfL3 and PvL2) is thought to be the key enzyme for the biosynthesis of the maleic anhydride, 
however, whether the DH catalyses both dehydration and anhydride formation is still unknown. 
Furthermore, there is also a stereochemical questions on DH, whether it can select only one citrate 
isomer as the substrate or different isomers.  
According to the in vivo heterologous expression studies,[3] the KSI-like enzymes (BfL6 
and BfL10) are involved in the dimerization step, and the PEBP-like (BfL5 and BfL9) enzymes 
seem to increase the production of dimerized products. Nevertheless, it is still a mystery why B. 
fulva can produce both nonadrides and heptadrides – do the KSI enzymes have a role in ring-size 
selectivity? We only know that the KSI-like enzymes are related to the dimerization step, but the 
exact function of the KSI-like enzymes and how they work on the maleic anhydride substrate is 
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still unknown. So further experiments in vitro should help to understand the mechanisms and 
selectivity of these ring-forming enzymes. Furthermore, other maleidride clusters seem to only 
encode single copies of KSI-like and PEBP-like enzymes. It is not known why the byssochlamic 
acid BGC is different and whether two copies of each gene are essential. 
The overall work plan will involve the cloning and expression of the relevant proteins in 
suitable host organisms, followed by protein purification and in vitro assay with suitable 
substrates which could be obtained synthetically or biochemically. 
 
3.2 Results 
The project started with gene synthesis. According to the transcriptome sequencing data and the 
gene cluster information we have obtained, a total of seven genes from the byssochlamic acid 1 
pathway were targeted.[1] These consist of the hydrolase (bfL1); citrate synthase (bfL2); citrate 
dehydratase (bfL3); two PEBPs (bfL5 and bfL9) and two KSIs (bfL6 and bfL10). One gene from 
the cornexstin 66 pathway, 2-Methyl citrate dehydratase pvL2, was also targeted. Eight codon 
optimised genes were therefore synthesized for E. coli expression. These genes were cloned into 
E. coli expression vector pRSET A.[165]  The genes bfL1 and bfL2 were successfully expressed in 
E. coli by our group member Dr. Steffen Friedrich. In this chapter, expression work of bfL3, 5, 6, 
9, 10 and pvL2 and their in vitro assay will be described. 
 
3.2.1 Protein production 
3.2.1.1 Whole length expression in E. coli 
The project started with the E. coli expression of full-length copies bfL5, 6, 9 and 10 using the 
vector pRSET A. First of all, pRSET A- bfL5, 6, 9 and 10 were transformed into E. coli Rossetta 
(DE3) host strains. It appeared that the BfL5 vector was toxic to the host strain: the colonies grew 
very slowly on solid media, and they could not grow in liquid medium. However, transformants 
containing pRSET A- bfL6, 9 and 10 grew well in LB medium. After 0.3 mM IPTG induction for 
12 h at 25 ℃, the cells were lysed by ultrasonication. The cell free extraction was separated into 









Fig. 3.2.1.1 SDS-PAGE results of pRSET-A- bfL6, 9  and 10 in Rossetta DE3. Control (-) is the transfomants without the 
IPTG induction. 
 
BfL9 appeared to be present in the soluble fraction compared with the control, and there was no 
specific expression in the insoluble fraction. However, neither BfL6 nor BfL10 had any visibly 
expressed protein in either the soluble or insoluble fractions. 
 BfL5 appeared to be toxic to E. coli. Therefore the toxic protein expression host strain BL21 
DE3 (pLysS) was tested for the expression. The vectors pRSET A-bfL5, 6, 9 and 10 were 
transformed into BL21 DE3 (pLysS). The transformants with bfL5 were able to grow this time, 
but it still grew slower than the bfL6, 9 and 10 tansformants. After 0.3 mM IPTG induction for 12 
h at 25 ℃, the expression was checked by SDS- PAGE (Fig. 3.2.1.2). In this case, only bfL9 
showed some expression in the insoluble fraction but without soluble protein. BfL5, 6 and 10 
again produced no protein in either soluble or insoluble fractions. 
 
 
Fig 3.2.1.2 SDS-PAGE results of pRSET-A- bfL 5, 6, 9 and 10 in BL21 DE3 (plysS). Control (-) is the transfomants 
without the IPTG induction. 
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3.2.1.2 Bioinformatic analysis  
Since it was quite difficult to express the KSI-like and PEBP-like enzymes in E. coli, 
bioinformatic analysis of the features and characters of these four proteins was done. First basic 
parameters were investigated using expasy.[157] This included the number of amino acids, 
molecular weight, theoretical PI, the number of negatively charged and positively charged 
residues, formulas of the proteins, instability and aliphatic index, and grand average of 
hydropathicity (Table 3.2.1.1). It should be noted that the instability index of BfL10 was more 
than 40. This indicated that the protein is likely to be unstable. This might be caused by the 
hydrophobic amino acid condensed region at the N terminus. The “Grand average of 
hydropathicity” prediction showed that only BfL5 had a positive value. This revealed that BfL5 
could be more hydrophobic compared with the other proteins (Table 3.2.1.1). 
 
  BfL5 BfL6 BfL9 BfL10 
Number of amino acids 214 242 210 229 
Molecular weight （Da） 23223.4 27944.6 23105.5 26602 
Theoretical pI 4.7 5.1 6.4 5.5 
negatively charged residues (Asp + Glu) 17 30 22 27 
 positively charged residues (Arg + Lys) 6 18 20 17 
Instability index 30.9 (stable) 32.6 (stable) 38.5 (stable) 40.1 (unstable) 
Aliphatic index 99.4 79.7 75.3 85.1 
Grand average of hydropathicity 0.2 -0.3 -0.4 -0.3 
 
Table 3.2.1.1 Expasy analysis and prediction of BfL5, 6, 9 and 10. 
 
Membrane associated proteins are usually difficult to express in E. coli. Proteins which contain 
transmembrane helices are not properly folded or modified in E. coli. Therefore, trans-membrane 
regions were predicted using the software TMHMM-2.0.[158] This showed that three of the KSI-
like and PEBP-like enzymes contained no obvious transmembrane region. However, BfL10 likely 
contains some hydrophobic amino acids at the N-terminus of the protein. This region could affect 
protein expression (Fig. 3.2.1.3). 
 
 
Fig. 3.2.1.3 TMHMM-2.0 prediction result of BfL5, 6, 9 and 10. 
Ⅲ  Expression in E. coli 
 
101 
We also applied the SignalP 4.1 Server [159] to predict the signal peptides. Signal peptides are a 
short amino acid sequences at the N-terminus of the newly synthesized proteins. They can direct 
the proteins towards the secretory pathway. Usually, one organism can only recognize its own 
signal peptide to transport the proteins. In the case of heterologous expression, especially for E. 
coli, eukaryotic signal peptides cannot usually be recognized, and the organism cannot modify 
the signal peptide after translation. This can block the translation of the proteins. It is therefore 
important to remove the signal peptides before transforming the genes to E. coli.[160] 
 
Fig. 3.2.1.4 Signal peptide prediction over residues 1 - 70 of BfL5, 6, 9 and 10. Score means the possibility to contain 
a signal peptide. The S-score for the signal peptide prediction is reported for every single amino acid position in the 
submitted sequence; C-score is the "cleavage site" score; Y-score is a derivative of the C-score combined with the S-
score resulting in a better cleavage site prediction than the raw C-score alone. 
 
The BfL5, 6 and 10 N-terminal sequences had a high score in SignalP 4.1 Server which means 
they probably contain signal peptides (18, 22, 20 amino acids of each) at the N terminus, whereas 
BfL9 does not (Fig. 3.2.1.4). This result might explain why only BfL9 can be directly expressed 
in E. coli. However, the other three genes could not be expressed in whole length form. 
 
3.2.1.3 Removing the signal peptide for expression  
According to the signal peptide prediction results, BfL5, 6 and 10 probably include a signal 
peptide at their N-termii which might affect their expression in E. coli. The first 22 AA of BfL10 
are also predicted to encode a trans-membrane domain. Therefore, new primers were designed to 
remove the signal peptides by creating shorter ORFs (Fig. 3.2.1.5). The new PCR fragments were 
cloned into pET-28a vectors and confirmed by colony PCR. 




Fig. 3.2.1.5 Vector construction: PCR fragments (bfl5 (∆1-18), bfl6 (∆1-22), bfl10 (∆1-20)) without the signal peptide 
regions, pET-28a cutting and infusion of PCR products. 
 
The new protein expression vectors pET-28a- bfl5 (∆1-18), bfl6 (∆1-22) and bfl10 (∆1-20) were 
then transformed into E. coli BL21 (DE3). After 0.3 mM IPTG induction for 12 h at 25 ℃, the 
expression was checked by SDS- PAGE (Fig. 3.2.1.6). 
The SDS-PAGE of the new expression showed that BfL5, 6 and 10 had expressed, but all 
of the visible expression was in the insoluble fraction. There was no evidence in the SDS-PAGE 
for any expressed protein in the soluble fraction. Even though the proteins were insoluble, this 
was the first time that bfL5, 6 and 10 were successfully expressed in E. coli. It means that 
removing the signal peptide helped the organism to start the translation properly.  
Although bfL5, 6 and 10 were expressed after removing the N-terminal signal peptide 
regions, the expressed protein was still insoluble. It means that the proteins are probably not 
correctly folding after the translation step. To obtain soluble expression, different conditions of 
expression were tried many times, including lower IPTG concentration, lower temperature and 
lower shaking speed. But none of these changes resulted in soluble expression.  
 
Fig. 3.2.1.6 SDS-PAGE results of pET-28a-bfl5 (∆18), bfl6 (∆22) and bfl10 (∆20). Control is the empty vector PET-28a 
transfomant. 
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3.2.1.4 Use of chaperones  
Insoluble proteins form inclusion bodies. This is usually caused by misfolding of the protein.[161] 
In nature, many organisms can produce proteins to help the other proteins fold properly 
(chaperone proteins have this function).[162] The major function of chaperones is to prevent newly 
synthesised polypeptide chains and assembled subunits from aggregating into non-functional 
forms.[163] 
 
              
Fig. 3.2.1.7 Chaperone protein expression plasmid.[x]   
 
We therefore attempted to introduce chaperone proteins into the expression systems.  The plasmid 
used in this experiment was pG-KJE8.[164] This plasmid can introduce five chaperone proteins 
which work as two functional groups (DnaK/DnaJ/GrpE and GroEL/GroES). They are  inducedby 
arabinose and tetracycline separately. The vector also contains a Cm
r (chloramphenicol) resistance 
marker for selection (Fig. 3.2.1.7). 
 
 
Fig. 3.2.1.8 Diagram to explain how the chaperone proteins work after protein translation. 
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The chaperones used in the pG-KJE8 system work as ATP-dependent foldases. Both the 
DnaK/DnaJ/GrpE and GroEL/GroES systems work after translation and are coupled to ATP 
hydrolysis (Fig. 3.2.1.8).[161]  The pG-KJE8 plasmid and the destination gene expression vectors 
were co-transformed into E. coli BL21 (DE3), then selected by both Cm and Kan antibiotics. The 
dnaK/dnaJ/grpE chaperone proteins were induced by addition of 0.5 mg/ml arabinose and 
groEL/groES were induced by addition of 5 ng/ml of tetracycline. The bfL5, 6 and 10 genes were 
induced by addition of 0.3 mM IPTG. After induction for 12 h at 25 ℃, expression was checked 
by SDS-PAGE. 
All three target proteins were observed in both soluble and insoluble fractions. The 
expression systems still produced quite a lot of protein in the insoluble fraction, however, with 
the help of the chaperone proteins, some soluble protein of the expected molecular weight was 
observed (Fig. 3.2.1.9).  
An experiment that only co-expressed chaperone proteins groEL/groES with the target 
genes was also performed. BfL5, 6 and 10 were only observed in the insoluble fraction, and there 
was no observed protein in the soluble fraction (Fig. 3.2.1.10). It means the single group of 
GroEL/GroES chaperone proteins were not enough for soluble expression of the target proteins. 
 
Fig. 3.2.1.9 SDS-PAGE results of PET-28a-bfl5(∆18), bfl6(∆22), bfl10(∆20) co-expression with DnaK/DnaJ/GrpE and 
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Fig. 3.2.1.10 SDS-PAGE results of PET-28a-bfl5 (∆18), bfl6 (∆22), bfl10 (∆20) co-expression with GroEL/GroES. 
Control is the empty vector PET-28a transfomant. 
 
In summary, in this section, KSI-like and PEBP-like proteins BfL5, 6, 9 and 10 were expressed 
in E. coli. The bfL9 gene could be directly expressed as a soluble protein in E. coli with the whole 
length of the gene. The bfL5,6 and 10 genes were co-expressed with chaperone proteins without 
the signal peptide region in the genes to give a mixture of soluble and insoluble protein products. 
 
3.2.1.5 Yeast expression 
3.2.1.5a Vector construction 
According to the results from Dr. Steffen Friedrich, 2-methyl citrate dehydratases BfL3 and PvL2 
did not expressed well in the E. coli system. So the yeast expression system was used to express 
these two enzymes. Compared with the E. coli system, yeast has a major advantage in its ability 
to catalyze post-translational modification. In addition it is a eukaryotic host which may be more 
suitable for fungal gene expression. The insolubility of the protein is usually caused by misfolding. 
This will result in the formation of inclusion bodies. However, the post-translational modification 
in yeast can help the heterologous protein to fold correctly to make soluble protein. The difficulty 
of production of soluble BfL3 and PvL2 in E. coli might be caused by misfolding. At the same 
time, the KI and PEBP genes bfL5, 6 and 10 were also tested in the yeast system, to determine if 
more soluble protein could be obtained them in the previously optimised E. coli system. 
 




Fig. 3.2.1.11 plasmid map of pESC-URA and the multiple cloning site. 
 
Saccharomyces cerevisiae strain W303-1b and vector pESC-URA (delivered by Prof. Kong) were 
used to set up the yeast expression system.[165] W303-1b is a nutrition defective strain which is 
auxotrophic in Ura, His, Leu, Ade and Trp.[166] The pESC vectors are a series of epitope-tagging 
vectors designed for expression and functional analysis of eukaryotic genes in S. cerevisiae. These 
vectors contain the GAL1 and GAL10 yeast promoters in opposing orientations.[167] With the 
pESC-URA vector, one or two cloned genes can be introduced into a yeast host strain under the 
control of a repressible promoter. Genes bfL3, pvL2 and bfL5, 6 and 10 were cloned into MCS2 
(multiple cloning site 2) between BamH I and Hind III restriction sites (Fig. 3.2.1.11).The In-
fusion cloning method was used for the construction of the plasmid (Fig. 3.2.1.12).[168] The whole 
ORF fragments of bfL3, pvL2 and bfL5, 6 and 10 were cloned into pESC-URA and confirmed by 
colony PCR. Plasmid DNA was extracted from positive colonies for yeast transformation. 
 
   
Fig. 3.2.1.12 Yeast expression plasmid construction. 
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3.2.1.5b Induction and Expression 
Individual pESC-URA plasmids containing the genes (bfL3, pvL2 and bfL5, 6 and 10) and the 
empty vector were transformed into yeast using a LiOAc procedure (section 5.2.5). The 
transformation mixture was plated on SM-URA agar plates. The yeast colonies grew on the plates, 
but the colour of the colonies changed to pink (Fig. 3.2.1.13), because the host strain W303-1b is 
an adenine defective strain. When the yeast cells find that there is not enough adenine in the 
environment, they try to synthesise adenine by themselves.[169] However, the adenine biosynthetic 
pathway of the W303-1b strain was blocked, so the cells could only produce the pink intermediate 
pigment. This phenomenon showed that the pink yeast colonies were not contaminated by other 




Fig. 3.2.1.13 Yeast transformation results of pESC-URA-bfL3, pvL2 and bfL5,6,10. 
 
The yeast cells were collected from the second plates and tested by colony PCR. The positive 
yeast colonies went into the next inducing and expression step. Because the expression vector 
contains the S. cerevisiae GAL1 promoter, it can be induced by galactose. By using media lacking 
uracil and containing galactose, the yeast was induced for 16 hours at 30 ℃ (section 5.2.6). Glass 
beads were then used to break the cells. The crude cell extract was then checked by SDS-PAGE.  
PvL2 and BfL3 have some weak but visible expression on SDS-PAGE compared to the 
empty vector transfomant. The molecular weight of PvL2 and BfL3 are 55 kDa, and this was 
consistent with the SDS-PAGE results (Fig. 3.2.1.14). However, BfL5, 6 and 10 had no visible 
protein on the SDS-PAGE, but this does not mean that there was no expression of these three 
genes, because, the promoters of the yeast were not as strong as the E. coli T7 promoters, and the 
growing speed of the yeast was also much slower than E. coli. Yeast protein expression is usually 
difficult to observe on the SDS-PAGE. The genes bfL5, 6 and 10 might have been expressed, but 
the detecting method was not sensitive enough to show the results. BfL5, 6 and 10 could directly 
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Fig. 3.2.1.14 SDS-PAGE results of yeast expression of pvL2/ bfL3 and blL5, 6 and 10. The control is empty vector 
transfomant. The red frame highlights the possible expression. 
 
To sum up, by using yeast expression methods, two citrate dehydratase genes (pvL2 and bfL3) 
were expressed. The genes bfL5, 6 and 10 were successfully transformed into the yeast, but the 
SDS-PAGE was not sensitive enough to confirm the expression. Besides, Dr. Steffen Friedrich 
successfully expressed the hydrolase (bfL1) and CS (bfL2) in E. coli. The gene bfL5 (∆18), 6 (∆22) 
and 10 (∆20) were expressed in E. coli (Table 3.2.1.2). 
 
                                   in E.coli     in yeast     





   
bfL1 (hydrolase)          √ - - -   × no expression 
bfL2 (CS)           √ - - -     √ soluble expression 
bfL3(DH)          乄 -         乄      √    乄 expressed but insoluble 
pvL2(DH)           × -          ×     √    ? not sure if it is expressed 
    ∆signal peptide      - not tried 
bfL5(PEBP1)          ×          乄        √       ?     
bfL6(KI1)          ×          乄        √       ?     
bfL9(PEBP2)           √ - -    -     
bfL10(KI2)          ×          乄       √       ?     
 
Table 3.2.1.2 Summary of expression. 
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3.2.2 In vitro studies 
3.2.2.1 In vitro study of citrate synthase  
As is shown in section 3.2.1, the enzymes BfL1 (hydrolase) and BfL2 (CS) were successfully 
expressed in E. coli by our group member Dr. Steffen Friedrich. He also carried out the in vitro 
study on the BfL1 and BfL2. BfL1 was shown to hydrolyze 2 - hexan/hexen-oyl – pantetheine 
228/229, 2 - hexan/hexen-oyl – CoA 230/107 and also holo-ACP - 2 - hexan/hexen-oate 231/232 
to form the released hexaketide. To make an overall story of byssoclamic acid biosynthetic 
pathway, Dr. Steffen Friedrich’s in vitro works on BfL2 will be briefly demonstrated in this 
section, and I will try to analyse these in vitro data. In addition, to analyse the stereochemistry of 
CS, I will also try to make the protein modelling of BfL2 to look into the catalysis mechanism of 
this enzyme. 
3.2.2.1a In vitro assay of BfL2 
CS is known to use oxaloacetate and either polyketide CoA or polyketide bound ACP as substrates 
to form alkyl citrate products. In this study, a series of hexaketide substrates were synthesized for 
in vitro assay (Scheme 3.2.2.1). 2 - Hexan/hexen-oyl – pantetheine 228/229, 2 - hexan/hexen-oyl 
– CoA 230/107 and holo-ACP - 2 - hexan/hexen-oate 231/232 were used as substrates for BfL2 
reactions. The ACP domain of holo-ACP - 2 - hexan/hexen-oate 231/232 substrate is from the 
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Scheme 3.2.2.1 Proposed hexaketide substrates for CS reactions. 
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1 mM Hexaketide substrates and 1 mM oxaloacetate with purified CS protein BfL2 at 30 ℃ for 
2 hours in 100 μL PBS buffer. The reaction was stopped by addition of 100 μL acetonitrile 
(section 5.3.5). Protein was removed by centrifugation and the supernatant was analysed by 
directly LCMS. According to the LCMS analysis of the reactions, BfL2 only showed the activity 
on 2 – hexan/hexen-oyl – CoA, and formed the citrate product (Fig. 3.2.2.1 and Fig. 3.2.2.2). 2 - 
Hexan/hexen-oyl – pantetheine 228/229 and holo-ACP - 2 - hexan/hexen-oate 231/232 did not 
showed activity in BfL2 reaction. Hexanoyl – CoA 230 has m/z [M - H]- 864. After the BfL2 
reaction, a new compound was observed by ELSD. The new peak had m/z [M - H]- 247 which 
was consistent with the citrate product 233. The boiled enzyme control showed no activity on the 
substrate (Fig. 3.2.2.1). 
 
Fig. 3.2.2.1 LCMS analysis of BfL2 reaction on hexaenoyl – CoA substrate. 
 
On the other hand, hexenoyl – CoA 107 was also used as substrate for BfL2 reaction. Hexenoyl 
– CoA 107 ([M - H]- 862) was catalyzed by BfL2 to form a new peak which has m/z [M - H]- 245. 
The molecular weight of this compound was consistent with the citrate product 108. The boiled 
enzyme control showed no activity on the substrate (Fig. 3.2.2.2).  
 
 
Fig. 3.2.2.2 LCMS analysis of BfL2 reaction on hexenoyl – CoA substrate. 
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The in vitro assay indicated that BfL2 can use both hexanoyl – CoA 230 and hexenoyl – CoA 107 
as substrates to form citrate products, but the configuration of the product was not clear. Because 
the production of the citrate in these analytical scale reactions was not enough for NMR analysis, 
the chemical synthesis of citrate 108 is a better way to compare with the BfL2 product. The citrate 





































racemic mixture of diastereomers  
Scheme 3.2.2.2 Synthesis route to alkyl citrate 108. 
 
According to proton NMR analysis, alkyl citrate 108 is a mixture of different stereoisomers and 
ring-open and ring-closed forms (Fig. 3.2.2.3). Comparing with the literature, the proton signals 
were annotated as follows: the proton indicated in blue was from the major anti - diasteromer 
108a (2R, 3S / 2S, 3R); and the proton indicated in yellow was the minor syn- diasteromer 108b 
(2R, 3R / 2S, 3S).[170-172] From HMBC data, we could see the difference between two 
diastereosomers (Fig. 3.2.2.4). It appeared that compound 108 seems to cyclises by itself, the 
proton signals in purple are from the cyclised isomers anti 238a and syn 238b. None of these 
compounds have any significant UV absorption when the mixture was examined by LCMS. 




Fig. 3.2.6.2 Proton NMR of the citrate and annotation of the isomers. 
 
 
Fig. 3.2.6.3 Proton NMR and HMBC data of two diastereosomers. 
 
The mixture of syn and anti diastereomers of the synthetic citrate 108 was analysed by LCMS. 
According to the analytical LCMS of 108, the retention time of 108a (major compound) is 3.3 
min, and 108b is 3.5 min. Neither of these two isomers have specific UV absorption. Both of 
these two isomers have [M - H]- 245 (Fig. 3.2.2.5). However, there was no signal (either ELSD 
or MS) of cyclised compound 238 on LCMS. This is consistent with previous results of Dr. 
Agnieszka Szwalbe, from the Cox group, who showed that 238 was volatile. 
 




Fig. 3.2.2.5 LCMS analysis of citrate substrate 
 
Extracted ion chromatogram analysis for the 245 ion showed two peaks. However, the BfL2 
reaction trace only showed one peak which had the same retention time as the anti - diasteromer 
108a (Fig. 3.2.2.6). It means BfL2 has a stereoselectivity on the substrate to form a single anti 
isomer. But whether the substrate is (2R, 3S) or (2S, 3R) is still unknown. 
 
 





Ⅲ  Modelling of CS 
 
114 
3.2.2.1b Multiple alignment and modelling of citrate synthase 
As described in section 1.5.3, BfL2 is a citrate synthase like enzyme encoded by the byssochlamic 
acid BGC. BfL2 catalyses the formation of an alkyl citrate using oxaloacetate 45 and polyketide 
CoA as substrate. Dr. Steffen Friedrich’s in vitro assay of BfL2 showed that BfL2 could use the 
tetraketide CoA (107 or 230) and 45 to produce (2R, 3S or 2S, 3R) distereoisomers (108 a/b or 
233 a/b Scheme 3.2.2.3). To additionally investigate the absolute configuration of the BfL2 
product, protein modelling and multiple alignment of BfL2 will be used to analyse the catalysis 
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Scheme 3.2.2.3 Proposed BfL2 reactions. 
 
During the 1990s, Karpusas et al obtained a crystal structure of Thermus thermophilus citrate 
synthase complexed with oxaloacetate 45 and the unreactive alkyl CoA derivative carboxymethyl 
CoA.[129] Based on this structure, the mechanism for the condensation reaction of citrate synthase 
was deduced. [173] The overall CS reaction is thought to proceed through three partial reactions 
and involves both closed and open conformational forms of the enzyme. These steps begin with 
generation of the carbanion (or equivalent) from acetyl-CoA 46 by base abstraction of a proton. 
The side-chain carboxylate of Asp-375 removes an acidic α proton from acetyl-CoA 46, while 
the side-chain NH of His-274 protonates the carbonyl oxygen, giving an enol. In the second step 
the nucleophilic attack of this carbanion on the Si face of oxaloacetate generates citryl-CoA. His-
274 deprotonates the acetyl-CoA enol 239, which adds to the ketone carbonyl group in an aldol-
like reaction. His-320 simultaneously protonates the oxaloacetyl carbonyl oxygen, producing S-
citryl CoA 240. Finally, the hydrolysis of citryl-CoA to produce citrate 241 and CoA is catalysed. 
S-citryl CoA 240 is hydrolyzed to citrate by a typical nucleophilic acyl substitution reaction, 








Scheme 3.2.2.4 Catalytic mechanism of citrate synthase in primary metabolism. 
 
In order to understand the reaction of the BfL2 citrate synthase better, we compared it to the well-
studied primary metabolism citrate synthases from T. thermophilus, Pyrococcus furiosus and E. 
coli that have been previously studied by crystallography and site direct mutation.[129, 175, 176] 
According to the basic information of the CS from primary metabolism of T. thermophilus,  
His-274, His-320 and Asp-375 are the conserved residues in the active site. So the amino acid 
sequences of primary metabolic CS from P. furiosus and E. coli (crystal structure already known), 
as well as secondary metabolic CS from B. fulva (BfL2 of byssoclamic acid 1 pathway) and P. 
variotii (PvL7 of cornexstin 66 pathway) were chosen to make a multiple alignment with ClustalX. 
The result indicated that the three residues (Fig. 3.2.2.7 highlighted with “*”) in the active site 
are conserved in both primary and secondary metabolic CS. Furthermore, the residues around the 
active site are also highly conserved. 
According to the result of multiple alignment with primary and secondary maetabolic CS, 
the residues around the active site are conserved between these two kinds of CS. It means that the 
protein structures of secondary metabolic CS are likely to be similar to the primary ones. In order 
to look into the protein structure and the active site information of BfL2, protein modelling was 
carried out in the next step. 
 
 




Fig. 3.2.2.7 Multiple alignment of primary metabolic and secondary metabolic CS sequences. Red highlight = 100% 
similarity; Yellow highlight = more than 60% similarity. 
 
By using online software SWISS-MODEL [177] and BLASTp, the closest structural model for 
BfL2 was found. A structure of citrate synthase (PDB ID: 2H12) [178] complexed with oxaloacetate 
(OAA) and carboxymethyldethia coenzyme A (CMX) from Acetobacter aceti was chosen as the 
structural model. Taking crystal structure of 2H12 as the template, a BfL2 protein structure model 
was built. The 2H12 and the BfL2 modelling structure were displayed and analysed on the 
software PYMOL.[179] The BfL2 model has a very similar structure as the 2H12 which is a dimer 
structure. The tertiary structure of the BfL2 (in green) and 2H12 (in blue) were highly similar in 
general (Fig. 3.2.2.8 A). In particular, the active site residues around the bound substrates OAA 
and CMX were very similarly located between the two structures (Fig. 3.2.2.8 B).  In addition, 
the residues around the OAA and CMX within 4 Å were displayed. The result showed that these 
active site residues were very closely overlapped between the two structures (Fig. 3.2.2.8 C and 
D). The key residues (His-284, His-323 and Asp-377) in BfL2 modelling are also very similarly 
located with 2H12 structure (Fig. 3.2.8.2 E). According to the polar contacts (yellow line) 
between substrate OAA / CMX and the active site residues, substrates are very likely to be bound 
in identical orientations. In particular, activation of oxaloacetate is likely to be identical in both 
cases. So the stereochemistry of BfL2 is extremely likely to be the same as the primary CS 2H12, 
resulting in an S-centre at the newly formed alcohol. 
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Fig. 3.2.8.2 Modelling of BfL2 (green) in byssochlamic acid pathway and structure of 2H12: A, alignment of BfL2 and 
2H12 structures; B, the residues around the OAA and CMX within 4 Å; C, residues around the OAA; D, residues around 
the CMX; E, key residues. 
 
To sum up, the catalytic residues are conserved in the protein sequence and are closely overlapped 
in the structure of both primary metabolic and secondary metabolic CS. This suggests that the 
two kinds of CS should have the same stereoselectivity. According to the enzymology of 2H12, 
it catalyses the formation of intermediate 2S-citryl CoA. Dr. Steffen Friedrich showed that the 
BfL2 catalyses the formation of 2R, 3S or 2S, 3R citrate product (section 3.2.1.1a ). If BfL2 has 
the same enzymology as primary CS, it should therefore synthesise the (2S, 3R) product. 
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3.2.2.2 In vitro assay of 2-Methyl citrate dehydratase 
BfL3 and PvL2 are 2-methyl citrate dehydratase-like enzymes involved in the biosynthetic 
pathway of byssochlamic acid 1 and cornexstin 66. The substrate of both BfL3 and PvL2 was 
shown to be alkyl citrate 108a as described in section 3.2.2.1. In this section, the in vitro assay of 
BfL3 and PvL2 was carried out, and the stereoselectivity of these two enzymes were explored. 
As described in section 3.2.1, by using yeast expression, 2-methycitrate dehydratase PvL2 
and BfL3 were expressed. The mixture of isomers of 108 was then used as the substrate for in 
vitro assay of the 2MDH proteins. Citrate mixture 108 1 mM was incubated with cell free extract 
of the yeast strain expressing PvL2 and BfL3 at 30 ℃ for 2 hours in 100 μL PBS buffer. The 
reaction was stopped by addition of 100 μL methanol (section 5.3.5). Protein was removed by 
centrifugation and the supernatant was analysed directly by LCMS. 
 
 
Fig 3.2.2.9 LCMS analysis of PvL2 and BfL3 reactions in vitro. 
 
Both PvL2 and BfL3 showed activity on the mixture of citrate diastereomers (Fig. 3.2.2.9). From 
the ELSD detector, it was obvious that the peak area at 3.5 min (from PvL2 reaction) increased 
compared with the empty vector control (Fig. 3.2.2.9 A/C), whereas, BfL3 didn’t show much 
difference with the control (Fig. 3.2.2.9 B). But when it comes to the UV detector, both PvL2 and 
BfL3 formed a new peak with λmax 269 nm (Fig. 3.2.2.9 B and C). The empty vector control had 
no UV absorption in the same position (Fig. 3.2.2.9 A).  
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From the previous study of Dr. Agnieszka Szwalbe,[29] the maleic anhydride monomer 110 
(Scheme 3.2.2.5) is known to decarboxylate spontaneously.[2] At the same time, 110 and its 
decarboxylated form 111 also equilibrate with ring-opened forms of 109 and 242, both of them 
had similar UV spectra (λmax = 269 nm) and the expected masses (m/z 227.5 and 183.5 [M + H2O 
- H]- respectively). The features of the compound 109 were consistent with the new compound 
synthesised from the PvL2 and BfL3 in vitro reactions (Fig. 3.2.6.5 B and C). However, this new 
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Scheme 3.2.2.5 Decarboxylation and ring opening of maleic anhydride monomer. 
 
In addition, when we observed the extracted UV chromatogram at 313 nm (the maximum 
absorption wavelength of maleic anhydride monomer), a small peak showed at 5.83 min (Fig. 
3.2.2.10 A). The ES- of this peak was 165 which corresponds to the fragment [M - COOH]-  from 
maleic anhydride monomer 110 (Fig. 3.2.2.10 B and C). However, the empty vector control had 
no peak in this region. The UV spectrum of this peak was too weak to detect. 
 
Scheme 3.2.2.10 Chromatography of PvL2 reaction: A, under UV 313nm; B, ES- 165; C, MS spectrum of the 5.8 min 
peak. 
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In summary, by using yeast expression cell-free extraction of PvL2 and BfL3 and a mixture of 
citrate isomers to do the in vitro reaction, one new compound with UV spectrum (λmax = 269 nm) 
formed. This compound corresponds to the maleic anhydride monomer ring-opened form 109. In 
addition, a very weak peak in PvL2 reaction was detected which is thought likely to be maleic 
anhydride monomer 110. The LCMS result of the in vitro assay on PvL2 and BfL3 indicated that 
the enzyme probably accepts the isomer 108a (2R, 3S / 2S, 3R) as its substrate. To make sure 
which isomer the citrate dehydratase uses as its the substrate, the single isomer should be used in 
the reaction. 
 
3.2.2.3 Stereoselectivity of 2-methyl citrate dehydratase  
Initial in vitro assays showed that both PvL2 and BfL3 were active, but the results did not reveal 
the stereoselectivity of the enzymes. Therefore, a purification method (prep-column and prep-
programming see section 5.5.3) was set up for separating the isomeric 108a anti (2R, 3S / 2S, 3R) 
and 108b syn (2S, 3S / 2R, 3R) diastereomers by prep-LCMS (Fig 3.2.2.11, section 5.3.3). Both 
108a (2R, 3S / 2S, 3R) and 108b (2S, 3S / 2R, 3R) had [M - H]- 245 (Fig. 3.2.2.11 A), and these 
two compounds were well-separated on a C18 reverse-phase prep-column. The two citrate isomers 
do not have UV absorption (Fig. 3.2.2.11 C) but can be observed by ELSD (Fig. 3.2.2.11  B). 
 
 
Fig. 3.2.2.11 LCMS purification result of citrate substrates, and the shaded peaks were purified: A, ES- 245 ion 
extraction; B, ELSD; C, UV chromatogram. 
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The pure racemic isomers of 108a (2R, 3S / 2S, 3R) and 108b (2S, 3S / 2R, 3R) were used for the 
DH assays in vitro. After 3 hours of incubation with substrate and enzymes (PvL2 and BfL3), the 
anti-isomer of 108a (2R, 3S / 2S, 3R) was clearly converted to a new product (the pink shade Fig 
3.2.2.12 A and B) compared with the control (Fig 3.2.2.12 C). However, syn diastereomer 108b 
(2S, 3S / 2R, 3R) had no reaction (Fig 3.2.2.12 D, E and F). Both PvL2 and BfL3 were selective 
for the 108a (2R, 3S / 2S, 3R) anti diastereomer.  
 
Fig 3.2.2.12 LCMS analysis of the DH reactions: A, B and C treated with (2R, 3S / 2S, 3R) anti substrate using enzyme 
BfL3, PvL2 and empty vector control respectively. D, E and F treated with (2R, 3R / 2S, 3S) syn substrate using enzyme 
BfL3, PvL2 and empty vector control respectively. 
 
The citrate substrate 108 has no conjugated double bond and therefore no significant UV 
absorption. The product 109 has a conjugated system, so the maximum absorption wavelength 
has a blue shift to 267 nm (Fig. 3.2.2.13 B). The molecular weight changed from [M - H]- 245 to 
[M - H]- 227. The fragment ion 165 [M - H2O - COOH]-  is due to decarboxylation (Fig. 3.2.2.13 
A). 




Fig. 3.2.2.13 UV and MS spectrum of product: A, UV spectrum; B, MS spectrum. 
 
The ES- extracted ion chromatogram (EIC) at m/z 245 and 227 were examined, the retention time 
of anti citrate substrate 108a (2R, 3S / 2S, 3R, grey shaded) was at 6.8 min (Fig. 3.2.2.14 A and 
C), while the double bond product 109 (pink shaded) was at 7.0 min (Fig. 3.2.2.14 D). In this 
chromatographic method, anti citrate substrate 108a (2R, 3S / 2S, 3R) had about 0.1 min time shift 
comparing with product 109. As for the reaction of empty vector control, there was no product 
peak shown on chromatogram (Fig. 3.2.2.14 B). 
 
Fig. 3.2.2.14 ES- spectrum of substrate and product: A and B, empty vector control in ES- 245 and 227; C and D, PvL2 
reaction in ES- 245 and 227. 
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It was interesting that when we observed the extracted UV chromatogram at 313 nm (the 
maximum absorption wavelength of maleic anhydride monomer), a small peak showed at 9.7 min 
(Fig. 3.2.2.15 B). The ES- of this peak was 165 which corresponds to the fragment [M-COOH]-  
from maleic anhydride monomer 110 (Fig. 3.2.2.15 B). The UV spectrum of this peak had a 
maximum absorption at 312 nm which was consistent with anhydride monomer 110 (Fig 3.2.7.5 
B). However, the empty vector control had no peak in this region (Fig. 3.2.2.15 A). It means that 
the DH enzyme can dehydrate citrate and at the same time the product 109 can cyclise by itself 
in the reaction conditions. Finally, we got a mixture of ring-opened and ring closed products. 
 
 
Fig. 3.2.2.15 Chromatography of PvL2 and empty vector control reaction under UV 313nm, and MS and UV 
spectrum of the maleic anhydride monomer: A, control; B, PvL2. 
 
To sum up, at this point, it has been determined that the 2-methyl citrate dehydratase can only 
accept the 108a anti diastereomer (2R, 3S / 2S, 3R) as its substrate to form the product 109. 
Compound 109 was a ring-opened form of maleic anhydride monomer, at the same time, a little 
amount of cyclised anhydride product 110 can also be found in the reaction mixture. It means 
product 109 and anhydride monomer 110 had a reversible reaction. Our previous analysis of the 
steroselectivity of the citrate synthase (section 3.2.2.1) strongly suggested formation of the 2S 
enantiomers. This therefore strongly suggests that the true substrate for 2MCDH is the (2S, 3R ) 
isomer (Scheme 3.2.2.6).    
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Scheme 3.2.2.6  A summary of citrate synthase and dehydratase reactions. 
 
3.2.2.4 In vitro study of dimerization step 
Our group has carried out the in vivo study on the biosynthesis of byssochlamic acid 1 through 
gene disruption and heterologous expression (see section 1.5.2).[3] The result indicated that the 
enigmatic ring formation appears to be catalysed by two proteins (BfL6 and BfL10) with 
homology to ketosteroid isomerases (KSI), and assisted by two proteins (BfL5 and BfL9) with 
homology to phosphatidyl ethanolamine-binding proteins (PEBP).  The substrate of KSI-like and 
PEBP enzymes is thought to be the maleic anhydride monomer 110. KSI-like and PEBP-like 

























Scheme 3.2.2.7 Proposed dimerization reaction based on KI and PEBP enzymes 
 
The maleic anhydride monomer 110 is the most important substrate for the in vitro assay. Our 
group member Dr. Steffen Friedrich worked on the synthesis of 110. But it was very difficult to 
obtain 110 by chemical synthesis due to the instability of this compound. On the other hand, it 
could be possible to purify 110 from extraction of byssochlamic acid intermediate producing 
strains of A. oryzae (from Dr. K. Williams). In this section, KSI-like genes (bfL6 and 10) and 
PEBP-like genes (bfL5 and 9) are expressed in E. coli and yeast. The enzymes were then used for 
in vitro assays with the substrate 110. 
 
3.2.2.5 Regrowing the byssochlamic acid biosynthetic pathway genes A. oryzae strains 
To obtain maleic anhydride monomer 110 and get better knowledge and information about the 
biosynthesis of byssochlamic acid 1 and the dimerization step, the A.oryzae transfomants which 
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contain core genes for monomer and KSI / PEBP genes inside were regrown (transformants are 
from Dr. K. Williams). In particular this included the genes PKS, hyd (bfL1), CS (bfL2), 2MCDH 
(bfL3) plus KSIs (bfL6 and 10) and PEBPs (bfL5 and 9). 
After 7 days’ fermentation (28 ℃ and 130 rpm) in CMP medium, compounds of each 
transformant were extracted and analysed by LCMS (Fig. 3.2.2.16). The transformant with two 
KSI alone and the transformant with two KI/PEBP co-expressed with core genes for monomer 
produce the expected final compound byssochlamic acid 1 (Fig. 3.2.2.16 A and B red shaded) 
and agnestadride A 70 (Fig. 3.2.2.16 A and B green shaded). Both compound 1 and 70 have a 
molecular ion of [M - H]- 331 (Fig. 3.2.2.16 C and D).  However, the A. oryzae NSAR1 wild type 
and the transformant with only core genes didn’t produce any dimerised products (Fig. 3.2.2.16 
C and D). Furthermore, from experiments A, B and C (Fig. 3.2.2.16 A/ B/ C), there was almost 
no detectable maleic anhydride monomer 109 observed in the chromatograms, and it might be 
because that the monomer was unstable after a long fermentation time. 
 
 
Fig 3.2.2.16 Chromatography of A. oryzae transfromants with genes from byssochlamic acid pathway: A, core genes 
with 2 KSI and 2 PEBP; B, core genes with 2 KSI; C, core genes; D, wild type. All these chromatograms show at the 
same scale. 
Both experiments A and B produced the cometabolites which corresponed to the ring-opened 
form of byssochlamic acid 1 (Fig. 3.2.2.17 A and B purple shaded). Compounds 113 and 114 
with the [M - H]- 349 (Fig. 3.2.2.17 A) have been previously identified and characterized.[98] 
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Compounds with the retention time 7.9 min (blue shaded) is most likely compound 243 or one of 
its isomers (Fig. 3.2.2.17 B)  which is a monomethylated ester from byssochlamic acid 1. This 
was because of the addition of methanol to dissolve the extraction mixture. The previous study of 
our group indicated that the closed anhydride form is more stable in an organic solvent like 




Fig 3.2.2.17 MS spectrum, UV spectrum and structures of the products: A,ring opened byssochlamic acid 113/114; 
B, methylated byssochlamic acid 243; C, agnestadride A 70; D, byssochlamic acid 1. 
 
In summary, KSI should be the most important enzyme for the dimerization step in the 
biosynthesis of  byssochlamic acid 1. The production of the dimerised compounds slightly 
increased when two PEBP enzymes were involved. However, from the previously published data, 
the PEBP-like enzyme take a very important role to increase production of the final compounds. 
However, in my case, the two KI transformants and the two KI with two PEBP transfromants 
didn’t show significant difference in the titer of the dimerised compounds, showing that the PEBP 
is not essential. 
 
































































Scheme 3.2.2.8 Proposed mechanism of the acid-catalysed anhydride opening reaction in byssochlamic acid 1 (R = 
H in reaction with water; R = CH3 in reaction with methanol). 
 
3.2.2.6 Preparing the decarboxylated maleic anhydride monomer substrate and in vitro test 
The maleic anhydride 110, the product of the DH reaction, was proposed to be the substrate for 
the KSI-like enzymes, so the A. oryzae transformant containing all of the byssochlamic acid 1 
biosynthesis genes was used for monomer production and purification. However, the experiment 
in section 3.2.10 showed that there was no anhydride monomer produced after seven days’ 
fermentation. A time-course experiment was therefore carried out to test when it would be the 
best time to get enough anhydride monomer for purification. The result showed that monomer 
110 was produced after three days and increased in the next days (Fig. 3.2.2.18 B and C), but it 
disappeared after seven days’ fermentation (Fig. 3.2.2.18 A). 
A large scale of fermentation (2 L, 4 days) was then used for purification. After the prep 
LCMS purification of compound 110, and freeze-drying, 1.5 mg of the pure compound was 
dissolved in DMSO and diluted in acetonitrile. The LCMS analysis showed that maleic anhydride 
110 seemed to decarboxylate to 111. Compound 110 had retention time at 5.7 min, however, the 
new peak 111 shifted to 7.4 min. In addition, although it had a similar UV spectrum to 110, the 
newly formed compound was not ionized well. This is in agreement with the previous 
observations of Dr. Agnieszka Szwalbe from the Cox group.[56] There was almost no compound 
110 left (Fig. 3.2.2.19). 
 




Fig. 3.2.2.18 Time course test for maleic anhydride monomer producing. 
 
Fig. 3.2.2.19 LCMS analysis of the purified maleic anhydride monomer. 
 
Even though the maleic anhydride monomer substrate decarboxylated, an in vitro test was still 
performed by using the compound 111 as a substrate. BfL6 (KI1) and BfL10 (KI2) from both 
yeast and E. coli expression (cell free extraction) were used in this assay. Empty vector 
transformants were used as controls. After three hours of incubation, the reaction was stopped by 
addition of 100 μL of CH3CN. Protein was precipitated by centrifugation and the reaction mixture 
was analysed by LCMS. No dimerization was observed (Fig. 3.2.2.20 A and C), however, the 
compound 228 was observed. This arises because of a ring-opening reaction (Scheme 3.2.2.9). 
The compound at retention time 7.6 min was converted to the compound at 4.5 min. And 
according to the UV spectrum of compound 4.5 min, it was the ring-opened form of 228. At the 
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Scheme 3.2.2.9 Maleic anhydride ring opening. 
 
 
Fig. 3.2.2.20  In vitro study on decarboxylated substrate 111. 
 
In addition, the in vitro dimerization test from Baldwin at al (section 3.1.1) suggested that the 
compound 111 could also be treated with DMSO and base (e.g. Et3N). The substrate used by 
Baldwin was 248 which was one carbon longer than 111.[154] In this experiment, 5 mg of 
compound 111 was incubated with 200 μL of DMSO and 10 μL of Et3N. The reaction system had 
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colour changes in 48 h (Fig. 3.2.2.21). After 48 h reaction, the sample was analysed by LCMS. 
The anhydride monomer at 7.4 min had almost disappeared and some new peaks appeared. But 
these peaks had weak UV absorptions (Fig. 3.2.2.22 D). Among these new peaks, ESI MS spectra 
indicated some putative dimerization products. These compounds gave the [M + H]+ 315 (Fig. 
3.2.2.22 A), [M - H]- 349 (Fig. 3.2.2.22 B) and [M + H]+ 333 (Fig. 3.2.2.22 C). According to the 











Fig. 3.2.2.21 Colour changes of in vitro reaction of the dimerization. 
 
 
Fig. 3.2.2.22 LCMS analysis of 48h reaction of in vitro study. 
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Our group member Dr. Agnieszka Szwalbe also previously carried out a similar experiment using 
synthetic sample 110 in her PhD project. The sample was placed in DMSO and colour changes 
recorded over time. When she analysed the DMSO sample after 48 h, the decarboxylated 
monomer 111 showed but also some new peaks. And one sample gave a low-resolution molecular 
ion of m/z 331.7 which could be an isomer of byssochlamic acid 1. But due to tiny amounts of the 
sample, the dimerised compound has not yet been purified and identified by NMR. 
 
3.2.2.7 Preparing the maleic anhydride monomer substrate 
Because the decarboxylated monomer 111 seemed to be not bioactive, different purification 
conditions were tested to protect the compound 110 from decarboxylation. Firstly, freeze-drying 
was found to be one reason for decarboxylation. Every time compound 111 was purified from 
prep-LCMS and freeze-dryied overnight, anhydride 111 would almost totally decarboxylate to 
110 (see section 3.2.10.1). Secondly, organic solvent like DMSO and CDCl3 would also make the 
compound 110 decarboxylate, and dimerization of the monomers would happen next (see section 
3.2.10.1). Thirdly, nucleophilic solvents such as MeOH would make the maleic anhydride 
monomer ring-open and esterify (see section 3.2.9). 
 
 
Fig. 3.2.2.23 LCMS analysis of maleic anhydride monomers: A, chromatogram; B, UV spectrum; C, MS. 
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The best way to prevent the decarboxylation and ring-opening problems was to purify compound 
110 by LCMS. Under these conditions 110 was obtained pure in a mixture of H2O and CH3CN. 
These solvents were then directly removed by rotary evaporation at 5 mbar and 40 ℃. After 
evaporation, 200 μL ddH2O was added to give a maleic anhydride monomer 110 suspension. The 
suspension was analysed by LCMS. The compound 110 was still in the sample at 6.0 min. The 
ring-opened citrate 109 elutes at 3.6 min, and there was some dicarboxylate compound 111 (Fig. 
3.2.2.23 A). The UV and MS spectra of these three compounds were identical to the previous 
study (Fig. 3.2.2.23 B and C). Therefore, this method could be used for making the substrate for 
the in vitro study of KSI and PEBP enzymes. 
 
3.2.2.8 In vitro study of yeast expressed KI and PEBP enzymes 
In 3.2.10.2, the substrate problem of decarboxylation has been resolved, so KSI and PEBP 
enzymes can be tested using compound 110. First of all, the pESC-URA vector with whole ORF 
of bfL5/6/9 and 10 were transformed into yeast host Saccharomyces cervisiae w303B, and 
checked by yeast colony PCR (Fig. 3.2.2.24). Then BfL5-2, BfL6-1, BfL9-2, BfL10-2 were 
chosen for protein expression. 
 
Fig. 3.2.2.24 Yeast colony PCR. 
 
Cell-free extracts of BfL5, 6, 9 and 10 yeast transfomants were prepared by using a glass bead 
vortex method (section 5.6.3). Maleic anhydride monomer suspension 110 (15μL) and each cell 
extraction BfL5 /6 /9 and 10 (20 μL) then mixed. After 8 hours’ reaction at 30 ℃, the reaction 
was stopped by adding 100 μL of acetonitrile. The protein was precipitated by centrifugation and 
the supernatant was analysed by LCMS.  
The result showed that the substrate 110 was converted to three products. These were 
decarboxylated product (peak 111) and ring-opened compound (peak 109). A new peak was 
observed in the chromatogram (Fig. 3.2.2.25 A). However, the empty vector control did not 
produce the new peak (Fig. 3.2.2.25 E). Analysis of the MS spectrum and UV spectrum of peak 
1 showed that the compound (red shade) was identical with byssochlamic acid 1. It had molecular 
ion of m/z 331 (Fig. 3.2.2.26) and maximum UV absorption at 248 nm which was the same as 
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byssochlamic acid 1 (Fig. 3.2.2.26). The retention time of peak 1 was also identical to the product 
form the A. oryzae transformants (Fig. 3.2.2.25 G).  The results indicated that the mixed protein 
of two KI (BfL6 and 10) and two PEBP (BfL5 and 9) could dimerise the maleic anhydride 
monomer. However, there is no evidence of heptadride 70 formation according to the LCMS 
results. 
 
Fig. 3.2.2.25 LC-MS analysis the in vitro test using yeast expression protein KI and PEBP: A, two KSI and two PEBP; B, 
two KI; C, BfL6; D, BfL10; E, empty vector control; F, only substrate; G, producing A.orzyae transformant. 
 
At the same time, BFL6 and BFL10 were also tested without PEBP enzymes. A weak 
byssochlamic acid 1 peak was also detected (Fig. 3.2.2.26 B). Two KSI proteins together could 
catalyse the dimerization step without the help of the PEBP proteins which was consistent with 
the previous in vivo study in A. oryzae.[3]  In addition, BfL6 and BfL10 were tested separately in 
two different reactions. Both BfL6 (Fig. 3.2.2.25 C) and BfL10 (Fig. 3.2.2.25 D) had a weak 
activity of dimerization to give a low concentration of byssochlamic acid 1. When we look into 
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the ES- 331 of LCMS data, it was clearer to see the production of byssochlamic acid 1 product 
from the KI enzymes (in red shade, Fig. 3.2.2.25 A/B/C/D and G) 
 
 
Fig. 3.2.2.26 MS spectrum and UV spectrum of peak 1 
 
 
Fig. 3.2.2.27 LCMS analysis the in vitro test using yeast expression protein PEBPs alone. 
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Finally, PEBP enzymes BFL5 and BFL9 were tested in this study to check if they were related to 
the dimerization reactions.  The result indicated that no matter whether both BFL5 and BFL9 (Fig. 
3.2.2.27 A) were tested together or they worked separately (Fig. 3.2.2.27 B and C), there was no 
byssochlamic acid 1 formation compared with empty vector control (Fig. 3.2.2.27 D) and A. 
oryzae transformant (Fig. 3.2.2.27 F). 
 
3.2.2.9 In vitro study of E. coli expressed KI and PEBP enzymes 
As it was displayed previously (see section 3.2.2), KI and PEBP enzymes were also expressed in 
E. coli. Due to N terminal signal peptide, it was difficult to express BfL5, BfL6, and BfL10 
directly using whole ORF amino acid sequence. The signal peptide sequence was removed by 
PCR when the expression vector was constructed. To improve the solubility, chaperone proteins 
were co-expressed with KI and PEBP enzymes. Two KI enzymes were used in this study. 
 
 
Fig. 3.2.2.28 LCMS analysis the in vitro assay using E. coli expression protein KSI and PEBP proteins. 
Ⅲ  Signal peptide 
 
136 
The crude E. coli cell extractions were used for in vitro assay. The experimental groups were set 
up as BfL6+10 (two KI Fig. 3.2.2.28 A), BfL6 (KI1 Fig. 3.2.2.28 B), BfL10 (Fig. 3.2.2.28 C) 
and empty vector control (Fig. 3.2.2.28 D). After the 8h reaction, reactions were stopped by 
addition 100 μL of CH3CN, then the samples were analysed by LCMS. From ES- analysis, the 
result indicated that none of this experimental group could give any dimerised product compared 
with A. oryzae transformant extraction (Fig. 3.2.2.28 F). It might be because the loss of  the N 
terminal signal peptide region made the proteins not stable or it can affect the proteins to get the 
right folding. 
 
 3.3 Discussion 
3.3.1 The signal peptide at the N terminus of the proteins 
When the KSI (BfL6 and BfL10) and PEBP (BfL5 and BfL9) enzymes were expressed as 
complete ORF in E. coli, no protein was observed. Bioinformatic analysis suggested that there 
were signal peptides containing 18 to 20 amino acids at the N-termini of proteins BfL5, 6 and 10. 
These signal peptides should direct the protein to specific sites within their native organisms.[180] 
So these KSI and PEBP enzymes should have protein targeting or protein sorting activities in B. 
fulva. 
Protein targeting or protein sorting is the biological mechanism by which proteins are 
transported to their appropriate destinations in the cell or outside it. Proteins can be targeted to 
the inner space of an organelle, different intracellular membranes, plasma membrane, or to the 
exterior of the cell via secretion. This delivery process is carried out based on information 
contained in the protein itself.[181] A signal peptide (sometimes referred to as signal sequence, 
targeting signal, localization signal, localization sequence, transit peptide, leader sequence or 
leader peptide) is a short peptide (usually 16-30 amino acids long) present at the N-terminus of 
the majority of newly synthesized proteins that are destined towards the secretory pathway. [180] 
Our in vitro study on KI and PEBP enzymes suggested that BfL6 and BfL10 tended to be 
active at the high concentration of maleic anhydride monomer substrate. So it can be proposed 
that BfL6 and BfL10 can also be transported to an appropriate destination which contains a high 
concentration of substrate. 
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3.3.2 The substrate and stereochemistry of citrate synthase 
3.3.2.1 Substrate of CS 
As described in section 3.1.1.1, the citrate synthase BfL2 can use 2 - hexan/hexen-oyl – CoA 
107/230 as its substrate and catalyses the condensation with OAA. However, holo-ACP - 2 - 
hexan/hexen-oate 231/232 are not active for BfL2 (Scheme 3.3.2.1 A). This result shows the CS 
function does not correspond with the supposition of the Tang group. Tang and co-workers 
reported the reconstitution studies of 254 in A. nidulans. They found that only three enzymes, 
HRPKS (Clz14), citrate synthase (Clz17) and hydrolase (Clz11) were needed to produce the 
compound 254. They inferred that citrate synthase Clz17 was essential in the biosynthesis as 
removing the gene from A. nidulans abolished production. They proposed that the HRPKS 
synthesized the polyketide, and Clz17 directly took the ACP bond polyketide 252 catalysing the 
addition to oxaloacetate. Clz11 was then responsible for directly hydrolysing 253 to yield 254 
(Scheme 3.3.2.1 B).[182]   
According to our in vitro assay on BfL2, CS uses polyketide CoA as its substrate but not 
an ACP bound polyketide. Byssochlamic acid BGC does not involve the key enzyme for the 
formation of polyketide CoA, Therefore, there should be a CoA ligase somewhere in the genome 
to produce the polyketide CoA substrate.  
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Scheme 3.3.2.1 Substrate of CS: A, BfL2 reaction with different substrate; B, proposed function of the CS and 
hydrolase in zaragozic acid A pathway. 
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3.3.2.1 Stereochemistry of CS 
According to the LCMS and NMR analysis of BfL2 reaction (section 3.1.1.1), BfL2 is shown to 
have a stereoselectivity to produce anti diastereomers 108a (2R, 3S / 2S, 3R Scheme 3.3.2.2 A). 
The primary metabolism CS from Thermus thermophilus is known to produce a S-citryl CoA 241 
(Scheme 3.3.2.2 B).[129]  Two 2-methylcitrate synthases MmgD from Bacillus subtilis [183] and 
PrpC from E. coli [184]  are repoted to catalyze the formation of either (2S, 3R)- or (2R, 3S)- 2- 
methylcitrate 256 (Scheme 3.3.2.2 C), which is consistent with BfL2. However, different from 
the enzyme catalysis, chemical synthesis of alkyl citrate can only produce a racemic mixture of 








































































Scheme 3.3.2.2 Stereochemistry of CS and chemical synthesis: A, BfL2; B, primary metabolic CS; C, MmgD; D, 
chemical synthesis. 
 
In this project, an in silico protein model of BfL2 was built by using a primary metabolism CS 
(PDB ID: 2H12) as the template (section 3.1.1.2). Compared with the 2H12 structure, the BfL2 
model is highly similar. In particular, the active site residues around the bound substrates are very 
similarly located between the two structures. Therefore substrates are likely to be bound in 
identical orientations. The catalytic residues are conserved and closely overlapped in both primary 
metabolic and secondary metabolic CS. This suggests that the two kinds of CS 
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are highly likely to have identical stereoselectivity. 2H12 catalyses the formation of 2S - citryl 
CoA. Dr. Steffen Friedrich showed that the BfL2 catalyses the formation of anti (2R, 3S / 2S, 3R) 
citrate product (section 3.2.1.1a). If BfL2 has the same enzymology as primary CS, it should 
obtain a 2S product. Because the in vitro experiment shows that BfL2 produces anti product, it 
means if C2 position is S, the C3 position must be R. Therefore BfL2 should produce a (2S, 3R) 
product. This also corresponds with 2S citrates in squalestatin S1 7 and viridiofungin A 2 which 
are also installed by CS enzymes. 
 
3.3.3 Stereochemistry of dehydratase 
To test the stereoselectivity of the dehydratase, two diastereoisomers produced by synthesis were 
separated by HPLC and individually tested as substrates. In vitro study on dehydratase BfL3 and 
PvL2 showed that both of these enzymes had stereoselectivity of citrate substrate (section 3.2.2.3). 











































Scheme 3.3.3.1 The three most common mechanisms for elimination: A, E1 reaction; B, E2 reaction; C, E1cB 
reaction. 
 
The citrate dehydratases PvL2 and BfL3 catalyse elimination reactions, which eliminate H2O to 
yield an alkene. There are three common mechanisms of elimination reactions: E1, E2 and E1cB. 
In the E1 reaction, the C-OH bond breaks first to give a carbocation intermediate 260 (Scheme 
3.3.3.1 A). However, E2 reaction gives the alkene 263 in a single step without intermediates 
(Scheme 3.3.3.1 B). In the E1cB reaction, the C-H bond breaks first, giving a carbanion or enol 
intermediate 265 to lose OH- (or H2O) to form the alkene 266 (Scheme 3.3.3.1 C). [61]  Among 
Ⅲ  Stereochemistry of dehydratase 
 
140 
three of the reactions, E1cB is the most common type of elimination in biological pathways. An 
example is the DH domain in the fatty acid synthase catalysis dehydration of the β-hydroxy 
thiolester to the unsaturated thiolester. [6] And for this example, the –H and –OH groups are 
eliminated from the same side of the molecule. So the knowledge of the exact stereochemistry of 
the substrate can help us to know the mechanism (i.e. syn) of the enzyme.  
It has been discussed in section 3.3.2 that citrate synthase BfL2 can only produce an anti 
(2S, 3R) diastereomer 108a. Dehydratase PvL2 and BfL3 directly take the citrate product 108a 
from BfL2 as substrate in the byssochlamic acid pathway. Therefore, PvL2 and BfL3 must 
eliminate the –H and –OH groups from opposite side (anti). 
Two 2- methylcitrate dehydratases MmgD from Bacillus subtilis and PrpC from E. coli are 
repoted to dehydrate at least two of the four diasteromers of  2-methylcitrate 256 to yield either 
E-2-methylaconitate 267 or Z-2-methylaconitate 268 (Scheme 3.3.3.2 A).[171, 183] Either MmgD 
or PrpC is not a stereospecific enzyme. However, in the case of BfL3 and PvL2, both of these two 
CMDH show stereospecificty on anti (2R, 3S / 2S, 3R) diastereomers. According to the BfL2 
modelling results, the substrate of BfL3 and PvL2 is more likely to be (2S, 3R). After the 
dehydration, the anti citrate substrate gives a Z-2-hexaconitate 109, and additional dehydration 
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Scheme 3.3.3.3 Stereochemistry of CMDH: A, MmgE and PrpD; B, BfL3 and PvL2. 
 
3.3.4 Maleic anhydride monomer 
The maleic anhydride 109 is thought to be the basic unit of the maleidrides. The in vivo study in 
A. oryzae indicates that introducing PKS, citrate synthase and 2-methylcitrate dehydratase was 
enough to obtain the maleic anhydride monomer.[7] However, from the in vitro study on citrates 
and dehydratase, it seemed that we could only get very little cyclised compounds. This 
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phenomenon might because of the maleic anhydride monomer with the spontaneous ring opening. 
[185] 
From Dr. Agnieszka Szwalbe’s study, maleic anhydride 110 was chemically synthesized.[2] 
However, the route is difficult to follow in our lab, because one reagent is no longer commercially 
available. To obtain the maleic anhydride substrate, the A. oryzae transfomant from Dr. Williams 
containing core genes and two KI and two PEBP genes was grown for monomer purification.[3] 
In this project, more detailed studies of maleic anhydride monomer 110 were carried out. 
From our previous study from Dr. Szwalbe, a maleic anhydride monomer tended to auto-
decarboxylate. When the fresh sample of monomer was analysed by 1H NMR, the presence of a 
signal at δH 3.6 (CH2-COOH) indicated that the compound was initially carboxylated. However, 
for the older sample, the presence of δH 2.1 (CH3) replaced the δH 3.6 peak which was susceptible 
to auto-decarboxylation.[2] In this study, we found a way to protect the maleic anhydride monomer 
from decarboxylation and ring-opening. There are several reasons for decarboxylation and ring-
opening. Firstly, freeze-drying turned out to be one reason for decarboxylation. Secondly, organic 
solvent like DMSO and CDCl3 would also make the compound 109 decarboxylate, and 
dimerization of the monomers would happen next. Thirdly, the solvent like MeOH would make 
the maleic anhydride monomer ring-open and esterify to 269. The decarboxylated product was 

























































Scheme 3.3.4.1 Chemical changes of maleic anhydride in different condition and different solvent. 
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3.3.5 Decarboxylation during the biosynthesis of maleidride 
Our experiment have previously identified that the maleic anhydride monomer 110 could 
decarboxylate spontaneously to give 111 (Scheme 3.3.5.1 A). This demonstrats that, at least for 
the shorter-chain maleic anhydrides, no enzymatic decarboxylation was necessary. Oikawa and 
co-workers suggested that the longer-chain decarboxylated monomer 186 isolated from their 
heterologous expression experiments was produced by an adventitious native decarboxylase 






























C stable and no decarboxylation
109  
Scheme 3.3.5.1 Decarboxylation of maleic anhydride monomer 
 
On the other hand, our group members Dongsong Tian and Dr. Eric Kuhnert worked on the 
biosynthesis of sporothriolide 77 (unpublished) and oryzine A 129 [105]. These two gene clusters 
encode the core enzymes for alkyl citrate synthesis including citrate synthase, 2-methyl citrate 
dehydratase, and fatty acid synthase. The BGC also encode one decarboxylase (m2L6 and oryM, 
Fig. 3.3.5.1). In the structure of sporothriolide 77 and oryzine A 129, there was no maleic 
anhydride monomer motif in their structure. The decarboxylation step of sporothriolide and 
oryzine A should be different from the maleic anhydride 110.  
Experiments show that maleic anhydride monomer 110 can decarboxylate spontaneously 
after formation of five-membered anhydride ring. However, the five membered ring precursor 
citrate 227 does not auto-decarboxylate (Scheme 3.3.5.1C). So it probably can be explained: 
because sporothriolide 77 and oryzine A 129 had decarboxylases involved in the gene clusters, 
the citrate precursor would decarboxylate in this stage other than cyclise into five-membered 
anhydride ring (Scheme 3.3.5.1). Our experiments show that the alkyl citrates 109 are stable and 
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do not easily decarboxylate, but after the 2MCDH step the products 110 decarboxylate easily. 
Since the sporothriolide and oryzine cluster lack a 2CMDH they require a dedicated decarboxylate 



















































Scheme 3.3.5.1 Proposed gene cluster and biosynthetic pathway of sporothriolide 77 and oryzine A 129. 
 
3.3.6 Dimerization 
The result in this study showed that compound 111 on its own was not a substrate for the KI 
reaction. It indicated that spontaneous decarboxylation of maleic anhydride monomer is important 
to drive the reaction. The in vitro test on compound 111 treating with DMSO and Et3N shows that 
the cyclization reactions were chemically feasible (section 3.2.4.1). Due to the low concentration 
of the product, it was difficult to purify the dimerized compounds 249-251 for characterization. 
However, these compounds were corresponded to Baldwin’s in vitro reaction with compound 248 
(scheme 3.3.6.1 A).[156] The LCMS results indicated that in vitro 248 could also be cyclized into 
different types of dimerized compounds 270-272 which could be related to Baldwin’s results 
(scheme 3.3.6.1 B). As was shown in the chemical reaction of the maleic anhydride monomer 
111, we were not able to observe byssocholamic acid 1 or angestadride 70 formation. This means 
KI took an important role to control the reaction type in dimerization step in fungus. 










































Et3N, DMSO + +
A
B
[M + H]+ 333 [M - H]
- 349 [M + H]+ 313
248 270 271 272
111
249 250 251  
Scheme 3.3.6.1 in vitro study of chemical reaction of dimerization. A, Baldwin’s result; B, proposed structure of the 
dimerised compounds. 
 
The in vitro assay showed that both KI enzymes (BfL6 and BfL10) had a weak activity of 
dimerization. The product is byssochlamic acid 1. But there was no evidence of heptadride 70 
product. No matter in the B. fulva strain or KI genes transformed A. oryzae strain, heptadride 70 
was always a very minor product compared with byssochlamic acid 1. Heptadride 70 might be a 
side product of KI enzymes. 
 
3.3.7 Function of PEBP enzymes 
According to our in vitro study on KI genes, the result suggested that either KI encoded by the 
byssochlamic acid gene cluster is able to catalyse the dimerization step. This is consistent with 
the fact that most maleidride BGC encode only a singal KI, and the byssochlamic acid BGC 
probably repeateds a gene duplication. However, the exact function of PEBP enzymes is still not 
clear yet. 
 
Fig. 3.3.7.1 Protein structure of the phosphatidylethanolamine-binding protein from bovine brain. 
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Phosphatidyl ethanolamine-binding protein (PEBP) is a basic protein found in numerous tissues 
from a wide range of species. The screening of gene and protein data banks defines a family of 
PEBP-related proteins that are present in a variety of organisms, including Drosophila and inferior 
eukaryotes. [186] PEBP binds to phosphatidyl ethanolamine and nucleotides in vitro, but its 
biological function in vivo is not yet known. Structures have been determined for several members 
of the PEBP-like family, all of which show extensive fold conservation. The structure consists of 
a large central beta-sheet flanked by a smaller beta-sheet on one side, and an alpha helix on the 
other (Fig. 3.3.7.1).[187] Sequence alignments show two conserved central regions, CR1 and CR2, 
that form a consensus signature for the PEBP family. These two regions form part of the ligand-
binding site, which can accommodate various anionic groups. In PEBP, a small cavity close to 
































Scheme 3.3.7.1 The mechanism of in vivo carbanion formation via decarboxylation. 
 
As we supposed previously, the maleic anhydride 110 is spontaneously decarboxylated and forms 
a carbanion intermediate 216-218 (Scheme 3.3.7.1). Then PEBP proteins were thought to be able 
to have the anionic binding ability. Therefore, it could be proposed that, because PEBP had a high 
affinity for anions, they could attract the carbanion of maleic anhydride monomer to make a 
relatively high concentration of substrate for the next dimerization step. In addition, it can also be 
explained that the N terminal signal peptide of KI and PEBP enzymes can target these proteins in 
a specific place in cells, then these enzymes can catalyse the reaction in a high concentration of 
substrate (Fig. 3.3.7.2). 
 
 




Fig. 3.3.7.2 Proposed function of PEBP based on the signal peptide. 
 
3.4 Conclusion and outlook 
The aim of this project was to explore the biosynthesis of byssochlamic acid 1 and angestadride 
70 and try to delineate the enzymes involved in the BGC of these two compound. Based on our 
previous in vivo study of heterologous expression, the BGC in A. oryzae, the enzymes related to 
the biosynthesis of byssochlamic acid 1 were expressed in E. coli or in yeast for in vitro assay. 
The stereoselectivities of the enzymes were also explored in this project. 
1. Protein expression 
 By using different organisms (E. coli and yeast) and different methods (different induction 
condition, removing signal peptide and co-expression with charpnones) the hydrolase (BfL1), 
citrate synthase (BfL2), 2- methyl citrate dehydratase (BfL3 and PvL2) and KI and PEBP proteins 
(BfL5 / 6 / 9  and 10) were expressed. 
2. In vitro assay of hydrolase and citrate synthase 
 Dr. S. Friedrich characterised the function of the hydrolase (BfL1) and citrate synthase (BfL2) 
using E. coli expression and in vitro assay. BfL1 shows the activity to hydrolysis both polyketide 
CoA and ACP bond polyketide.   
Citrate synthase BfL2 can take polyketide CoA (but not ACP bond polyketide) as a 
substrate together with oxaloacetate to form the anti citrate product (2R, 3S / 2S, 3R).  
The citrate synthase BfL2 protein structure modelling result shows that the modelling is 
very similar with the CS from primary metabolism (stereoselectivity 2S). The active site residues 
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were very closely overlapped between the two structures. Substrates are likely to be bound in 
identical orientations. Based on this information, BfL2 possibly has a steroselectivity of (2S, 3R). 
3. In vitro assay of 2MCDH 
 2-methly citrate dehydratase BfL3 and PvL2 were expressed in yeast and treated with 
diastereosomers of citrate substrates. Both BfL3 and PvL2 can only recognise the anti 
diastereoisomer of (2R, 3S / 2S, 3R) citrate other than syn (2S, 3S / 2R, 3R) and dehydrated the 
substrate to form an alkene 109. In addition, the product from BfL3 and PvL2 can spontaneously 
cyclised into a five-membered maleic anhydride 111, and the anhydride had a balance between 
the cyclised form and the ring-opening form 109. 
4. In vitro assay of dimerization step 
The dimerization-related enzymes KI and PEBP were examined by in vitro. The maleic anhydride 
110 is thought to be the substrate of dimerizaiton related enzymes. The dehydrated compound 
110 was very easily decarboxylated to form 111 which was inactive in downstream reactions. 
However an effective purification protocol allowed 110 to be prepared for in vitro assay with the 
KI and PEBP cell-free preparations. In vitro study on KI (BfL6 / 10) and PEBP (BfL5 / 9) 
suggested that both BfL6 and BfL10 had a weak activity on maleic anhydride monomer to cyclise 
and form the byssochlamic acid 1. In the in vitro assay, single KI is active to catalysis the 
dimerization. Whereas, the in vitro assay showed that BfL5 and BfL9 were not related to the 
dimerization, 
5. Future work 
In the future, the heterologous expression system like Pichia pastoris or other eukaryotic system 
should be used to get better producing of BfL6 and BfL10. Because the activity of BfL6 and 
BfL10 produced by Saccharomyces cerevisiae is very weak, the mean reason for this should be 
that Saccharomyces cerevisiae didn’t produce enough protein for the in vitro test. If it is possible 
to get a good amount of protein, BfL6 and BfL10 could be sent for the identification of protein 
structure. The structural biology information of BfL6 and BfL10 can help us to get a better 
knowledge of the mechanism of dimerization function, and it can also help us to set up a strategy 
for site direct mutation of the KI enzymes. On the other hand, the KI genes in different 
biosynthetic pathway such as cornexstin 66, zopfielin 68 and viburspiran 69 can be exchanged by 




Chapter 4. Molecular Basis of Chain-Length Programming in a 
Fungal Iterative Highly Reducing Polyketide Synthase 
4.1. Background and aims of the project. 
4.1.1 Introduction. 
PKS-NRPS systems can be widely found in different fungal genomes. Highly reducing PKS (hr-
PKS) have sophisticated programming which control the keto-reduction, dehydration, specific C-
methylation and enoyl reduction steps during each cycle (Section 1.2.3),[109] and the chain-length 
is also programmed. However, the programming mechanism of hr-PKS is still unknown. The 
programming in hr-PKS has been rarely investigated. One of the biggest problems is that in an 
iterative PKS the extension steps are cryptic. [188] The structure of the polyketide cannot be 
predicted by sequence analysis. However, the biosynthesis of a few polyketides has been 
investigated in considerable detail and some information is starting to be discovered. In particular, 
the cases of tenellin 3 [10] and lovastatin 6 [189] have revealed key information about programming. 
 


























































Scheme 4.1.1.1 Biosynthetic pathway and gene cluster of Tenellin. 
 
As described in section 1.1, the gene cluster of tenellin 3 encodes four proteins. TenS is a PKS-
NRPS enzyme, and TenC is a trans-enoyl reductase. TenS and TenC work together to catalyse 
the formation of pretenellin A 273. TenA and TenB are P450 enzymes. TenA is involved in the 
ring expansion step from pretenellin A 273 to the pyridone pretenellin B 274. TenB then catalyses 




has a highly reducing PKS (hr-PKS) unit which form a doubly methylated pentaketide. The NRPS 





















































































































Scheme 4.1.1.2 TENS and DMBS KR domain swap experiments. 
 
In 2011 the Cox group reported a rational domain swap experiment using TenS and DMBS. 
DMBS catalyses the biosynthesis of desmethylbassianin (DMB) in the insect pathogen Beauveria 
bassiana.[10] Both of these compounds are initiated by a typical fungal hr-PKS which is fused to 
a single module of NRPS consisting of C, A, T and Dieckmann cyclase (DKC) domains. In pre-
DMB 275, the programmed polyketide is a singly methylated hexaketide. Therefore, TenS and 
desmethylbassianin synthase (DMBS) differ in programming with respect to both methylation 
pattern and chain length. The Cox group used a procedure involving homolous recombination in 
yeast to construct chimaeric tenS/dmbS genes, which were then transferred to a fungal expression 
vector containing the trans-acting ER gene (tenC). 
The results showed that the C-MeT-ψKR swap of dmbS produced a monomethylated 
pentaketide 276 as the main product with minor amounts of dimethylated pentaketide 273. The 
single KR domain swap led to four products in which hexaketides dominated 276/277 (80%) over 
pentaketides 273/275 (20%), and dimethylated products 275/276 (66%) over monomethylated 
273/277 (34%) (Scheme 4.1.1.2).[197] The results showed that C-MeT-ψKR takes part in the 




Another example of fungal iterative hr-PKS programming study is from lovastatin 
biosynthesis. LovB is a hr-PKS which catalyses the biosynthesis of the lovastatin nonaketide 
precursor dihydromonaconlin L 278. The C-MeT domain only acts once, after the third elongation 
of LovB. It has been suggested that the outcome of the modifying steps was determined by the 
relative activity of each domain towards specific substrates (Scheme 4.1.1.3 A).  KS, C-MeT, KR, 
DH and ER domains are all involved in the hr-PKS programming in the third elongation step 
catalysing the formation of pentaketide 279 from tetraketide 280.[189] 
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Scheme 4.1.1.3 Third elongation step of LovB and LovC in the biosynthesis of dihydromonaconlin L 278. 
 
Tang and coworkers showed an example of hr-PKS programming particularly in 
methyltransferase domain.  Full-length LovB was expressed with a mutation in the DH domain 
which was used for stopping the further modification (LovB-DH0). Several acyl-N-
acetylcysteamine (NAC) substrates (compound 281, 282, 283 and 284) and cofactor S-Adenosyl 
methionine (SAM) were used for the in vitro study. The LovB-DH0 has no activity on 281 and 
284. But LovB-DH0 can catalyse the methylation of triketide 282 and tetraketide 283 to obtain 
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Scheme 4.1.1.3 in vitro study of mutant LovB (LovB-DH0) on different substrates. 
 
 In addition, to test the competition between the KR and C-MeT domains in the presence of the 
corresponding cofactors SAM and NADPH, triketide 282 and tetraketide 283 were also tested 
with the LovB-DH0. The result indicates that triketide 282 has a higher affinity to the KR (91% 
285) than the C-MeT (9% 287). While tetraketide 283 shows a high affinity to the C-MeT (100% 






























Scheme 4.1.1.4 Competitive enzyme assays of KR and C-MeT domains. 
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The result of the LovB programming study shows  competition between KR and C-MeT which is 
consistent with hypothesis about the domain completion among the KR, C-MeT and TE domain 
in TenS domain swap research. 
Because hr-PKS are the key enzymes for the biosynthesis of various bioactive compounds, 
e.g. cytochalasans 43, lovastatin 6 and squalestatins 7, it is important to find more information 
about the mechanism of programing with the long-term aim to combine the biosynthetic pathways 
and engineer the different hr-PKS systems. To get better understanding of hr-PKS programing, 
the desmethylbassianin (hexaketide) synthetase (DMBS) and militarinone (a heptaketide 
compound also belonging to 2-pyridone class) synthetase (MILS) will be used for domain swap 
experiment with the tenellin 3 synthetase (TenS). 
Sub-domain swap to make fewer amino acid changes in the KR and C-MeT domains is a 
good way to find the key region or even key residues which are responsible for the substrate 
selection and PKS programming. This project focused on the TenS KR sub-domain swap with 
DMBS and MILS KR domain.  
 
4.1.2 Aims of the project. 
 
The overall aim of this project is to explore the programming of the hr-PKS. More 
concretely, we want to achieve the goals as follows: 
 
1. Try to understand the programming mechanism for hr-PKS, especially which 
individual catalytic domains such as the KR have a component of intrinsic selectivity 
for their substrates. 
2. Try to find the evidence for the hypothesis that competition by different catalytic 
domain for the ACP-bound intermediates can affect the overall programming. 
3. Try to find out the important region or residues in the KR domain protein sequence 









4.2.1 Strategy for domain swaps. 
No structure of a complete fungal hr-PKS has yet been reported. However, there is a good crystal 
structure of mammalian FAS (mFAS, section 1.3.3). hr-PKS and mFAS are homologous in terms 
of domain structure and therefore mFAS could be used as a model for hr-PKS. In the previous 
domain swap study, C-MeT-ψKR and KR domains of TenS were mapped to the mFAS (Fig. 
4.2.1.1). The TenS catalytic KR domain is predicted to span from 1181 aa to 2162 aa containing 
281 amino acid residues. 
 
Fig. 4.2.1.1 Cartoon model of the quaternary structure of TenS. 
 
In this project, the previously investigated 281 residues of the TenS KR domain were divided into 
four approximately equal fragments (Fig. 4.2.1.2) spanning the length of the KR region. These 
were used these to reconstruct a series of 9 chimeric genes using rapid recombination in yeast. 
Swap sequences are from two halves of dmbS KR (experiments TDS1 / 2), four quarter of dmbS 
KR including (experiments TDS3 / 4 / 5 and 6), one full milS KR (experiment TMS1) and a third 
quarter of milS KR (experiment TMS2). The final experiment TMS3 involves only 12 residues 
changes at positions within the KR active site which are introduced by PCR. 
 
 
Fig. 4.2.1.2 Protein positions used for swaps:  TenS, blue; DMBS, yellow; MILS, red. 
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The reconstruction procedure consisted simply of combining overlapping DNA fragments 
constructed from tenS, dmbS or milS templates with the linearised tenS cloning vector and 
transforming the mixture into yeast (Section 5.3.x). For example, the exchange of the 281 AA 
fragment TMS1 into tenS was achieved using a 5' PCR fragment obtained from tenS, a ca 843 bp 
fragment spanning TMS1 from milS with ca 30 bp tails matching the tenS sequence, and a 3' 
fragment from tenS. The reconstructed plasmids were rescued in E. coli and then transferred by 
in vitro recombination (Gateway) methodology into the expression vector (which already 
contained tenC), and this was then transformed into A. oryzae NSAR1 (Fig. 4.2.1.3). Multiple  A. 
oryzae transformants are selected and then grown in parallel on media containing maltose, and 




Fig. 4.1.2.3 Cloning strategy for rapid fragment swaps of tenS and typical results. 
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4.2.2. DMBS KR sub-domain swap. 
It was previously shown that swap of the entire TenS KR with DMBS resulted in good titres of 
pentaketides 273 and 276 and the hexaketides 275 and 277, with dimethylation (70% total product) 
and hexaketides (80%) predominating.[197] To get a better understanding about the hrPKS 
programming of the KR domain, this project is planned to carry out the half and quarter swaps 
(Fig. 4.2.2.1) of the DMBS KR domain. The strategy of the swap experiment has been described 
in section 4.2.1.  
In this part of work, the yeast recombination and pE-YA plasmid construction of 
experiments TDS1-6 was accomplished by Dr. K. Williams. The LR recombination and fungal 
transformation of  experiments TDS1-3 and TDS1 compound extraction were carried out by Dr. 
S. Friedrich. I worked on the LR recombination and transformation of experiments TDS4-6, and 
all the extractions and analysis of experiments TDS2-6.  
 
 
Fig. 4.2.2.1 Cartoon examples of different DMBS KR sub-domain swap. TenS part is in blue, DMBS part in yellow and 
TenC (ER) in green. 
 
4.2.2.1. TDS1. 
The result from Dr. S. Friedrich showed that swap of the first half of the KR (TDS1) was also 
productive, giving predominantly the previously identified and characterized pentaketides 273 
and 288, and only a little bit of known hexaketide 277 and its isomers. At the same time, the 
known pretenellin A isomer 289, proto DMB-B 290, and desmethyl pretenellin A 276 were also 
produced (Fig. 4.2.2.2). 
 





























pretenellin A isomer 289 proto DMB-B 290  
 
Fig. 4.2.2.2 Analysis of the crude extracts of TDS1 and the control (TenS with TenC). 
 
4.2.2.2. TDS2. 
We next swapped the second half of the KR which led to a low yield of predominantly 291, 
accompanied by some 277. Both compound 277 and 291 are hexaketides, and 291 is an oxidised 
form of compound 277. In this swap almost no pentaketides were produced (Fig. 4.2.2.3). 
 
 
Fig. 4.2.2.3 Analysis of the crude extracts of TDS2 and the control (TenS with TenC). 
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4.2.2.3 TDS3.  
The individual first quarter of the DMBS KR was exchanged. Transfer of fragment TDS3 resulted 
in production of 273 in titre was similar to the A. oryzae NSAR1 system, but with an additional 
low content of 289 (Fig. 4.2.2.4). 
 
 
Fig. 4.2.2.4 Analysis of the crude extracts of TDS3 and the control (TenS with TenC). 
 
4.2.2.4 TDS4.  
Exchange of the second quarter of the KR, produced protopretenellin A 288 as the major product, 




Fig. 4.2.2.5 Analysis of the crude extracts of TDS4 and the control (TenS with TenC). 
 
4.2.2.5 TDS5.  
The third quarter of the KR domain was then exchanged. Transfer of TDS5 resulted in a system 
almost identical to TDS2, but it was much more productive. In overall high titre, TDS5 gave the 
production of at least four compounds. This consisted of predominantly compound 291. However, 
according to the HPLC result, the peak of compound 291 was not a single peak, it means that it 
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Fig. 4.2.2.6 Analysis of the crude extracts of TDS5 and the control (TenS with TenC). 
 
Because TDS5 gave good production of compound 291, the fermentation was scaled up which 
allowed purification of 291. A crude extract from 5L of CMP medium was purified by 
preparative-HPLC. 8 mg of purified compound 291 was obtained. Compound 291 has a 
distinctive UV spectrum with absorption maxima at 225 and 398 nm (Fig 4.2.2.7 A). The 
compound had a molecular ion of 396.5 [M - H]-  (Fig. 4.2.2.7 B). HRMS calculated for 
C23H26NO5 (396.1811 [M - H]-) was obtained as 396.1768. 
 
 
Fig. 4.2.2.7 UV spectrum and MS of compound 13: A, UV spectrum; B, MS. 
 
Key COSY and HMBC correlations were used to confirm the assignment of the 1H- and 
13C NMR spectra (Table 4.2.2.1). The major component of peak 291 turned out to be a 
hydroxyprebassianin A 291 which was hydroxlated at C-16. 
 






























COSY H to H HMBC H to C
291  
 
position dH /ppm Mult./J dc / ppm COSY HMBC (H to C ) 
2 - - 163.6 - - 
3 - - 110.4 - - 
4 - - 194.9 (C) - - 
5 4.06 (1H) m 62.4 (CH) 18 4 
6 - - 172.4 (C) - - 
7 7.04 (1H) d (15.1 Hz) 119.6 (CH) 8 6, 9 
8 7.46 (1H) dd (15.0, 11.4 Hz) 144.9 (CH) 7, 9 6, 10 
9 6.53 (1H) m 125.7 (CH) 8, 10 7 
10 6.88 (1H) m 149.0 (CH) 9 8, 12 
11 - - 137.1 - - 
12 5.18 (1H) m 135.1 (CH) 13 12, 15 
13 2.35 (1H) m 42.5 (CH) 12, 14, 16  
14 1.15 (2H) m 24.3 (CH2) 13, 15 15, 17 
15 3.29 (2H) m 64.3 (CH2) 14 13, 16 
16 1.15 (2H) m 24.3 (CH2) 13 15, 17 
17 1.59 (3H) s 12.9 (CH3) - 13, 10 
18 2.83 (2H) broad s 35.8 (CH2) 5  
19 - - 126.0 - - 
20 6.92 (2H) m 130.7 (CH) 21  
21 6.61 (2H) m 114.9 (CH) 20  
22 - - 155.9 (C) - - 
 
Table 4.2.2.1 Summary of NMR data of compound 291. 
 
4.2.2.6 TDS6.  
Finally the fourth quarter of the KR domain was exchanged. Transfer of fragment TDS6 resulted 
in a system almost identical to the untransformed A. oryzae NSAR1 strain. There were no 
observable new compounds produced (Fig. 4.2.2.8). 
 




Fig. 4.2.2.8 Analysis of the crude extracts of TDS6 and the control (TenS with TenC). 
 
4.2.3 MILS KR full domain swap 
From the previous domain swap experiments, the hexaketide PKS DMBS KR domain swap gives 
80% of the hexaketides and 20% of the pentaketides (section 4.1.1). This project is focused on 
the militarinone synthase (MILS) which synthesises a heptaketide product. Militarinone C 292 is 
heptaketide congener of pretenellin A 273 which has three methyl groups and is reduced twice by 
its trans-acting ER. The single MILS KR domain swap will be constructed to see if the hybrid 



















































Scheme 4.2.3.1 Domain structure and swaps of MILS, cartoon view of a hybrid PKS-NRPS. 
 
4.2.3.1 Vector construction of TMS1. 
As described in seciton 4.2.1, the plasmid pE-YA-tenS was digested with XbaI and AgeI to 
produce the vector fragment VF3 (Fig. 4.2.3.1 A). Fragment F35 (Patch) was amplified by PCR 
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(Q5) using tenSF1 and tenSR1 as primers and pE-YA-tenS as the template to create a patch for 
VF3. Fragments F51 and F52  were amplified by PCR using TDSLk1-F and TDSLk1-R, T2A-F 
and TDSLk2-R respectively as primers and pE-YA-tenS as the template. Fragment F50 (MilS-
KR) harbouring the swap sequence was amplified by PCR using TMS-F and TMS-R as primers 




Fig. 4.2.3.1 Fragments for yeast recombination. 
 
Yeast recombination was used to assemble the vector fragment VF3 with F35, F50, F51 and F52. 
The resulting plasmid pE-YA-tenS(ΔmilS-KR) harbouring the domain swap was confirmed by 
restriction cutting with XbaI using pE-YA-tenS as a control. The pE-YA-tenS give two bands 
with the sizes 14950 and 3198bp.  The reconstructed plasmid (2) obtains 3 bands with the sizes 
13134, 3198 and 1816bp (Fig. 4.2.3.2). 
 
Fig. 4.2.3.2 Restriction cutting conformation. 
The positive construction of yeast recombination was then transferred to the expression vector 
pTYGS-arg-tenC using Gateway LR in vitro recombination (Invitrogen) leading to pTYGS-arg-
tenC-tenS (ΔmilS-KR TMS1). 




4.2.3.2 Fungal transformation of TMS1 and chemical analysis. 
TMS1 plasmids of KR domain swap were transferred into A. oryzae following the general method 
in section 5.5.3, and eight transformants were obtained. The transformants were then grown in 
100 mL CMP medium for 7 days. The compounds form the cultures were then extrated and 
analysied by LCMS following the general method in section 5.6.4. 
The whole MILS KR domain was exchanged with TENS KR (span from 1181 aa to 2162 
aa). The chimeric synthetases (in two transformants) produced pentaketide pretenellin A 273, 
hexaketide prebassianin A 277 and, surprisingly, the putative heptaketide 293. Hexaketide 
prebassianin A 277 and 293 were the major components with pretenellin A 273 as minor 























putative heptaketide 293  
 
Fig. 4.2.3.3 Analysis of the crude extracts of TMS1 and the control (TenS with TenC) transformants by HPLC (10 - 90% 
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As expected, compounds 273, 277 and 293 showed an increase λmax from 373 nm for the dieneone 
273 to 426 nm for the tetraeneone 293. And the molecular weight also showed an increase from 
355 for 273 to 407 for 293 (Fig. 4.2.3.4). 
The result of TMS1 indicates that the whole MILS KR domain swap gives the mixture of 
pentaketide, hexaketide and heptaketides. This is again the evidence that KR domain of the hr-
PKS controls the programming of the chain length. However the overall titre was very low 
showing that the chimeric system does not function well. 
 
 
Fig. 4.2.3.4 Results of MILS KR swap: A, HPLC chromatograph from 8.5 to 11 min; B, UV analysis of indicated 
compounds; C, ESMS- analysis of indicated compounds. 
 
 
4.2.4 MILS KR sub-domain swap. 
According to the result of the TDS2 and TDS5 swap experiment, the chimeric synthetases could 
produce longer chain compounds as the major components. It means that the third quarter of the 
KR domain must contain some important regions or residues which take part in the programming 
of the PKS especially for the chain length control. Therefore, the third quarter of the MILS KR 









Transfer of the third quarter swap of MILS KR (TMS2) resulted in a system almost identical to 
TMS1, but it was about 10 times more productive. Hexaketide prebassianin A 277 and the putative 




Fig. 4.2.4.1 Analysis of the crude extracts of TMS2 and TMS1. 
 
Because experiment TMS2 gave enough production of compound 293, large scale of fermentation 
was carried out for the compound purification. A crude extract from 8 L of CMP medium was 
purified by preparative-HPLC. 6 mg of purified compound 293 was obtained. Compound 293 has 
a distinctive UV spectrum with absorption maxima at 224 and 426 nm This has a molecular ion 
of 406.2 [M - H]-. HRMS calculated for C23H26NO5 (406.2018 [M - H]-) was obtained as 
406.2021 (Fig. 4.2.4.2). 
 
 
Fig. 4.2.4.2 UV spectrum and MS of compound 14: A, UV spectrum; B, MS. 




Key COSY and HMBC correlations were used to confirm the assignment of the 1H- and 13C NMR 
spectra (Table 4.2.4.1). The major component of peak 293 turned out to be a new compound 






























COSY H to H HMBC H to C293  
 
Pos dH /ppm mult. / Hz dc / ppm COSY HMBC (H to C) 
2 - - 175.1 - - 
3 - - 102.5 - - 
4 - - 191.2 - - 
5 3.68 m 69.9 20  
6 - - 174.1 - - 
7 7.55 d, J = 15.8 129.1 8 6 
8 7.18 m 139.5 7, 9  
9 6.47 m 131.3 8, 10  
10 6.63 m 140.2 9, 11  
11 6.34 m 127.0 10, 12 13 
12 6.42 m 141.3 11  
13 - - 133.1 - - 
14 5.41 d, J = 9.6 142.2 15, 19 12, 19 
15 2.42 m 34.5 14, 18 13, 16 
16 1.28, 1.36 m 29.8 15, 17 14, 15, 17, 18 
17 0.81 t, J = 6.9 12.3 16 15, 16 
18 0.95 d, J = 6.6 21.1 15 14, 15, 16 




dd, J = 13.9, 3.9 
37.5 5 22 
21 - - 128.5 - - 
22 6.96 d, J = 8.2 130.8 23 21, 23, 24 
23 6.60 d, J = 8.2 115.2 22 21, 22, 24 
24 - - 156.1 - - 
24-OH 9.11 brs - - 23 
 










4.2.4.3. TMS3  
Since TMS2 worked quite nicely, so a more focused swap was carried out in the third quarter of 
the KR domain. By comparing the protein sequences (third quarter) of TENS, DMBS and MILS, 




Fig. 4.2.4.3 Sequence alignment in third quarter (5A part) swap of KR domains. Yellow highlight = identity among PKS; 
green highlight = identity among mFAS; The red box highlights the most variations part of the domain. 
 
We therefore attempted to swap this focused region from MILS into the TenS KR domain. 
Exchange of a 12-residue fragment corresponding to Q2398 - V2409 of the TenS KR was 













Fig. 4.2.4.4 Sequencing result of the swap. Red line highlights the changed part. 
 
Transfer of TMS3 lead to a similar result as TMS1 although the overall titre was very low. 
Hexaketide prebassianin A 277 and prefarinosone A 293 were the major components with 
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4.3. Discussion  
4.3.1 Summary of the observations and attempt to explain the result using model structure 
From the MILS entire KR domain swap (experiment TMS1), the exchange resulted in small 
amounts of penta- 273, hexa- 277 and putative  heptaketides 293, all of which are dimethylated 
and singly reduced, with a majority of the heptaketide. Compared to the MILS whole KR 
exchange, the previous DMBS KR swap results in good titres of pentaketides 273 and 276 and 
the hexaketide 275 and 277, with demethylation (70%) and hexaketides (80%). Both entire KR 
swaps provide evidence that the KR domain takes part in the chain length control in hr-PKS 
programming. 
Sub-domain swaps of DMBS KR were then carried out. Swaps of the first half of the 
DMBS KR (experiments TDS1, 3 and 4) were also productive, giving predominantly the 
pentaketides 273 and 288 but no hexaketides. It indicates that the first half of the KR exchange 
does not affect the chain length programming. Swap of the second half (experiment TDS2) of the 
KR gave low titres with few new compounds, while swap of the final quarter (experiment TDS6) 
resulted in an inactive synthase. Significantly, swap of the third quarter alone (experiment TDS5) 
was most associated with the production of hexaketide 277 and its hydroxlylated derivative 291, 
presumably created by adventitious oxygenation in A. oryzae. 
According to the sub-domain swap of DMBS KR, the third quarter of the KR domain is an 
important region for the synthase to control the formation of longer chain compounds. The third 
quarter of MILS KR (experiment TMS2) was also exchanged. It gave a similar distribution of 
products as TMS1, but in around 5-fold higher titre. In a final experiment, a 36 bp sub-fragment 
of the KR (experiment TMS3) domain corresponding to residues Q2398 to V2409 of TenS was 
exchanged. This produced the same distribution of 273, 277 and 293, but in overall low titre. 
A                B  
Fig. 4.3.1.1 KR domain modelling: A, TMS3; B, wild type. The changed part highlighted in red. 
Ⅳ Domain competition hypothesis 
 
169 
Our group member Mr Oliver Piech helped me to make two KR domains model structures of 
experiment TMS3 (Fig 4.3.1.1 B) and WT (Fig 4.3.1.1 A). Our result shows that experiment 
TMS3 can produce heptaketide 293 as the dominant product even only with 12 aa exchange in 
TenS. The wild type TenS however can only produce pentaketide 273. Compared to the WT KR 
domain structure, the changes of experiment TMS3 almost focus on one helix (in red). This helix 
is located exactly in the active site of the KR domain. The modelling of TMS3 KR shows that the 
helix tends to change into a loop which might make a bigger pocket for active site. The active site 
therefore can take a longer chain substrate to make a longer chain product. 
 
4.3.2 Domain competition hypothesis 
Our observations on KR domain swaps are consistent with a programming mechanism which 
arises by competition between the selective domains (C-MeT, KR and NRPS C domain) for the 
ACP-bound substrate. For example, in the first condensation (Scheme 4.3.2.1 A) of PKS-NRPS 
hybrid (TenS, DMBS, MILS), the fastest reaction is methylation.  In the cases of TENS, DMBS 
and MILS the C-MeT must be significantly faster than KR to give 296.  
In the second condensation (Scheme 4.3.2.1 B), the C-MeT domains of TenS and MILS is 
faster than their KR domains after the second round of extension to give 303. However, in the 
case of DMBS, KR is faster than C-MeT giving 302. This is consistent with the previous study 
that the C-MeT-ψKR swap provides mostly monomethylated products. The TenS and DMBS 
trans-acting ERs cannot reduce triketides, so the chain is sequentially extended by KS/AT to give 
tetraketide 304.In the third extension (Scheme 4.3.2.1 C), both TenS and DMBS C-MeT domains 
cannot methylate therefore giving 305 due to the faster speed of the KR domain. MILS C-MeT 
domain is presumably active in this step to provide306. 
It then comes into the fourth condensation (Scheme 4.3.2.1 D). At this stage the TenS KR 
cannot reduce the β-carbonyl and the default pathway is release by the NRPS C domain to obtain 
pentaktide 309 and then pretenellin 273. On the other hand, the DMBS and MILS KR are still 
able to reduce pentaketides faster than off-loading to give 310, in addition to dehydrate to 311. 
Triene 311 is extended again by KS/AT to give hexaketide 312. This is consistent with the DMBS 
KR swap which can convert TenS to a hexaketide synthase. 
Additionally, in the fifth extension (Scheme 4.3.2.1 E), the DMBS KR and C-MeT 
domains cannot react with 312 so the default pathway is again C-catalysed offloading to give 
hexaketide 313 and then 275. MILS KR however can still compete with the off-loading C-domain 
to give 314. If the KR can reduce hexaketides to give 314, after dehydration the KS/AT will 
extend the chain again to heptaketide 315.  
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Scheme 4.3.2.1 Course of polyketide biosynthesis catalysed by hybrid PKSNRPS: (A), first condensation and subsequent selectivity; (B) second condensation and subsequent 
selectivity; (C) third condensation and subsequent selectivity; (D) fourth condensation and subsequent selectivity; (E) fifth condensation and subsequent selectivity. 
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4.3.3 In vitro study on hrPKS C-MeT and KR domains 
From these TENS swap experiments, it was shown that C-MeT and KR domains are the key 
factors effecting the programming of hr-PKS by controlling the chain length and methylation 
pattern. However, this in vivo study suggests that domain swaps of individual domains, swaps of 
sub-domains, or even possibly mutations of single amino acid residues, are unlikely to lead to the 
predictable and clean production of desired compounds. High quality crystallographic data of the 
TENS or even the specific domain like C-MeT and KR or the in vitro study on the domain 
combining with site direct mutation are needed to get better knowledge of the hrPKS 
programming. 
Stereocontrol is an important aspect of hrPKS programming. At the moment, there are 
already some studies on stereocontrol of PKS and mFAS. During the 1990s, Cernon Aderson and 
Gordon Hammes’s in vitro study showed that stereo-chemistries in fatty acids were strictly 
controlled by mFAS.[190] For example, the stereochemistry at C-2 of the malonyl-CoA inverts 
during chain extension; the KR uses the 4’-pro-S hydride of NADPH to attack the 3-Si face of 
the ACP bound polyketide. Due to the close relationship between hrPKS and mFAS, the 
steropreferences in mFAS could somehow enlighten the study on hrPKS. However, the hrPKS is 
usually differently programed in the β-processing steps while mFAS always do the same. This 
behaviour of iterative hrPKS made it even more difficult and complicated to understand how the 




Fig. 4.3.3.1 Strategy of in vitro enzyme assay on SQTKS 
 
Our group has already carried out some in vitro studies on a hrPKS squalestatin tetraketide 
synthase (SQTKS). A series of individual domains and multi-domain units of SQTKS were 
expressed for in vitro assay (Fig. 4.3.3.1). According to the in vitro results from Dr. H. Yao 
(unpublished), ER in the DH-KR tetradomain can be used as a general catalyst which was 
consistent with the previous monodomain study, and all the products of DH, KR and ER were 
also found by LCMS analysis. Stereoselectivity of ER, KR and C-MeT domains were also tested 
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by diketide panthethine substrates. For ER in the DH-KR tetradomain, it preferred an S-2methyl 
butanoyl panthethine product 317. The hydride donor of the KR domain reaction is 4’-pro-S 
proton of NADPH. So far, the stereopreferences involved in KR, DH and ER (319-322) of 




















































Scheme 4.3.3.1 In vitro assay reveals stereochemistry in the first cycle biosynthesis of squalestatin tetraketide. 
 
In addition, Dr. O. Piech in our group also worked on the site direct mutation in the active site of 
DH and ER domain. Different polyketide panthethine substrates were used for in vitro assay of 
different mutated protein, and the result indicated that mutations could affect the substrate 
preference of DH and ER domain.[191] 
For the tenellin project, more details of C-MeT and KR domain from TENS can also be 
explored by in vitro study to discuss how active site changes can influence on the chain length 
and methyl group processing. 
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4.4. Conclusion and outlook 
The overall aim of this project was to explore the programming of the hr-PKS based on the domain 
swaps between TenS and DMBS/MILS. In this project, we focused on the KR domain and its 
effect on the chain length control for hr-PKS programming. 
Firstly, our results support a programming mechanism for hr-PKS in which individual 
catalytic domain like KR have a component of intrinsic selectivity for their substrates. The 
experiments TDS5, TMS2 and TMS3 provide the evidence that the changes taking place in the 
active site of KR domain can affect the chain length of the product. The amino acid changes 
around the active site can change the intrinsic selectivity of the hr-PKS and therefore the 
programming. 
Secondly, the results show that the intrinsic selectivity is not the only feature determining 
overall programming when competition for different catalytic domains is possible. The result of 
all KR domain or sub-domain swap always tend to give a mixture of products. Experiments TDS2 
and 5 give the mixture of pentaketides and hexaketides. Experiments TMS1, 2 and 3 give the 
mixture of pentaketide, hexaketide and heptaketide. This is the case for the β-keto ACP thiolester 
intermediates formed by the KS which can be substrates for four different catalytic domains (KR, 
C-MeT, C and KS) in hybrid PKS-NRPS systems and it must be the ratios of the intrinsic and 
extrinsic selectivities which determine the final outcome. 
Thirdly, we find out the important region in KR domain protein sequence for chain length 
programming. In this project, experiments TDS5 and TMS2 show that the third quarter of KR 
domain takes an important role for the chain length programming. Experiment TMS3 is 
additionally carried out to show that a small number of amino acid changes (12 aa) in the synthase 
can lead to the production of longer chain compounds. This result provides the evidence for the 











Chapter 5. Materials and Methods 
5.1 Solvents and chemicals 
All the chemicals, materials and enzymes were purchased from one of the following companies: 
Amresco (Solon, OH, USA), Applichem (Darmstadt), Bio-Rad (München), New England Biolabs 
(Beverly, MA, USA), Roth (Karlsruhe), Sigma Aldrich (Steinheim), Stratagene (Amsterdam, 
Netherland), and Thermo Fisher Scientific (Waltham, MA, USA). 
5.2 Growth media, buffers and solutions 
All media, buffers and solutions are summarized in Table 5.2.1 . All media, buffers and solutions 
were prepared with millipore water (GenPure Pro UV/UF milipore device, Thermo Scientific) or 
distilled water. Growth media and transformation solutions were sterilised at 121 °C for 15 min 




LB  5 g/L NaCl, 10 g/L tryptone, 5 g/L yeast extract 
LB agar LB Medium, 15 g/L Agar 
YPAD  1 % (w/v) Yeast extract, 2 % (w/v) Tryptone, 2 % (w/v) D(+)-Glucose Monohydrate, 0.03 % (w/v) Adenine  
YPAD agar YPAD Medium, 1.5 % (w/v) Agar  
SM-URA agar 
0.17 % (w/v) Yeast nitrogen base, 0.5 % (w/v) (NH4)2SO4, 2 % (w/v) D(+)-Glucose Monohydrate, 0.077 % (w/v) 
Complete supplement mixture minus Uracil, 1.5 % (w/v) Agar  
glucose-ura  
 0.67% (w/v) yeast nitrogen base, 0.13% (w/v) of complet supplement mixture minus uracil, 2% (w/v) glucose 
monohydrate 
galactose-ura 
 0.67% (w/v) yeast nitrogen base, 0.13% (w/v) of complet supplement mixture minus uracil, 2% (w/v) galactose 
monohydrate 





3.5 % (w/v) Czapek Dox broth, 18.22 % (w/v) D-sorbitol, 0.1 % (w/v) (NH4)2SO4, 0.15 % (w/v) L-methionine, 
0.05 % adenine, 1.5 % (w/v) agar 
CZD/S soft 
agar 
3.5 % (w/v) Czapek Dox broth, 18.22 % (w/v) D-sorbitol, 0.1 % (w/v) (NH4)2SO4, 0.15 % (w/v) L-methionine, 
0.05 % adenine, 0.8 % (w/v) agar  
CZD/S1 agar   
3.5 % (w/v) Czapek Dox broth, 18.22 % (w/v) D-sorbitol, 0.1 % (w/v) (NH4)2SO4, 0.15 % (w/v) L-methionine 
(optional), 1.5 % (w/v) agar  
DPY  
2 % (w/v) Dextrin from potato starch, 1 % (w/v) Polypeptone, 0.5 % (w/v) Yeast extract, 0.5 % (w/v) KH2PO4, 
0.05 % (w/v) MgSO4* x H2O  
DPY agar DPY Medium, 2.5 % (w/v) Agar  
CMP Czapek Dox, 2% (w/v) Maltose and 1% (w/v) peptone 







PDB 2.4% (w/v) Potato dextrose broth 
PDB agar PDB medium, 2.5 % (w/v) Agar  
YMG   0.4% (w/v) D(+)-Glucose monohydrate 0.4% (w/v) Yeast extract 1% malt extract 
YPAD 1% (w/v) yeast extract 2% (w/v) tryptone 2% (w/v) D(+)-glucose monohydrate 0.03% (w/v) adenine 
YES  4% (w/v) yeast extract 16% (w/v) sucrose 
YGMO  0.4% (w/v) D(+)-Glucose monohydrate 0.4% (w/v) Yeast extract 1% (w/v) malt extract 2% (w/v) oat meal fock 
producing M 5% (w/v) yellow cornmeal, 0.1% (w/v) yeast extract, 8% (w/v)surose 
CMP  Czapek Dox, 2% (w/v) Maltose and 1% (w/v) peptone 
GNB 2 % (w/v) D(+)-Glucose Monohydrate, 3 % (w/v) Nutrient broth Nr. 2 from Oxoid  




25 % (w/v) acetic acid, 10 % (w/v) Isopropanol, 0.1 % (w/v) 
Coomassie  
Coomassie bleach 25 % (w/v) acetic acid, 10 % (w/v) Isopropanol  
IMAC loading buffer 50 mM Tris-HCl, pH 8, 150 mM NaCl, 10 mM Imidazole  
IMAC elution buffer 50 mM Tris-HCl, pH 8, 150 mM NaCl, 40-500 mM Imidazole  
50 xTAE buffer 2 M Tris acetate, 0.05 M EDTA, pH 8.3  
4X Lämmli buffer  
10 % (v/v) β-Mercaptoethanol, 2,5 mg/l Bromophenol Blue 0.25 % 
(w/v) Bromophenol Blue, 30 % (v/v) Glycerine, 0.25 % (w/v) Xylene 
Cyanol,  
Loading-dye (6 x) 
50 mM Na2HPO4, pH 8 25 mM Tris, 192 mM Glycine, 0.1 % (w/v) 
SDS, pH 8.3  
10X SDS running buffer 25 mM Tris, 192 mM Glycine, 0.1 % (w/v) SDS, pH 8.3  




A. oryzae  
Solution 1 0.8 M NaCl, 10 mM CaCl2, 50 mM Tris-HCL, pH 7.5  
Solution 2 60 % PEG 3350, 0.8 M NaCl, 10 mM CaCl2, 50 mM Tris-HCl, pH 7.5  
T. viride  
protoplast 
buffer 0.8M MgSO4, 50 mM CaCl2, 50 mM Tris-HCl, pH 7.5  
Solution 3 50 % PEG 8000, 1 M Sorbitol, 50 mM CaCl2, 50 mM Tris-HCl, pH 7.5  
Solution 4 1M sorbitol, 50 mM CaCl2, 50 mM Tris-HCl, pH 7.5  
Table 5.2.1 E Solutions used for fungal transformations. 
 
5.3 Antibiotics and enzymes 
Antibiotic stock solutions were prepared in millipore water or ethanol and filter sterilized through 
0.45 µm syringe filters and stored at - 20 °C. Carbenicillin was used in place of ampicillin. Stock 





Name  Concentrantion Final concentration Reference 
Carbenicillin  (Carb) 50 mg/ml in H2O 50 µg/ml Roth 
Chloramphenicol 
(Cm) 
30 mg/ml in EtOH 30 µg/ml Roth 
Kanamycin (Kan) 50 mg/ml in H2O 50 µg/ml Amresco 
Hygromycin B   50 mg/ml in H2O 100-200 µg/ml Roth 
5.3.1 Antibiotics used in this work. 
 
All enzymes used in this study were obtained from NEB or Thermo Scientific and used following 
the manufacturers’ instructions 
 
5.4 Strains  
Microbial strains which were kindly provided for this work or purchased from Thermo Fischer 
Scientific, Stratagene or Novagen are listed in Table 5.4.1 and Table 5.4.2. 
 
 
Strain  Genotype Origin 
BL21 (DE3) F– ompT hsdSB (rB–, mB–) dcm gal λ(DE3) Thermo Fisher Sicientific 
OneShot Top10 
F- mcrA Δ( mrr-hsdRMS-mcrBC) Φ80lacZΔM15 Δ 
lacX74 recA1 araD139 Δ( araleu)7697 galU galK 
rpsL (StrR) endA1 nupG Thermo Fisher Sicientific 
OneShot ccdB 
survival 2T1R 
F-mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 
ΔlacX74 recA1 araΔ139 Δ(ara-leu)7697 galU galK 
rpsL (StrR) endA1 nupG fhuA::IS2 Thermo Fisher Sicientific 
Rosetta 2 
F- ompT hsdSB(rB- mB-) gal dcm (DE3) pRARE2 
(CamR) Novagen 
Table 5.4.1 E. coli strains used in this work. 
 
Strain  Feature Reference 
A. oryzae NSAR1 ΔargB sC adeA niaD  Lazarus group, Bristol 
T.  viride 
(MF5628,  ATCC 
74084) wild type  CBS-KNAW 
S. cerevisiae 
CEN.PK2  
MATa/a ura3-52/ura3-52 trp1-289/trp1-289 
leu23_112/leu2-3_112 his3 D1/his3 D1MAL2-
8C/MAL28C SUC2/SUC2  Hahn group, Hannover 
S. cerevisiae  
W303b 
ade-, His-, Ura-, Leu-, Trp- 
Kong group, Beijing 





5.5 Microbiology methods 
5.5.1 E.coli growth and transformation 
E. coli strains were cultivated on liquid or solid LB medium/ agar with appropriate antibiotics. 
Cultures were incubated at 37 °C for 12 to 18 h shaking at 200 rpm. For long term storage glycerol 
stocks (25 % glycerol) were stored in cryovial at -80 °C. 
Frozen chemically competent E. coli cells (kindly provided by technical staff, 50 µL aliquot) 
were thawed on ice. 1 µl of purified plasmid DNA or 10 µl of ligation mixture were added and 
mixed gently with the cells. The mixture was cooled on ice for 30 min followed by a heat shock 
at 42 °C for 10 sec (BL21, Rossetta2 and BL21 codonPlus RP) or for 40 sec (ccdB and Top 10). 
Afterwards, the cell suspension was placed on ice for 2 min and 250 µL SOC-Medium was added, 
followed by an incubation of 45 min at 37 °C under shaking (250 rpm) conditions. 50 - 200 µL 
of bacteria suspension 
 
5.5.2 Yeast transformation and expression 
5.5.2.1 Yeast transformation 
Transformation of S. cerevisiae was conducted based on lithium acetate/single-stranded carrier 
DNA/PEG protocol. A single colony of S. cerevisiae was inoculated into a 10 mL YPAD starter 
culture and grown overnight at 28 °C with shaking at 200 rpm. The starter culture was then added 
to 40 mL of YPAD in a 250 ml flask and incubated at 28 °C with shaking at 200 rpm for 5 hours, 
after which the culture was centrifuged at 3000 x g for 5 min and the supernatant discarded. The 
cells were washed with 25 ml sterile H2O and the centrifugation repeated; the pellet was then 
resuspended in 1 mL 0.1 M LiOAc and transferred to a 1.5 ml microfuge tube. The cells were 
then pelleted at 14500 x g for 15 sec and the supernatant discarded, after which the cells 
resuspended with 400 μL 0.1 M LiOAc and transferred 50 μL to a new 1.5 mL microfuge then 
pelleted again at 14500 x g for 15 sec and the supernatant discarded. Then, it was added 240 μL 
of PEG solution (50% (w/v) PEG 3350), 36 μL 1M LiOAc, 50 μL SS-DNA (denaturated salmon 
testis DNA, 2 mg/mL in TE buffer) and up to 34 μL of DNA then mixed by vortexing and 
incubated at 30 °C for 30 min and 42 °C for 30 min. The cells were pelleted at 6500 rpm for 15 
sec then gently resuspended in 1 mL of sterilized H2O. For each transformant 200 μL aliquots 
were spread on SM-URA plates and incubated at 28 °C for 3-4 days until colonies appeared. 
5.5.2.1 Yeast expression 
pESC-Ura vector was transformed to w303B S. cerevisiae cell following the procedure of 5.5.2.1. 
The transformation reaction onto two SM-URA plates with dextrose (D-glucose) as the carbon 
source. Incubate the plates at 30°C for 2-3 days. When the colony showed on the plates, 8 colonies 




plate, and incubate at 30°C overnight. The transformed colony was then inoculated into 50 mL of 
glucose-ura medium at 30°C overnight. The yeast cells were harvested and inoculated into 100 
mLof galactose-ure medium for 16 hours at 30°C. The cells were harvested by centrifugation at 
1000 × g for 5 minutes. The cells were ready for further biochemical analysis. 
 
5.5.3 Transformation of Aspergillus oryzae NSAR1 
Aspergillus oryzae NSAR1 was grown on DPY agar plates or in DPY medium at 28 °C for 3-7 
days (120 rpm). For long term storage A. oryzae spores were collected from plates by adding 3 
ml distilled water, mixed with glycerol (final concentration 50 %) and stored in cryovials at 
−80 °C. 
Spores of A. oryzae NSAR1 were prepared by inoculation of the fungus onto MEAplates 
and incubating at 30 °C for 1-2 weeks or until sporulation occurred. The spores were harvested 
from plates and inoculated into GN medium then incubated at 28 °C with shaking 200 rpm 
overnight. The culture was harvested by centrifugation at 8000 x g for 10 min and the supernatant 
discarded. The pellet was washed once with sterilized water and once with sterile 0.8 M NaCl. 
The pellet was resuspended in 10 mL of filter sterilized protoplasting solution (20 mg/mL 
Trichoderma lysing enzyme and 5 mg/mL driselase in 0.8 M NaCl) and incubated at room 
temperature with rotary shaking. After 1- 1.5 hours, protoplasts were release from hyphae by 
pipetting with a wide-bore tip then filtered through 2 layers of sterile miracloth. The filtrate was 
centrifuged at 1000 x g for 5 min and the supernatant discarded. The pellet was washed with 
solution 1 (0.8 M NaCl, 10 mM CaCl2, 50 mM Tris-HCl pH 7.5). The pellet was resuspended in 
200-500 μL of solution. Then, 100 μL of protoplast was mixed gently with 5-10 μg (10 μL) of 
plasmid DNA and incubated on ice 2 min. The mixture was added 1 mL of solution 2 (60% (w/v) 
PEG 3350, 0.8 M NaCl, 10 mM CaCl2, 50 mM Tris-HCl pH 7.5) and incubated for 20 min. 
Finally, the mixture was added 40 mL of molten (50 °C) CZSB and overlaid onto 4 prepared 
plates which each plate containing 15 mL of CZDT. The plates were incubated at 28 °C for 3-5 
days until colonies appeared. 
 
5.5.4 Transformation of Trichoderma viride MF5628 
One agar plug of T.viride was inoculated into PDB medium and incubated at 28 °C and 200 rpm 
for 10 days. Then the culture (OD600 = 0.3) was subcultured into PDB and incubated with shaking 
incubator at 200 rpm, 28 °C for 2 days. The mycelia was collected from the culture by filtration 
using sterile miracloth as a filter then rinsed with sterilized distilled water and 0.8 M MgSO4. The 
mycellia was added to 10 mL of sterilized KCl 0.7 M containing 200 mg of driselase and 300 mg 




mixture was filtered using sterilized miracloth. The filtrate was centrifuged at 3, 000 x g for 3 
minutes. The pellet was rinsed with 10 mL of solution STC (STC: Sorbitol 1.2 M, 10 mM of Tris–
HCl pH 7.5, 50 mM of CaCl2·2H2O) and centrifuged at 3, 000 x g for 3 minutes. The pellet was 
dissolved with 500 uL solution STC then the protoplast contained in the aliquot was counted 
under phase contrast microscope.  
For transformation, 200 uL of the aliquot was added to 20 μL of plasmid and mixed for 2-
10 min then added to 200 μL of 25 μL PEG solution and incubated on ice for 40 minutes then 
added to 200 μL PEG solution (50% (w/v) PEG 8000, 50 mM CaCl2, 10 mM Tris-HCl pH 7.5). 
After incubation at 25˚C for 40 minute, the aliquot was added to 500 μL of STC and plated out 
on 15 mL of soft malt extract agar containing 1M sorbitol and incubated at 25˚C. After 16-18 
hours, it was overlaid with 15 ml of MEA containing 75 μg/mL of hygromycin.  
After the growth, the transformant was subcultured 2 or 3 times under selection conditions.  
 
5.6 Chemistry methods 
5.6.1 Trichoderma viride extraction 
A plug of fungi (Trichoderma viride MF5628, ATCC 74084) was inoculated into 50 mL 
producing medium in 500 mL Erlenmeyer flask and incubated at 200 rpm and 28°C for 7 days. 
Each culture was then homogenized by hand blender and twice extracted with ethyl acetate with 
ratio = 1:1 v/v. The organic extracts were pooled and dried using MgSO4 and filtered then dried 
by rotary evaporator. The extract was dissolved in methanol and de-fatted using n-hexane (2 times) 
then dried. Finally, the extract was dissolved in HPLC grade methanol and analysed by LCMS 
with solvent system 10-90% acetonitrile containing 0.05 % formic acid for 15min. 
 
5.6.2 Extraction of Aspergillus oryzae NSAR1  
A. oryzae NSAR1 was grown on malt extract medium until sporulation (3-7 days), after which 
the spores were harvested and added to 5 ml sterilized H2O and grown for 6 days at room 
temperature with shaking at 200 rpm. Cultures was homogenized by hand blender and extracted 
with ethyl acetate with ratio = 1:1 for 2 times. The organic layer was dried MgSO4 and filtered 
then dried by rotary evaporator. The extract was dissolved in methanol and de-fatted using n-
hexane (2 times) then dried. Finally, the extract was dissolved in HPLC grade methanol and 
analysed by LCMS with gradient solvent system 10-90% acetonitrile containing 0.05 % formic 





5.6.4 LCMS  
5.6.4.1 Analytical LCMS  
LCMS data were obtained with using a Waters LCMS system comprising of a Waters 2767 
autosampler, Waters 2545 pump system, a Phenomenex Kinetex column (2.6 μ, C18, 100 Å, 4.6 
× 100 mm) equipped with a Phenomenex Security Guard precolumn (Luna C5 300 Å) eluted at 1 
mL/min. Detection was by Waters 2998 Diode Array detector between 200 and 600 nm; Waters 
2424 ELSD and Waters SQD-2 mass detector operating simultaneously in ES+ and ES- modes 
between 100 m/z and 650 m/z. Solvents were: A, HPLC grade H2O containing 0.05% formic acid; 
B, HPLC grade MeOH containing 0.045% formic acid; and C, HPLC grade CH3CN containing 
0.045% formic acid. Gradients were as follows. Method 1. Kinetex/CH3CN: 0 min, 10% C; 10 
min, 90% C; 12 min, 90% C; 13 min, 10% C; 15 min, 10% C.  
 
5.6.4.2 Semi-Preparative LCMS and Compound Purification.  
Purification of all compounds was generally achieved using a Waters mass-directed 
autopurification system comprising of a Waters 2767 autosampler, Waters 2545 pump system, a 
Phenomenex Kinetex Axia column (5μ, C18, 100 Å, 21.2 × 250 mm) equipped with a 
Phenomenex Security Guard precolumn (Luna C5 300 Å) eluted at 20 ml/min at ambient 
temperature. Solvent A, HPLC grade H2O + 0.05% formic acid; Solvent B, HPLC grade CH3CN 
+ 0.045% formic acid. The post-column flow was split (100:1) and the minority flow was made 
up with HPLC grade MeOH + 0.045% formic acid to 1 ml·min-1 for simultaneous analysis by 
diode array (Waters 2998), evaporative light scattering (Waters 2424) and ESI mass spectrometry 
in positive and negative modes (Waters SQD-2). Detected peaks were collected into glass test 
tubes. Combined fractions were evaporated (vacuum centrifuge), weighed, and residues dissolved 
directly in solvent for use or analysis. 
 
5.6.5 High Resolution Mass Spectrometry (HRMS)  
High Resolution Mass Spectrometry (HRMS) was performed on a Q–Tof Premier mass 
spectrometer (Waters) coupled to an Acquity UPLC–domain. Positive and negative ions were 
measured for accurate mass analysis.   
  
5.6.6 Nuclear Magnetic Resonance (NMR) Analysis  
NMR measurements were done by the NMR department of Organic Chemistry Department, 
Leibniz University Hannover. 1H and 13C NMR spectra were recorded on either on a Bruker 
DRX 400 or 500 MHz. Chemical shifts are given in parts per million (ppm) relative to the TMS 
(tetramethylsilane) standard and the coupling constants J were shown in Hz. 2D experiments were 








5.7 Molecular biology methods 
5.7.1 Oligonucleotides 
All oligonucleotides used in this work were purchased from Sigma Aldrich (Table 5.7.1.1). 
 
Primer Template Direction sequence 5' - 3' Amplification ID 
CS-LF T.v gDNA 
fwd 
GCCAACTTTGTACAAAAAAGCAGGCTCCGCTCCTGCTCAAGAGCCCTCAACTTTT tvCS-LF SYp201 
CS-LR T.v gDNA 
rev 
CTCGACAGACGTCGCGGTGAGTTCAGGCATCGCCGAAATGCCAGCTAGAAGCATA tvCS-LF SYp202 
CS-RF T.v gDNA 
fwd 
CCCAGCACTCGTCCGAGGGCAAAGGAATAGAATGCTGATCACGGCATGACCAACT tvCS-RF SYp203 
CS-RR T.v gDNA 
rev 
TGCCAACTTTGTACAAGAAAGCTGGGTCGGATATAGTGTCATCATCCCATGCCAT tvCS-RF SYp204 
HygF pTH-GS-egfp 
fwd 
TCTAGTGGATCTTTCGACACT hyg cassette SYp205 
HygR pTH-GS-egfp 
rev 
TCGAGTGGAGATGTGGAG hyg cassette SYp206 
CSLF-F pE-YA-tvCSKO 
fwd 
TCCTGCTCAAGAGCCCTCAACTTTT transtvCS-LF SYp207 
CSRF-R pE-YA-tvCSKO 
rev 
GTGTCATCATCCCATGCCAT transtvCS-RF SYp208 
THygF pE-YA-tv(x)KO 
fwd 
AATTCAGCGAGAGCCT transtvx(x)-RF SYp209 
THygR pE-YA-tv(x)KO 
rev 
TGTCGTCCATCACAGTTT transtvx(x)-LF SYp210 
CS-1 CSKO gDNA 
fwd 
AGCGTGATGAGCCCTCTACTG KO confirming SYp211 
CS-2 CSKO gDNA 
fwd 
TGCTTGATTTGGGAACCCTGACT KO confirming SYp212 
CS-3 CSKO gDNA 
rev 
CATTTCGACAGCGCCGC KO confirming SYp213 
CS-4 CSKO gDNA 
rev 
AGGCAAACAGTGCTTTTGCACT KO confirming SYp214 
HCS-1 CSKO gDNA 
fwd 
GGGATACGTACCGGAAA KO confirming SYp215 
HCS-2 CSKO gDNA 
rev 
AAGCTGTTGGCAGCCTTAAA KO confirming SYp216 
HCS-3 CSKO gDNA 
fwd 
TACTCTGATAGCTTGACTATGAAA KO confirming SYp217 
HCS-4 CSKO gDNA 
rev 
AAGAAGCATGGTTCTATTTCTAT KO confirming SYp218 
tvR4-LF T.v gDNA 
fwd 
GCCAACTTTGTACAAAAAAGCAGGCTCCGCATGAAGCACGAGGAGCT tvR4-LF SYp219 
tvR4-LR T.v gDNA 
rev 
ACGTATTTCAGTGTCGAAAGATCCACTAGAGTGTATTCGGTGGACCT tvR4-LF SYp220 
tvR4-RF T.v gDNA 
fwd 
TGTAAGCGCCCACTCCACATCTCCACTCGATTCCTGAACCCCAATACA tvR4-RF SYp221 
tvR4-RR T.v gDNA 
rev 
TGCCAACTTTGTACAAGAAAGCTGGGTCGGTCAAGCAAAACGGATGTT tvR4-RF SYp222 
tvR4LF-F pE-YA-tvR4KO 
fwd 
CCGCATGAAGCACGAGGAGCT transtvR4-LF SYp223 
tvR4RF-R pE-YA-tvR4KO 
rev 
CGGTCAAGCAAAACGGATGTT transtvR4-RF SYp224 
HR4-1 tvR4KO gDNA 
fwd 
CCCTTCATCTTCATTTG KO confirming SYp225 
HR4-2 tvR4KO gDNA 
rev 
AAGCTGTTGGCAGCCTTAAA KO confirming SYp226 
HR4-3 tvR4KO gDNA 
fwd 
TACTCTGATAGCTTGACTATGAAA KO confirming SYp227 
HR4-4 tvR4KO gDNA 
rev 
TCTTGGAGCTCCACCT KO confirming SYp228 
tvR2-LF T.v gDNA 
fwd 
GCCAACTTTGTACAAAAAAGCAGGCTCCGCGGTGAAGCTCTATCTACAATT tvR2-LF SYp229 
tvR2-LR T.v gDNA 
rev 
ACGTATTTCAGTGTCGAAAGATCCACTAGATTCAACTGTGGTGTTGAG tvR2-LF SYp230 
tvR2-RF T.v gDNA 
fwd 




tvR2-RR T.v gDNA 
rev 
TGCCAACTTTGTACAAGAAAGCTGGGTCGGATACCATACATCATTGAGGC tvR2-RF SYp232 
tvR2LF-F pE-YA-tvR2KO 
fwd 
GCGGTGAAGCTCTATCTACAATT transtvR2-LF SYp233 
tvR2RF-R pE-YA-tvR2KO 
rev 
GATACCATACATCATTGAGGC transtvR2-RF SYp234 
tvR3-LF T.v gDNA 
fwd 
GCCAACTTTGTACAAAAAAGCAGGCTCCGCTTCAGCGTCAAATTTTACGG tvR3-LF SYp235 
tvR3-LR T.v gDNA 
rev 
ACGTATTTCAGTGTCGAAAGATCCACTAGAAGTGTCTATGCCATATTTC tvR3-LF SYp236 
tvR3-RF T.v gDNA 
fwd 
TGTAAGCGCCCACTCCACATCTCCACTCGATGTCCAACTGCCGTAATAT tvR3-RF SYp237 
tvR3-RR T.v gDNA 
rev 
TGCCAACTTTGTACAAGAAAGCTGGGTCGGATGGCACAAACTTCGG tvR3-RF SYp238 
tvR3LF-F pE-YA-tvR3KO 
fwd 
GCTTCAGCGTCAAATTTTACGG transtvR3-LF SYp239 
tvR3RF-R pE-YA-tvR3KO 
rev 
ATGGCACAAACTTCGG transtvR3-RF SYp240 
tvL2-LF T.v gDNA 
fwd 
GCCAACTTTGTACAAAAAAGCAGGCTCCGCGCCAATCATCAAACCAAC tvL2-LF SYp241 
tvL2-LR T.v gDNA 
rev 
ACGTATTTCAGTGTCGAAAGATCCACTAGAACATACAAAGTAGTCAGAGG tvL2-LF SYp242 
tvL2-RF T.v gDNA 
fwd 
TGTAAGCGCCCACTCCACATCTCCACTCGACAATTACCCTTATACACAGAAGC tvL2-RF SYp243 
tvL2-RR T.v gDNA 
rev 
TGCCAACTTTGTACAAGAAAGCTGGGTCGGAGCAGTATTTAAAATGGCACAA tvL2-RF SYp244 
tvL2LF-F pE-YA-tvL2KO 
fwd 
GCGCCAATCATCAAACCAAC transtvL2-LF SYp245 
tvL2RF-R pE-YA-tvL2KO 
rev 
CAGTATTTAAAATGGCACAA transtvL2-RF SYp246 
tvL3-LF T.v gDNA 
fwd 
GCCAACTTTGTACAAAAAAGCAGGCTCCGCCTTGAATAGACACTACCGTGA tvL3-LF SYp247 
tvL3-LR T.v gDNA 
rev 
ACGTATTTCAGTGTCGAAAGATCCACTAGAGGATCCTCTCTTTGTTGGC tvL3-LF SYp248 
tvL3-RF T.v gDNA 
fwd 
TGTAAGCGCCCACTCCACATCTCCACTCGATCAAAGCTGTATTTATCCAAATGG tvL3-RF SYp249 
tvL3-RR T.v gDNA 
rev 
TGCCAACTTTGTACAAGAAAGCTGGGTCGGTCTGGGTAGAATGTAGATTTGT tvL3-RF SYp250 
tvL3LF-F pE-YA-tvL3KO 
fwd 
TTGAATAGACACTACCGTGA transtvL3-LF SYp251 
tvL3RF-R pE-YA-tvL3KO 
rev 
CTGGGTAGAATGTAGATTTGT transtvL3-RF SYp252 
tvL4-LF T.v gDNA 
fwd 
GCCAACTTTGTACAAAAAAGCAGGCTCCGCCCAATTCATCTACAGATGCAT tvL3-LF SYp253 
tvL4-LR T.v gDNA 
rev 
ACGTATTTCAGTGTCGAAAGATCCACTAGACATAGTTATCATCTGGTCAACC tvL3-LF SYp254 
tvL4-RF T.v gDNA 
fwd 
TGTAAGCGCCCACTCCACATCTCCACTCGAAAATGCAGACTCTGCTGC tvL3-RF SYp255 
tvL4-RR T.v gDNA 
rev 
TGCCAACTTTGTACAAGAAAGCTGGGTCGGACTGCCTTCTTGATGAACG tvL3-RF SYp256 
tvL4LF-F pE-YA-tvL4KO 
fwd 
CAATTCATCTACAGATGCAT transtvL3-LF SYp257 
tvL4RF-R pE-YA-tvL4KO 
rev 
CTGCCTTCTTGATGAACG transtvL3-RF SYp258 
dsRNA-pkiF T.r gDNA 
fwd 
GTAAAACACAACATATCCAGTCATATTGGCacgaaccgggggggat PpkiF SYp259 
dsRNA-pkiR T.r gDNA 
rev 
CGAGACGGACCAACGGCACAACCACCCATCggttaagagggttcttccgg PpkiF SYp260 
dsRNA-re F T.v cDNA 
fwd 
GATGGGTGGTTGTGCCGT dsRNA SYp261 
dsRNA-reR T.v cDNA 
rev 
AGTGTAAAGCCTGGGGTGCCTAATGCGGCCTACCGGCTGCGGTAAC dsRNA SYp262 
1argCSP1F T.v cDNA 
fwd 
TTTCTTTCAACACAAGATCCCAAAGTCAAAATGGATGTCAATAAAACTCTACAGT tvCS SYp263 
2argCST3R T.v cDNA 
rev 
GGTTGGCTGGTAGACGTCATATAATCATAC TTAGGCGTCATCGTGTGA tvCS SYp264 
3argCSP2F T.v cDNA 
fwd 
TAACAGCTACCCCGCTTGAGCAGACATCACATGGATGTCAATAAAACTCTACAGT tvCS SYp265 
4argPhaP1F T.v cDNA 
fwd 
TTTCTTTCAACACAAGATCCCAAAGTCAAAATGTATACCCCGTACATCACA tvR3 SYp266 
5argPhaT1R T.v cDNA 
rev 
TTCATTCTATGCGTTATGAACATGTTCCCTCTAACATCTGGGGTGAAAGG tvR3 SYp267 
6argCSP3F T.v cDNA 
fwd 
GTCGACTGACCAATTCCGCAGCTCGTCAAAATGGATGTCAATAAAACTCTACAGT tvCS SYp268 
7argACoP2F T.v cDNA 
fwd 




8argACoT2R T.v cDNA 
rev 
ACGACAATGTCCATATCATCAATCATGACCTTAAGAAACAAGCAGAGGAAAC tvL3 SYp270 
9adeP450P1F T.v cDNA 
fwd 
TTTCTTTCAACACAAGATCCCAAAGTCAAAATGATCTTGGAAATTGATCGAATT tvL4 SYp271 
10adeP450T3R T.v cDNA 
rev 
GGTTGGCTGGTAGACGTCATATAATCATACCTAAATGTATGAGTCTCGCC tvL4 SYp272 
11adeMoP1F T.v cDNA 
fwd 
TTTCTTTCAACACAAGATCCCAAAGTCAAAATGCTGCGGTTCAGC tvR2 SYp273 
12adeMoT3R T.v cDNA 
rev 
GGTTGGCTGGTAGACGTCATATAATCATACTCAGATAAATCCAAGAACATCGC tvR2 SYp274 
13adeP450T2R T.v cDNA 
rev 
ACGACAATGTCCATATCATCAATCATGACCCTAAATGTATGAGTCTCGCC tvL4 SYp275 
14adeMoP3F T.v cDNA 
fwd 
GTCGACTGACCAATTCCGCAGCTCGTCAAAATGCTGCGGTTCAGC tvR2 SYp276 
15adeP450T1R T.v cDNA 
rev 
TTCATTCTATGCGTTATGAACATGTTCCCTCTAAATGTATGAGTCTCGCC tvL4 SYp277 
16adeDHP2F T.v cDNA 
fwd 
TAACAGCTACCCCGCTTGAGCAGACATCACATGGGCGTCCCAACA tvL2 SYp278 
17adeDHT2R T.v cDNA 
rev 
ACGACAATGTCCATATCATCAATCATGACCTTATGCGTTTATAGTGATCGAGA tvL2 SYp279 
18argACoP1 F T.v cDNA 
fwd 
TTTCTTTCAACACAAGATCCCAAAGTCAAAATGCTGACGGAAGTCG tvL3 SYp280 
peyatRNA F T.v cDNA 
fwd 
GCCAACTTTGTACAAAAAAGCAGGCTCCGCATGAAGCACGAGGAGCT tvR4 SYp281 
peyatRNA R T.v cDNA 
rev 
TGCCAACTTTGTACAAGAAAGCTGGGTCGGTCAAGCAAAACGGATGTTTG tvR4 SYp282 
Table 5.7.1.1 Primers used in Chapter 2. 
 


































































































fwd GGAGAAAAAACCCCGGATCCATGAGCATTCTGGCGTAT Fyeast9 SYp320 
urabfL9R 
pRSETa-bfL9 


















Primer Template Direction sequence 5' - 3' Amplification ID 
tenSF1 
pE-YA-
tenS fwd GGTCCTTGTCTGAAGAGTTG F35 SYp401 
tenSR1 
pE-YA-
tenS rev GGATATCACAAGCAAGAAGC F35 SYp402 
TDSLk1-F 
pE-YA-
tenS fwd AGATCAGCAGGATAAGCAGC 
F36, F41, F43, 




tenS rev AAGCCCACGGGTCTGGAG F36, F51 SYp404 
TDSLk2-F 
pE-YA-
tenS fwd GCCGCATCGGCGGTAGAC F44, F52 SYp405 
TDSLk2-R 
pE-YA-
tenS rev TCCTTTGGTGGTGGTGATG 
F37, F39, F44, 




tenS fwd GCCATTCTGAATAATACAGGCC F37 SYp407 
T2A-R 
pE-YA-
tenS rev CTCAGAGACACTCATGACTCG F48 SYp408 
T1B-F 
pE-YA-
tenS fwd ACTGTGGTGGACATGATTCG F39 SYp409 
T1B-R 
pE-YA-
tenS rev AGCGCTCGAGCTTAGCAA F43 SYp410 
T2B-F 
pE-YA-
tenS fwd ACGGATGTGCATCATGCCTT F46 SYp411 
T1A-R 
pE-YA-
tenS rev CTGCACAGAGTCTTTGCTGC F41 SYp412 
D1A-TLk-F 
pE-YA1-
dmbS fwd ACTGTACCGCCCCTCCAGACCCGTGGGCTTTTCAAGAGCGACAGGACCTA F38, F40 SYp413 
D1A-TLk-R 
pE-YA1-
dmbS rev CATGGTGGCACGAATCATGTCCACCACAGTCTGCACAGAGTCTTTGTTGC F40 SYp414 
D1B-TLk-F 
pE-YA1-
dmbS fwd ATGGACGCTTGCAGCAAAGACTCTGTGCAGACTGTCGTGGATACGATTCG F42 SYp415 
D1B-TLk-R 
pE-YA1-
dmbS rev GTTTGACTGGCCTGTATTATTCAGAATGGCAGCGGCAGAACCAAGCAGAA F38, F42 SYp416 
D2A-TLk-F 
pE-YA1-
dmbS fwd GACTTTTTTGTCTTGCTAAGCTCGAGCGCTGCCATCTTGAATAACATGGG F45, F47 SYp417 
D2A-TLk-R 
pE-YA1-
dmbS rev CGCCTCAGCAAAGGCATGATGCACATCCGTCTCAGAGAGCCTCATAGCTC F47 SYp418 
D2B-TLk-F 
pE-YA1-
dmbS fwd GGTACCACGCGAGTCATGAGTGTCTCTGAGACTGACGTGCATCACGCCTT F49 SYp419 
D2B-TLk-R 
pE-YA1-
dmbS rev CGCTAGACTGTCTACCGCCGATGCGGCGGCTGCTTGCCCCGAGGCAATCA F45, F49 SYp420 
TMS-F 
PE-YA1-
milS fwd ACTGTACCGCCCCTCCAGCCCGTGGGCTTTTCCAGAGCGACAAACCT F50 SYp421 
TMS-R 
PE-YA1-








tenS fwd GACGTCATGCGAGCCACGACACTCTCGGAGACGGATGTGCATCATG F54 SYp424 
TenS(3/4)-F 
PE-YA1-
milS fwd ACTATCGCGAACAACATAG F55 SYp425 
TenS(3/4)-R 
PE-YA1-
milS rev CTCCGAGAGTGTCGT F55 SYp426 
LK2sub-F 
pE-YA-
tenS fwd CACAGCAACCGAGACGTCATGCGAGCCACGACACTCTCTGAGACGGATGTGC F57 SYp427 
LK1sub-R 
pE-YA-
tenS rev GAGTGTCGTGGCTCGCATGACGTCTCGGTTGCTGTGCACCTTGGTGTCGTCA F58 SYp428 








5.7.2 DNA isolation and PCR 
5.7.2.1 Isolation of Small Scale gDNA  
The GenElute Plant Genomic DNA miniprep kit (Sigma) was used to extract gDNA from fungi. 
Isolation of gDNA was carried out according to the manufacturer’s protocol.  
 
5.7.2.2 Isolation of Large Scale gDNAs  
A plug of S. tenacellus was inoculated into 100 mL of MEB and incubated on shaker incubator 
at 200 rpm and 25 oC. After 15 day, the mycelia were collected by filtration using a filter paper 
then squeezed. Approximately 6 g of squeezed mycelia were ground to a fine powder under liquid 
nitrogen. The powder was added to 15 mL of DNA extraction buffer (Tris-HCl, pH 8.0, 10 mM; 
EDTA 10mM; SDS 0.5%) and mixed gently by inversion then added with 10ml of phenol:iso-
amyl alcohol (25:24:1) and shaked gently for 15 minutes then centrifuged at 8.500 rpm (biofuge 
primo R from heraeus) for 10- 20 minutes. This step was carried out two times or until the clear 
interface between the aqueous and organic phases. Then, 10 mL aqueous phase was extracted 
with 10 mL phenol:chloroform:iso-amyl alcohol (25:24:1) and shaken gently for 25-30 minutes 
then centrifuge at 8.500 x g for 10-20 minutes. The 9.5 mL aqueous phase was added 950 μL 3M 
sodium acetate and 25 mL absolute ethanol (pH 5.2) then centrifuged at 8.000 x g 10 minute. The 
pellet was rinsed with 10 mL ethanol 70% then centrifuged at 8.000 x g for 2 minutes and then 
dissolved in 1 mL TE buffer (Tris-HCl, pH 8, 10 mM; EDTA 1mM). Genomic DNA was purified 
by equilibrium centrifugation in a continuous CsCl-ethidium bromide gradient. Finally, the 
quality of genomic DNA were analysed by electrophoresis. 
 
5.7.2.3 Isolation of Small Scale DNA Plasmid from E. coli  
GeneJET Plasmid Miniprep Kit was used to isolate small scale DNA plasmid from E. coli. 
Isolation was performed based on manufacturer’s protocol. 
 
5.7.2.4 Isolation of DNA Plasmid from S. cerevisae 
The Zymoprep II yeast plasmid miniprep kit (Zymo research) was used to extract plasmid DNA 
from S. cerevisiae. Yeast cell walls were digested using the Zymolyase enzyme according to the 
manufacturer’s protocol. Primary transformation plates containing multiple colonies were used 
as the source of yeast cells for plasmid extraction 
 
5.7.2.5 Analytical or Preparative PCR  
Analytical PCR was performed using reagent KOD Hot Start DNA polymerase throughout 
(Novagen). Reagent composition for 25 μL reaction was as follow 0.5 uL of KOD Hot Star DNA 




each primer 3μM, 0.5 μL of DMSO and distilled water until 25 μL in total. The DNA template 
was added at 1 pg – 10 ng (low complexity) and 50 - 250 ng (high complexity). The PCR condition 
was initially denatured by heating at 95 °C for 2 min, followed by 35 cycles of amplification, i.e. 
denaturation at 95 °C for 30 s, 66 °C for 20 s (depend on the best annealing and long product), 
70 °C for 15s and final extension 70 °C for 10 min.  
 
5.7.2.6 Colony PCR or Analytical PCR  
Colonies of E. coli transformants were screened by PCR. Cells of E. coli were picked by steriled 
toothpick and resuspended into PCR reaction. PCR reaction consists of 5 μL of Biomix, 0.5 μL 
of each reverse and forward primer, and 4 μL of deionized water on in 10 μL volume total. PCR 
program were performed as follow: 95°C for 5 min then 35 cycles with 95 °C for 15 s, 55° for 30 
s, 72 °C for 15-20 s/kb, finally 72°C for 10 min. 
 
5.7.2.7 Restriction Analysis of Plasmid DNA  
Approximately 2 μL of plasmid DNA (0.1- 0.2 μg) was added 1 μL of enzyme buffer, 0.25 μL of 
certain restriction enzyme and sterilized water until final volume of 10 μL. The mixture was 
incubated at 37 °C for an hour. DNA electrophoresis was used to check the digested DNA.  
 
5.7.2.8 DNA Electrophoresis  
Agarose gels were prepared in TAE buffer with agarose at concentrations between 0.8 – 1.5% 
(depend on fragment size) and with Midori green advance added for DNA visualisation. DNA 
was loaded on gels either using loading dye already present within a reaction (FastDigest Green 
Buffer (Fermentas)) or after addition of 0.1 vol 10 x loading buffer (0.25% (w/v) bromophenol 
blue in 10% (v/v) glycerol). Electrophoresis was performed using TAE buffer (0.04 M Tris-
acetate, 0.001 M EDTA) and run at 200 volt and 100 mA for 20 min. Gels were visualised by UV 
light using a transilluminator. 
 
5.7.3 Cloning procedure  
5.7.3.1 Restriction enzyme digestion  
Restriction enzyme digestions (single or double) of plasmids or PCR products were performed 
following the manufacturer’s guidelines of the enzymes (New England Biolabs or Thermo 
Scientific). DNA sample were mixed with the enzyme or enzyme mixture and the appropriate 
buffer. The reaction mixture was incubated at 25 °C or 37 °C (depending on the restriction enzyme) 
for 1 to 12 h. Enzymes were inactivated by heating the sample at 65 °C or 80 °C for 20 min. 
Digested DNA or plasmid were purified using the NucleoSpin® Gel and PCR Clean–up kit 





5.7.3.2 Dephosphorylation and ligation  
Digested plasmids were dephosphorylated using shrimp alkaline phosphatase (SAP) to prevent 
self ligation. 1 µl of enzyme was added after digestion to the reaction mixture and incubated at 
37 °C for 1 h. T4 DNA ligase (New England Biolabs) and its appropriate buffer were used for 
ligation reaction (final volume 10 µl) following the manufacturer’s introductions. Molar ration of 
1:5 plasmid to insert was used. Ligation reactions were incubated at 4 °C overnight or at room 
temperature for 30 min followed by heat inactivation at 65 °C.   
  
5.7.3.3 Gateway cloning  
LR-recombination between the entry clone and the destination vector was performed using 
Gateway LR Clonase enzyme mix II kit (Invitrogen) following the manufacturer’s instructions. 
For transformation of competent E. coli T10 cells 1 - 2 µl of the reaction mixture was used.  
  
5.7.3 Obtained and constructed vectors in this thesis 
Construction of fungal and bacterial expression vectors was performed using the described in 
vitro cloning procedures (section 5.7.3) and in vivo homologous recombination in S. cerevisiae 
(section 5.5.2). 
 
Name Selective marker Origin 
pE-YA Kan Lazarus Group, Bristol  
pTYGSargB Amp, △Arg Lazarus Group, Bristol  
pTYGSade Amp, △Ade Lazarus Group, Bristol  
pTYGSmet Amp Lazarus Group, Bristol  
pTH-GS-egfp Amp, Hyg Lazarus Group, Bristol  
pET28a (+) Kan Hahn group, Hannover  
pG-KGE8 Cm Takara Bio 
pESC-URA Amp, △Ura Prof. Jianqiang Kong 










Name Insert Fragments Selective Marker ID 
pE-YA-tvCSKO tvCS KO cassette Kan SYv01 
pE-YA-tvL2KO tvL2 KO cassette Kan SYv02 
pE-YA-tvL3KO tvL3 KO cassette Kan SYv03 
pE-YA-tvL4KO tvL4 KO cassette Kan SYv04 
pE-YA-tvR2KO tvR2 KO cassette Kan SYv05 
pE-YA-tvR3KO tvR3 KO cassette Kan SYv06 
pE-YA-tvR4KO tvR4 KO cassette Kan SYv07 
pTYH-GS-pki-reGOI Ppki, reGOI Amp SYv08 
pTYH-GS-pki-eGFP Ppki, eGFP Amp SYv09 
pE-YA-SY2133-8 tvL4 Kan SYv10 
pTY-GSarg-SY2133-1 tvL4, tvCS Amp, △Arg SYv11 
pTY-GSarg-SY2133-2 tvL4, tvCS, tvR3 Amp, △Arg SYv12 
pTY-GSarg-SY2133-3 tvL4, tvCS, tvR3, tvL3 Amp, △Arg SYv13 
pTY-GSarg-SY2133-9 tvL4 Amp, △Arg SYv14 
pTY-GSarg-SY2133-10 tvL4, tvCS, tvL3 Amp, △Arg SYv15 
pTY-GSade-SY2133-4 tvL4 Amp, △Ade SYv16 
pTY-GSade-SY2133-5 tvR2 Amp, △Ade SYv17 
pTY-GSade-SY2133-6 tvL4, tvR2 Amp, △Ade SYv18 
pTY-GSade-SY2133-7 tvL4, tvL2, tvR2 Amp, △Ade SYv19 
Table 5.7.3.2 Vectors constructed in Chapter 2. 
 
Name Insert Fragments Selective Marker ID 
pRSETa-bfL1 bfL1 Amp SYv20 
pRSETa-bfL2 bfL2 Amp SYv21 
pRSETa-bfL3 bfL3 Amp SYv22 
pRSETa-pvL2 pvL2 Amp SYv23 
pRSETa-bfL5 bfL5 Amp SYv24 
pRSETa-bfL6 bfL6 Amp SYv25 
pRSETa-bfL9 bfL9 Amp SYv26 
pRSETa-bfL10 bfL10 Amp SYv27 
pET28a-bfL5 bfL5 Kan SYv28 
pET28a-bfL6 bfL6 Kan SYv29 
pET28a-bfL9 bfL9 Kan SYv30 
pET28a-bfL10 bfL10 Kan SYv31 
pET28a-bfL5(△18) bfL5(△1-18) Kan SYv32 
pET28a-bfL6(△22) bfL6(△1-22) Kan SYv33 
pET28a-bfL10(△20) bfL10(△1-20) Kan SYv34 
pESC-URA-bfL3 bfL3 Amp, △Ura SYv35 
pESC-URA-pvL2 pvL2 Amp, △Ura SYv36 
pESC-URA-bfL5 bfL5 Amp, △Ura SYv37 
pESC-URA-bfL6 bfL6 Amp, △Ura SYv38 
pESC-URA-bfL9 bfL9 Amp, △Ura SYv39 
pESC-URA-bfL10 bfL10 Amp, △Ura SYv40 








Name Insert Fragments Selective Marker ID 
pE-YA-TDS1 TDS1 swap Kan SYv41 
pE-YA-TDS2 TDS2 swap Kan SYv42 
pE-YA-TDS3 TDS3 swap Kan SYv43 
pE-YA-TDS4 TDS4 swap Kan SYv44 
pE-YA-TDS5 TDS5 swap Kan SYv45 
pE-YA-TDS6 TDS6 swap Kan SYv46 
pE-YA-TMS1 TMS1 swap Kan SYv47 
pE-YA-TMS2 TMS2 swap Kan SYv48 
pE-YA-TMS3 TMS3 swap Kan SYv49 
pTY-GSarg-TDS1 TDS1 swap Amp, △Arg SYv50 
pTY-GSarg-TDS2 TDS2 swap Amp, △Arg SYv51 
pTY-GSarg-TDS3 TDS3 swap Amp, △Arg SYv52 
pTY-GSarg-TDS4 TDS4 swap Amp, △Arg SYv53 
pTY-GSarg-TDS5 TDS5 swap Amp, △Arg SYv54 
pTY-GSarg-TDS6 TDS6 swap Amp, △Arg SYv55 
pTY-GSarg-TMS1 TMS1 swap Amp, △Arg SYv56 
pTY-GSarg-TMS2 TMS2 swap Amp, △Arg SYv57 
pTY-GSarg-TMS3 TMS3 swap Amp, △Arg SYv58 
Table 5.7.3.4 Vectors constructed in Chapter 4. 
 
5.7.4 Heterologous Protein Production and Purification 
Each constructed plasmids was transformed into chemically competent E. coli BL21 (DE3) cells 
via heat shock transformation. A Single colony was picked to inoculate an overnight culture (LB 
medium with kanamycin) which was used to inoculate kanamycin containing 2TY medium. 
Cultures were grown to an OD600 of 0.4-0.6 at 37 °C before protein production was induced with 
0.1 mM isopropyl–β–D–thiogalactopyranoside (IPTG). The cultures were further incubated at16 
or 25°C for 20 h to increase the solubility of the produced protein. Cells were harvested by 
centrifugation (5000 x g, 4 °C, 15 min).  
The harvested cell pellets were resuspended in 10 mL cold IMAC loading buffer. Lysis of 
the cells was done by sonication using a SonoPlus Ultrasonic homogenizer from Bandelin. The 
cells were intermittently sonicated on ice for 30 s with 30 s allowed for cooling. The total 
sonication time was 7 min. The cell lysate was centrifuged at 12000 rpm for 45 min at 4 °C. 
Samples of the supernatant and the pellet were used for SDS PAGE. The protein of interest was 
purified using immobilized metal ion affinity chromatography. During the whole time the cell 
samples were kept on ice. 
Purification of histidine-tagged recombinant proteins were done by immobilized metal ion 
affinity chromatography using Ni-NTA agarose (Qiagen). All buffers, washing solutions and 
samples were filtered through a 0.45 µm filter prior to usage. The crude lysate was passed through 




Elution was performed with a stepwise gradient of imidazole (20 - 500 mM). 2 mL fractions were 
collected over the course of elution and analysed using SDS–PAGE. The eluate was concentrated 
and the binding buffer was replaced by storage buffer (50 mM potassium phosphate buffer, pH 
8.0) using amicon ultra centrifugal filter units, cut off 10000 MW, from Merck. The purified 
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